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 Resumo 
 
Hoette, S. Avaliação do ventrículo direito em pacientes com hipertensão 
pulmonar (tese). São Paulo: Faculdade de Medicina da Universidade de São 
Paulo (2012). 
 
Introdução: A fração de ejeção do ventrículo direito (FEVD) é um importante 
fator prognóstico em pacientes com hipertensão pulmonar (HP), porém a sua 
medida é complicada e demorada devido à complexidade anatômica do 
ventrículo direito (VD). O TAPSE (Tricuspid Annular Plane Systolic Excursion) é 
um bom índice da FEVD, mas ele avalia apenas o componente longitudinal da 
contração ventricular direita. A RVFAC (Right Ventricular Fractional Area 
Change) parece ser um melhor índice da FEVD por incluir os componentes 
longitudinal e transversal da contração ventricular direita. O objetivo deste 
estudo foi avaliar a performance da RVFAC de acordo com a gravidade do 
acometimento hemodinâmico em dois grupos distintos de pacientes portadores 
de HP pré-capilar: hipertensão arterial pulmonar (HAP) e tromboembolismo 
pulmonar crônico hipertensivo (TEPCH).  
 
Métodos: 62 pacientes realizaram cateterismo cardíaco direito e ressonância 
magnética cardíaca em ±72h. As áreas sistóica e diastólica finais do ventrículo 
direito (ASFVD, ADFVD), a área diastólica final do ventrículo esquerdo (ADFVE) 
e o TAPSE foram medidos nas imagens de quatro cavidades. A RVFAC 
(ADFVD-ASFVD/ADFVD) e a relação entre as áreas diastólica finais 
ventriculares (ADFVD/ADFVE) foram calculadas. Os diâmetros entre as paredes 
livre e septal (dL-S) e antero-posterior (dA-P) do ventículo esquerdo (VE) foram 
medidos nas imagens em eixo curto e o índice de excentricidade do VE (IE) foi 
calculado (=dA-P/dL-S). A FEVD foi calculada a partir de imagens consecutivas 
de 6mm no eixo curto.  
. 
Resultados: A população tinha 58 anos em média, a maioria era do sexo 
feminino e estava em classe funcional III, 23 tinham HAP e 39 TEPCH. A FEVD 
apresentou correlações fracas com as medidas hemodinâmicas de sobrecarga e 
de função do VD. A RVFAC apresentou melhor correlação (R2=0,65, p < 0,001)  
do que o TAPSE (R2=0,35, p<0,001) com a FEVD e melhor capacidade para 
estimar FEVD<35% do que o TAPSE (TAPSE: AUC 0,73 e RVFAC: AUC 0,93, 
p=0,0065). Dividimos a população pela mediana da resistência vascular 
pulmonar (RVP) e observamos que no grupo com maior gravidade 
hemodinâmica essa diferença se acentuou: no grupo com RVP<8,5UW (RVFAC: 
R2=0,66, p<0,001 e TAPSE: R2=0,30, e p=0,002) e no grupo com RVP>8,5UW 
(RVFAC: R2=0,51, p<0,001 e TAPSE: R2=0,14, e p=0,041). O grupo com 
RVP>8,5UW apresentou maior ADFVD/ADFVE e maior IE. As correlações da 
RVFAC e TAPSE com FEVD foram semelhantes entre os grupos HAP e 
TEPCH. 
 
Conclusão: A RVFAC se correlacionou melhor com a FEVD do que o TAPSE 
tanto no grupo com menor como no grupo com maior gravidade hemodinâmica. 
No grupo com maior gravidade as correlações com a FEVD foram ainda mais 
significativas, não havendo diferenças na performance da RVFAC entre os 
pacientes com HAP e TEPCH. A RVFAC foi um melhor índice da FEVD talvez 
por incluir o movimento transversal da contração ventricular. 
 
Descritores: disfunção ventricular direita, hipertensão pulmonar, ventrículos 
cardíacos, hemodinâmica.    
    
 
Summary 
 
Hoette, S. Right ventricle evaluation in pulmonary hypertension (tese). São 
Paulo: Faculdade de Medicina da Universidade de São Paulo (2012). 
 
Introduction: The right ventricular ejection fraction (RVEF) is a surrogate marker 
in pulmonary hypertension (PH), but its measurement is complicated and time 
consuming. The TAPSE (Tricuspid Annular Plane Systolic Excursion) is a good 
index of RVEF, though it measures only the longitudinal component of right 
ventricular contraction. The RVFAC (Right Ventricular Fractional Area Change) 
seems to be a better index of RVEF because it takes into account the 
longitudinal and the transversal components of right ventricular contraction. The 
aim of our study was to evaluate the RVFAC performance according to 
hemodynamic severity in two groups of patients with PH: pulmonary arterial 
hypertension (PAH) and chronic thromboembolic pulmonary hypertension 
(CTEPH).  
 
Methos: Sixty-two patients with PAH and CTEPH underwent right heart 
catheterization and cardiac MR in a 72-hour delay. The right and left ventricle 
end diastolic areas (RVEDA, LVEDA), the right ventricle end systolic area 
(RVESA) and TAPSE were measured in the four chamber view. The RVFAC (= 
RVEDA – RVESA/RVEDA) and the RVEDA/LVEDA relationship were calculated. 
The diameter between the left ventricle (LV) free wall and the septum (dL-S) and 
the diameter between the anterior and posterior walls (dA-P) were measured and 
the LV eccentricity index (EI) was calculated (=dA-P/dL-S). The RVEF was 
calculated by using 6 mm RV short axis cines.  
 
Results: The population had mean age of 58 years with female majority, most of 
the patients were in functional class III, 23 had pulmonary arterial hypertension 
(PAH) and 39 had chronic thromboembolic pulmonary hypertension (CTEPH). 
The RVEF was weakly correlated to the hemodynamic variables of RV afterload 
and function. The RVFAC was more strongly correlated to RVEF (R2=0.65, 
p<0.001) than TAPSE (R2=0.35, p<0.001). RVEF<35% was better predicted by 
RVFAC than TAPSE (TAPSE: AUC 0.73 and RVFAC: AUC 0.93, p=0.0065). We 
divided the population by the median of the pulmonary vascular resistance (PVR) 
and we observed that in the group with worse hemodynamic severity this 
difference increased: in the group with PVR<8,5WU (RVFAC: R2=0.66, p<0.001 
and TAPSE: R2=0.30, p=0.002) and in the group with PVR>8,5 WU (RVFAC: 
R2=0.51, p<0.001 and TAPSE: R2=0.14, p=0.041). The group with PVR>8,5WU 
had an increased RVEDA/LVEDA and an increased EI. There was no differences 
in the RVEF relationships between the groups of PAH and CETPH.  
 
Conclusion: The RVFAC was better correlated to RVEF than TAPSE in the 
groups with less severe and more severe hemodynamics. In patients with 
increased hemodynamic severity, with no difference in the performance in the 
HAP or CTEPH groups. RVFAC was a better index of RVEF possibly because it 
takes into account the transversal component of right ventricular function.  
 
Descriptors: right ventricular dysfunction, pulmonary hypertension, cardiac 
ventricles, hemodynamics.  
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A importância do ventrículo direito (VD) foi subestimada até 
recentemente. Trabalhos experimentais em modelo de cães com pericárdio 
aberto mostravam que não havia redução do débito cardíaco ou aumento da 
pressão venosa sistêmica quando VD era cauterizado e perdia sua função 
contrátil1. Assim, durante mais de quatro décadas, o VD foi considerado 
como tendo uma função de condução passiva com insignificante relevância 
circulatória. Na década de 80, estudos em modelos de cães com tórax 
fechado mostraram comprometimento hemodinâmico significativo no infarto 
de VD2. Nesta época, estudos clínicos começaram a mostrar também o 
maior risco de morte, arritmia e choque cardiogênico em pacientes com 
infarto de VD3.   
 
O papel do VD passou a ser então reconsiderado, levantando a 
hipótese de que os modelos iniciais não encontravam alterações com a 
exclusão do VD porque não levavam em conta a interdependência 
ventricular, uma vez que esses eram baseados em modelos com pericárdio 
aberto1. A partir de então, a função do VD começou a ganhar importância e 
em 2006 o Instituto Nacional de Coração, Pulmão e Sangue nos Estados 
Unidos identificou a fisiologia do ventrículo direito como prioridade na 
pesquisa cardiovascular1,4. 
 
 
 
3 
1.1. Particularidades do ventrículo direito 
 
Em condições normais, o VD, ao contrario do ventrículo esquerdo 
(VE), está acostumado a um regime de baixa pressão porque a circulação 
pulmonar tem características bastante diferentes da circulação sistêmica. A 
principal característica da circulação pulmonar é a capacidade de acomodar 
grandes aumentos de volume sanguíneo sem elevação da pressão do 
circuito. Isso é possível pela distensibilidade dos vasos pulmonares e pelo 
recrutamento de capilares5. Essa elevada complacência da circulação 
pulmonar associada a uma baixa resistência vascular pulmonar (RVP) (cerca 
de um sexto da resistência vascular sistêmica) faz com que o lado direito do 
coração trabalhe com pressões bastante inferiores do que o lado 
esquerdo6,7. As características anatômicas do VD diferem muito das do VE; 
o VD tem paredes finas e bastante trabeculadas e possui formato semilunar 
ou em crescente. Já o VE tem formato concêntrico e paredes bem mais 
espessas (a massa miocárdica do VD é aproximadamente um quarto da 
massa do VE).  
 
A perfusão sanguínea também se dá de forma diferente entre o VD e 
o VE. O fluxo na artéria coronária descendente anterior tem padrão bifásico, 
sendo praticamente nulo durante a sístole, e significativo apenas durante a 
diástole, estando assim a perfusão miocárdica do VE limitada à diástole. Já 
o fluxo da artéria coronária direita tem padrão monofásico permanecendo 
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praticamente inalterado durante a sístole e a diástole, garantindo perfusão 
miocárdica ao VD durante todo o ciclo cardíaco4.  
 
Estas diferenças anatômicas proporcionam ao VD uma complacência 
muito maior do que a do VE e o levam a responder de forma diferente aos 
insultos. O VD responde de formas diferentes quando ocorre aumento de 
pressão ou de volume e também dependendo da rapidez com que o insulto 
se instala, seja de forma aguda ou crônica; tendendo a tolerar melhor 
sobrecarga de volume do que de pressão. Quando ocorre aumento súbito da 
pós-carga o VD dilata significativamente e o volume sistólico diminui quase 
que linearmente com o aumento da pós-carga. Assim, um VD normal é 
incapaz de gerar pressões de artéria pulmonar maiores que 40mmHg 
quando ocorre aumento abrupto na pós-carga. Em contrapartida, o VD 
consegue lidar bem com aumentos significativos de volume, mesmo que de 
forma abrupta. Aumentos súbitos em fluxo, como ocorre no exercício físico, 
não levam a aumentos significativos da pressão arterial pulmonar5. 
 
Uma causa importante de sobrecarga ventricular direita é a 
hipertensão pulmonar (HP). A HP é definida pelo achado de elevação da 
pressão pulmonar média (PAPm ≥ 25 mmHg) no cateterismo cardíaco direito 
e a sua classificação diagnóstica engloba achados hemodinâmica e 
fisiopatológicos8. Quando a pressão da artéria pulmonar ocluída (PAPo) é > 
15 mmHg a HP é pós-capilar e classificada no grupo 2 da classificação 
diagnóstica que consiste na HP causada por doença do coração esquerdo. 
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Os outros 4 grupos da classificação diagnóstica envolvem a HP com PAPo ≤ 
15 mmHg, chamada HP pré-capilar. O grupo 1 é denominado hipertensão 
arterial pulmonar (HAP) e engloba HAP classificadas como: idiopática, 
hereditária, induzida por drogas ou toxinas, hipertensão persistente do 
recém-nascido, doença pulmonar veno-oclusiva e/ou hemangiomatose 
capilar pulmonar e HAP associadas a doença do tecido conjuntivo, infecção 
pelo vírus da imunodeficiência humana, hipertensão portal, cardiopatia 
congênita, esquistossomose e anemia hemolítica crônica. A HP causada por 
doença pulmonar e/ou hipoxemia pertence ao grupo 3 e o grupo 4 consiste 
no tromboembolismo pulmonar crônico hipertensivo (TEPCH). No grupo 5 
são classificados os casos de HP com mecanismos multifatoriais não 
esclarecidos9. 
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1.2. Resposta do ventrículo direito ao aumento da pós-carga 
  
Quando ocorre aumento da pós-carga o VD precisa se adaptar. 
Ocorre dilatação da cavidade ventricular, o que modifica sua forma inicial 
semilunar, deixando-o mais parecido com o VE, ou seja, mais concêntrico. O 
septo interventricular fica retificado podendo haver abaulamento e 
compressão da cavidade ventricular esquerda. A hipertrofia da parede 
muscular é outra importante alteração que ajuda o VD a vencer o aumento 
da RVP. Estudos experimentais mostram hipertrofia ventricular direita em 
apenas 96 horas de sobrecarga e aumento significativo da massa muscular 
do VD em 7 dias de hipóxia, sendo esse aumento progressivo, caso o 
estímulo seja mantido5,10. 
 
A maior massa muscular do VD leva ao aumento da demanda de 
oxigênio; porém, a oferta de oxigênio está associada à perfusão coronária do 
VD e esta se encontra alterada conforme a massa muscular do VD aumenta. 
Em pacientes com HP e hipertrofia do VD, o fluxo na artéria coronária direita 
muda de padrão; passa do padrão monofásico para o padrão bifásico, como 
o apresentado pela artéria coronária descendente anterior. O VD passa 
então a ser perfundido somente durante a diástole, como o VE. Essa 
mudança no fluxo coronariano é diretamente proporcional aos aumentos da 
pressão sistólica do VD e de sua massa muscular4. 
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A resposta do VD ao incremento da pós-carga varia mesmo dentro de 
subgrupos da HP, podendo a disfunção ventricular direita estar presente de 
forma mais precoce em alguns grupos, mesmo que o padrão hemodinâmico 
seja similar2. Existe diferença na contratilidade cardíaca entre pacientes com 
HAP idiopática e associada à esclerose sistêmica, apesar dessas duas 
patologias estarem classificadas no mesmo grupo na classificação 
diagnóstica da HP. Overbeek et al.11 mostraram que os pacientes com 
esclerose sistêmica apresentavam menor contratilidade ventricular direita 
que os pacientes com HAP apesar da mecânica vascular semelhante nos 
dois grupos; não havia diferença significativa na RVP nem na complacência 
vascular pulmonar. Essa diferença na contratilidade ventricular estaria 
associada à variação do acometimento do miocárdio entre essas duas 
patologias, como a presença de fibrose miocárdica e o envolvimento de 
vasos coronários intramiocárdicos. 
 
Desta forma, acredita-se que o aumento da pós-carga induz 
alterações na morfologia, na massa muscular e na perfusão do VD, sendo 
que a dilatação do VD pode ainda levar a alterações na complacência do 
VE, pelo abaulamento septal. Todos estes fatores associados contribuem 
para a redução do débito cardíaco, que leva à diminuição da pressão de 
perfusão coronária. O aumento da massa miocárdica associado às 
mudanças na perfusão coronária podem causar isquemia relativa, piorando 
ainda mais a performance do VD, gerando assim um ciclo vicioso, com auto-
agravamento12. 
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Define-se, portanto, como disfunção do VD, o conjunto de alterações 
estruturais ou funcionais que levam ao comprometimento do enchimento ou 
da contração ventricular direita. Já a falência do VD se refere à síndrome 
clínica complexa que resulta destas alterações12. As principais 
manifestações clínicas desta síndrome são: retenção hídrica, que pode levar 
a edema periférico, ascite e anasarca; redução da reserva sistólica e baixo 
débito cardíaco, que pode levar a intolerância ao exercício físico e fadiga; e 
arritmias atrial e ventricular.  
 
A capacidade funcional do VD é o principal determinante do 
prognóstico na HP. Enquanto o VD consegue manter o débito cardíaco (DC), 
apesar de aumentos na pós-carga, o paciente permanece pouco 
sintomático2. A função ventricular direita é, portanto, fundamental nos 
pacientes com HP. 
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1.3. O papel prognóstico da função ventricular direita na hipertensão 
pulmonar 
 
Estudos têm comprovado que a função do VD é um importante fator 
prognóstico na HP2. As medidas do índice cardíaco e do volume sistólico do 
VD já foram estabelecidos como marcadores de sobrevida nesta doença13,14. 
van de Veerdonk et al.15 mostraram que pacientes com HP e disfunção grave 
de VD, definida por uma fração de ejeção (FEVD) menor do que 35%, 
tiveram sobrevida pior independente da RVP apresentada na avaliação 
inicial. No seguimento desses pacientes, a diminuição da FEVD foi marcador 
de pior prognóstico enquanto o aumento da RVP não teve papel prognóstico. 
Ou seja, independente do comprometimento hemodinâmico, o fator 
prognóstico mais importante foi a maneira como o VD conseguiu lidar com 
esse aumento de pós-carga. 
 
Em um estudo mais recente também em pacientes com HP, o mesmo 
grupo comparou pacientes com sobrevida maior do que cinco anos (grupo 
dos sobreviventes) com pacientes que morreram entre 1 e cinco anos (grupo 
dos não sobreviventes) da avaliação inicial16. O grupo dos não sobreviventes 
apresentava FEVD significativamente menor no momento da inclusão no 
estudo do que o grupo dos sobreviventes. A FEVD permaneceu estável 
entre a avaliação inicial e após um ano de tratamento no grupo dos 
sobreviventes, porém apresentou redução progressiva no grupo dos não 
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sobreviventes, reforçando a importância da FEVD como fator prognóstico 
nos pacientes com HP. 
 
A sobrevida dos pacientes com HP varia não só entre os diferentes 
grupos, mas também dentro de cada um dos grupos existentes da 
classificação diagnóstica. A sobrevida dos pacientes com HAP associada à 
doença do colágeno é inferior a de pacientes com HAP idiopática que por 
sua vez é inferior a de pacientes com HAP associada à cardiopatia 
congênita13. Recentemente, Fernandes et al.17 mostraram que os pacientes 
com HAP associada à esquistossomose apresentaram sobrevida maior do 
que pacientes com HAP idiopática. Se a função ventricular direita varia entre 
as patologias associadas a HP11, talvez o acometimento miocárdico distinto 
seja um fator que contribua para essa diferença de sobrevida. 
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1.4. Avaliação não invasiva da função ventricular direita 
 
A fração de ejeção é considerada o método padrão para se avaliar a 
função ventricular de forma não invasiva. Para o cálculo da fração de ejeção 
é necessário que sejam medidos os volumes sistólico e diastólico finais. A 
medida dos volumes é realizada pelo contorno da borda endocárdica no final 
da sístole e da diástole em diversos cortes paralelos, da base ao ápice dos 
ventrículos. Este processo é trabalhoso e demorado18. A avaliação da FEVD 
é ainda mais complicada do que do VE pela complexidade anatômica do VD. 
A parede mais trabeculada do VD dificulta a definição da borda endocárdica 
e o formato semilunar dificulta o desenvolvimento de modelos geométricos 
para o cálculo da sua função de forma automatizada19. A posição 
retroesternal ainda atrapalha a aquisição de boas imagens do VD pela 
ecocardiografia, já que a janela acústica é prejudicada pela interposição do 
esterno20. 
 
  Pelas dificuldades técnicas que existem para a determinação da 
função do VD, formas para estimar a sua função que dispensam o cálculo da 
FEVD começaram a gerar interesse21. Para tal foi necessário compreender 
melhor a forma como se dá a contração do mesmo.  
 
Estudos da década de 50 já mostravam o interesse em entender 
como ocorria a contração cardíaca. Rushmer et al.22 fizeram um dos 
primeiros estudos que mostrou diferença na contração do VD e do VE em 
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cães. Eles suturaram pequenos pedaços de fio de metal na parede do VD e 
do VE e depois fizeram imagens com cinefluorografia. A análise das 
imagens permitiu identificar o principal eixo de aproximação desses pedaços 
de metal, definindo assim qual era o principal eixo de encurtamento das 
fibras musculares nas cavidades cardíacas. O VD se caracterizou 
principalmente pela aproximação das peças no sentido longitudinal, ou seja, 
o movimento da base em direção ao ápice do coração22.  
 
Recentemente, o uso de uma técnica mais moderna com a inserção 
cristais microtransdutores ultrassônicos possibilitou uma análise mais 
detalhada da contração cardíaca. Leather et al.23 associaram essa técnica 
com monitorização hemodinâmica e infudiram volume ou garrotearam a 
artéria pulmnar para avaliar a resposta a mudanças na pré e pós-carga do 
VD. O estudo mostrou que a variação no volume sistólico apresentou 
correlação forte com a variação dos microtransdutores no eixo longitudinal e 
fraca com a variação no eixo transversal. As variações na pré e pós-carga 
também se correlacionaram melhor com a variação no eixo longitudinal do 
que no eixo transversal. Os autores concluíram então que a contratilidade 
regional longitudinal refletia melhor a contratilidade global do VD do que a 
transversal. 
 
Com base nesses achados, a avaliação da contratilidade longitudinal 
parecia ser a melhor forma de estimar a função global e assim a medida da 
movimentação do anel tricúspide foi estudada como forma de estimar a 
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FEVD já que refletia o movimento longitudinal, ou seja, o movimento da base 
em direção ao ápice cardíaco24.  
 
Uma maneira de se aplicar esse conceito clinicamente é a avaliação 
do padrão de movimentação da válvula tricúspide. A medida do TAPSE 
(Tricuspid Annular Plane Systolic Excursion) é rápida e fácil de ser obtida, 
não requer o delineamento da borda interna do miocárdio e ainda é 
altamente reprodutível25. Ueti et al.26 compararam a medida do TAPSE 
realizadas por ecocardiografia com a medida da fração de ejeção pela 
angiografia de radionuclídeos e encontraram forte correlação entre as duas 
medidas. A medida do TAPSE ainda apresentou boa capacidade em 
discriminar pacientes com boa função daqueles com disfunção de VD.  
Estudos com acompanhamento de longo prazo mostraram que o TAPSE é 
também um bom marcador prognóstico nas cardiopatias27.  
 
Na HP, esse índice também se mostrou útil. Forfia et al.24 estudaram 
o TAPSE em 63 pacientes com HP. O TAPSE apresentou alta sensibilidade 
e especificidade como indicador de volume sistólico reduzido. Pacientes com 
TAPSE menor que 1.8 cm apresentaram menor índice cardíaco e menor 
trabalho sistólico de VD, ou seja, disfunção ventricular direita mais 
avançada. A sobrevida foi significativamente menor nos pacientes com 
TAPSE menor que 1,8 cm do que nos paciente com mais de 1,8 cm. Quando 
o TAPSE inicial era menor que 1,5 cm os pacientes apresentaram 
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mortalidade ainda maior. Assim, a medida do TAPSE mostrou ser também 
marcador de prognóstico em HP. 
 
Brown S et al.28 analisaram as áreas diastólica e sistólica finais do VD 
para avaliar os componentes longitudinal e transversal da contração 
ventricular. Em relação à área total reduzida entre a diástole e a sístole, o 
maior percentual de redução de área aconteceu no eixo longitudinal (77%). 
Quando analisaram o grupo com HP o achado foi semelhante: o principal 
componente na contração do VD continuou sendo o encurtamento 
longitudinal. Mas o interessante foi que quando comparado ao grupo 
controle, a importância do componente transversal foi significativamente 
mais importante no grupo HP (componente transversal representou 37% da 
redução total da área no grupo HP contra 23% no grupo controle). Quando 
um subgrupo de pacientes com HP foi analisado antes e após tratamento, a 
melhora na função ventricular direita esteve associada a ganho 
principalmente no componente longitudinal. Os autores concluem que o 
principal componente da contração do VD é o longitudinal em sujeitos 
normais e nos pacientes com HP e que a resposta à redução na pós-carga 
se reflete também no componente longitudinal.  
 
Entretanto, os dados desse estudo28 mostram que nos pacientes com 
HP o componente transversal é proporcionalmente mais importante do que 
nos controles, levantando a hipótese que neste grupo de pacientes o 
componente transversal não deve ser desprezado. Essa hipótese é 
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reforçada por outros estudos que não encontraram relação tão significativa 
do TAPSE com a função ventricular direita.  Anevkar et al.29 encontrou 
correlação fraca entre a medida do TAPSE pelo ecocardiograma e a FEVD 
medida por ressonância nuclear magnética cardíaca (RMC). Em pacientes 
com HP, o TAPSE apresentou correlação também apenas fraca com a 
FEVD quando ambos foram medidos pela RMC30 e moderada quando 
ambos foram medidos pelo ecocardiograma tri-dimensional31.  
 
A RMC vem ganhando importância no estudo do VD e na HP. Os 
avanços nas técnicas de aquisição e processamento das imagens de RMC 
representaram um grande avanço na avaliação do VD, pois a RMC é um 
método não invasivo e com elevada resolução espacial que permite a 
avaliação do VD de forma tridimensional20. Este exame promove 
visualização tomográfica detalhada da morfologia do VD além de oferecer 
definição nítida entre o miocárdio e o sangue intracavitário. Estudos já 
validaram as medidas dos volumes, massa muscular e FEVD por RMC. A 
RMC é considerada hoje o padrão ouro para a avaliação não invasiva do 
VD12,19. 
 
Estudos utilizando RMC mostraram que pacientes com HP, quando 
comparados a grupo controle, apresentam aumento significativo dos 
volumes sistólico e diastólico finais e da massa muscular do VD, assim como 
redução significativa da FEVD32. Essas diferenças tiveram papel prognóstico 
na HP. Em pacientes com HP que tiveram RMC realizada no início do 
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acompanhamento e um ano após, a redução no volume sistólico, o aumento 
do volume diastólico final do VD e a diminuição do volume diastólico final do 
VE foram fatores fortemente preditores de falência de tratamento e 
mortalidade14. 
 
 Kind T et al.30 usaram as imagens de RMC no corte de quatro 
cavidades e estudaram a variação entre sístole e diástole dos componentes 
longitudinal e transversal. Para avaliar o componente transversal, eles 
traçaram segmentos entre a parede livre e septo e, para avaliar o 
componente longitudinal, segmentos do anel tricúspide ao ápice cardíaco. 
Esse estudo mostrou que o a redução no componente transversal teve 
melhor correlação com a FEVD do que a redução no sentido longitudinal em 
pacientes com HP. Eles ainda mostraram que quando comparados a um 
grupo controle, os pacientes com HP apresentam diferença no padrão de 
contração. A contração no eixo transversal apresenta maior redução nos 
segmentos apicais em indivíduos normais. Nos pacientes com HP essa 
diferença ocorre principalmente nos segmentos próximos a base do coração. 
O estudo conclui que o movimento transversal nos pacientes com HP se 
correlaciona melhor com a medida da função global do VD do que a medida 
do movimento longitudinal, pela RMC. Os autores acreditam que esse 
achado está associado ao fato do movimento transversal incluir o movimento 
septal. Quando a pós-carga aumenta e o VD dilata, o septo acaba sendo 
empurrado em direção ao VE e esse abaulamento septal não é levado em 
conta quando apenas o componente longitudinal é medido.  
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Assim outras formas de se estimar a FEVD continuaram a ser 
pesquisadas, entre elas a RVFAC (Right Ventricular Fractional Area 
Change). A RVFAC expressa o percentual de variação entre as áreas 
diastólica e sistólica finais do VD (ADFVD e ASFVD, respectivamente). As 
imagens são obtidas no corte de quatro-cavidades no eixo longitudinal e 
apenas duas imagens, a diastólica final e a sistólica final, são usadas. Para a 
determinação da RVFAC, ainda é necessário fazer o contorno da borda 
endocárdica, porém, como esse contorno é feito em apenas duas imagens, 
sua medida se torna muito mais rápida do que a da FEVD, que requer 
contorno em diversos cortes. O processo para o cálculo da RVFAC pode ser 
de 8 a 12 vezes mais rápido do que a determinação da FEVD16. A RVFAC, 
por ser uma medida bidimensional, engloba os componentes longitudinal e 
transversal da contração ventricular, incluindo a movimentação septal. Os 
estudos mostraram que ela tem boa correlação com a função ventricular 
direita medida pela RMC e ainda se mostrou ser um fator prognóstico em 
cardiopatias29,33. Essa ferramenta começou então a ser estudada em 
pacientes com HP.  
 
O estudo já mencionado de Kind et al.30 mostrou forte correlação 
deste índice com a FEVD (R2 = 0,76, p < 0,001) e o estudo de Mauritz et 
al.16 mostrou o valor prognóstico da RVFAC em pacientes com HP. A 
RVFAC parece ser melhor do que o TAPSE como índice da FEVD em 
pacientes com HP por incluir o movimento transversal enquanto que o 
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TAPSE avalia apenas o movimento longitudinal. No entanto, não se sabe 
qual o comportamento dessa medida em grupos com diferente 
comprometimento hemodinâmica e como ela se comporta nas diferentes 
etiologias de HP. 
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20 
2.1. Objetivo principal 
 
 Avaliar a performance da RVFAC de acordo com a gravidade do 
acometimento hemodinâmico em dois grupos distintos de pacientes 
portadores de hipertensão pulmonar pré-capilar: HAP e TEPCH. 
 
2.2. Objetivo secundário 
 
 Comparar a performance da RVFAC com a do TAPSE como índices 
da FEVD. 
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3.1. População do estudo 
 
A população estudada consistiu nos pacientes encaminhados para 
avaliar possível doença vascular pulmonar no Centro de Referência Francês 
para HP, o Hospital Antoine Béclère, em Clamart, na França, vinculado à 
Universidade de Paris XI. Todos os pacientes que eram avaliados pela 
primeira vez neste centro e que tinham indicação de cateterismo cardíaco 
direito foram entrevistados para realização de RMC. Pacientes que 
concordavam em participar do estudo realizavam então a ressonância 
cardíaca. 
 
Os critérios de inclusão foram: idade maior que 18 anos, HP pré-capilar 
ao cateterismo cardíaco direito (caracterizada pela presença de PAPm ≥ 25 
mmHg e pressão da artéria pulmonar ocluída ≤ 15 mmHg), RMC realizada 
em até 72 horas da realização do cateterismo cardíaco. 
 
Os critérios de exclusão foram: gravidez, as contra-indicações para 
realização de ressonância cardíaca (claustrofobia conhecida, marcapasso ou 
desfibrilador implantável, clip de aneurisma cerebral, fragmento metálico 
ocular e implante coclear, obesidade mórbida), presença de hipertensão 
pulmonar associada a doenças pulmonares crônicas ou com componente 
multifatorial ou incerto. 
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3.2. Avaliação hemodinâmica 
 
Todos os pacientes incluídos na análise final foram submetidos a 
cateterismo cardíaco direito. O cateterismo era realizado no laboratório de 
hemodinâmica do próprio centro por pneumologistas especialistas em HP. 
Os pacientes ficavam em posição supina e o cateter da artéria pulmonar era 
inserido através de punção venosa do membro superior direito ou da veia 
jugular interna direita. A medida da PAPo era realizada com o balão 
insuflado na artéria pulmonar após confirmação por radioscopia de que o 
cateter estava adequadamente posicionado. O débito cardíaco foi medido 
pelo método de termodiluição e a média de três medidas foi considerada. 
Eram registradas as pressões de átrio direito, ventrículo direito e da artéria 
pulmonar (PAP), assim como a freqüência cardíaca. Amostra de sangue 
venoso misto, ou seja, da artéria pulmonar, foi coletado em 57 pacientes. A 
RVP foi calculada: RVP=(PAPm–PAPo)/DC. O volume sistólico foi calculado 
de acordo com a fórmula: VS=DC/FC. A complacência vascular pulmonar foi 
calculada pela divisão do volume sistólico pela pressão de pulso (PAP 
sistólica – PAP diastólica). 
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3.3. Ressonância magnética cardíaca 
 
Os exames foram realizados em equipamento de 1,5 Tesla de campo 
principal (Magnetom Avanto, Siemens Medical Solutions, Germany) com 
sincronização eletrocardiográfica e em pausa inspiratória. As imagens 
cardíacas foram adquiridas no eixo curto e no eixo longo do VE através da 
técnica de SSFP (balanced steady-state free procession pulse sequence). 
Uma seqüência de imagens em eixo curto foi adquirida da base ao ápice do 
VE com intervalos de aproximadamente 5 mm, totalizando em média 10 
cortes para cobrir todo o VE. Para análise do VD, outra seqüência de 
imagens cortes de 6 mm de espessura, contíguos, ou seja, sem intervalos, 
foi adquirida em paralelo ao plano da valva tricúspide, da base ao ápice do 
VD. As imagens em quatro cavidades foram adquiridas no eixo longo que foi 
realizado perpendicularmente ao eixo curto. Imagens de cine-ressonância da 
artéria pulmonar foram também adquiridas. 
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3.4. Análise das imagens da ressonância cardíaca 
 
Todas as imagens foram analisadas por um radiologista que 
desconhecia os resultados do cateterismo cardíaco e os diagnósticos dos 
pacientes.   
 
A ASFVD e a ADFVD foram determinadas através do delineamento 
manual da borda endocárdica do VD nas imagens em quatro-cavidades 
(Figura 1). A RVFAC foi calculada: RVFAC= 100x(ADFVD-ASFVD)/ADFVD. 
A área diastólica final do VE (ADFVE) também foi determinada pelo 
delineamento manual da borda endocárdica nas imagens em quatro 
cavidades e a relação ADFVD/ADFVE determinada (Figura 2). A medida do 
TAPSE foi realizada também no corte de quatro-cavidades e a distância 
percorrida pelo anel da válvula tricúspide foi medida entre a sístole e a 
diástole máximas do VD (Figura 3). O diâmetro entre as paredes anterior e 
posterior (dA-P) e entre as paredes livre e septal (dL-S) do VE foram 
medidos nas imagens em eixo curto na sístole máxima e na diástole máxima 
do VE. O índice de excentricidade (IE) do VE foi calculado: IE=dA-P/dL-S 
(Figura 4).  
 
Para o cálculo da fração de ejeção, as áreas sistólicas e diastólicas 
finais do VE e VD foram delineadas nas imagens em eixo curto, 
possibilitando a determinação dos volumes sistólico e diastólicos finais dos 
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mesmos. O software ARGUS (versão VA 50C, Siemens Medical Solucions, 
Erlangen, Germany) foi utilizado para cálculo das frações de ejeção 
ventricular.  
 
O diâmetro do tronco da artéria pulmonar foi medido e as áreas 
máximas e mínimas da artéria pulmonar (AmaxAP e AminAP, 
respectivamente) foram determinadas para o cálculo da pulsatilidade da 
artéria pulmonar (Pulsat AP=100 x (AmaxAP – AminAP) / AminAP). 
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Figura 1. Áreas diastólica e sistólica finais do ventrículo direito. 
 
 
 
 
 
 
 
 
Imagem em corte de quatro cavidades: à esquerda, a área diastólica final 
(em verde) na diástole máxima e à direita, a área sistólica final (em azul) na 
sístole máxima do VD. 
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Figura 2. Áreas diastólica finais dos ventrículos direito e esquerdo. 
 
 
 
Imagem em corte de quatro cavidades mostrando as áreas diastólica final do 
VD (em amarelo) e diastólica final do VE (em vermelho). À esquerda: 
ADFVD/ADFVE = 0,59 em paciente sem HP (PAPm = 10 mmHg). À direita: 
ADFVD/ADFVE = 2,28 em paciente com HP (PAPm = 51 mmHg). 
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Figura 3. TAPSE. 
 
 
 
Imagem em corte de quatro cavidades: à esquerda na diástole máxima e à 
direita na sístole máxima do VD. A seta em vermelho indica a distância 
percorrida pelo anel da válvula tricúspide da base em direção ao ápice 
cardíaco. 
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Figura 4. Índice de excentricidade do ventrículo esquerdo. 
                              
 
 
Imagem no corte em eixo curto na diástole máxima do VE. Em verde o 
diâmetro entre as paredes anterior e posterior (dA-P) e em vermelho o 
diâmetro entre as paredes septal e livre (dL-S) do VE. À esquerda paciente 
com HP (índice de excentricidade = 2,4 e PAPm = 53 mmHg) e a à direita 
paciente sem HP (índice de excentricidade = 0,9 e PAPm = 10 mmHg). 
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3.5. Análise estatística 
 
Os valores estão apresentados em média ± desvio padrão. Para 
comparação entre as médias utilizamos o Teste T de Student. As 
correlações foram testadas através de regressão linear, usando o método de 
média dos mínimos quadrados. Curvas ROC (Receiver Operating 
Characteristic) foram construídas para testar a capacidade da RVFAC e do 
TAPSE em detectar FEVD < 35%. O valor de p < 0,05 foi considerado 
estatisticamente significante. Para comparação das variáveis categóricas 
utilizou-se o teste do Chi-quadrado ou o teste exato de Fisher, conforme 
apropriado. As análises estatísticas foram realizadas no Software Medcalc®, 
versão 12.2.1.0 (Mariakerke, Belgium).  
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4.1. População do estudo 
  
No período de Maio de 2009 a Fevereiro de 2011, 170 pacientes 
realizaram RMC. Foram incluídos para análise 62 pacientes com diagnóstico 
final de HAP e TEPCH (Figura 5). 
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Figura 5 – Fluxograma da seleção da população incluída para análise.       
 
RMC: ressonância magnética cardíaca, PAPm: pressão da artéria pulmonar 
média, PAPo: pressão da artéria pulmonar ocluída, HP: hipertensão 
pulmonar, FEVD: fração de ejeção do ventrículo direito.      
151 
19 pacientes tinham duas RMC 
143 
8 pacientes não realizaram cateterismo cardíaco 
121 
22 pacientes apresentaram PAPm < 25 mmHg 
113 
8 pacientes não tiveram PAPo aferida 
78 
72 
107 
64 
170 
6 pacientes apresentaram PAPo > 15 mmHg 
29 pacientes não tiveram a FEVD medida 
6 pacientes com HP associada a doença pulmonar 
8 pacientes com HP de causa multifatorial/incerta 
2 RMC com  artefato respiratório 
 
 62 pacientes 
incluídos na 
análise final 
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4.2. Dados clínicos e hemodinâmicos 
 
As características clínicas e hemodinâmicas da população estão 
expostas nas tabelas 1 e 2 respectivamente. Quando dividimos a população 
conforme a classificação diagnóstica, obtivemos 23 pacientes no grupo 1 
(HAP) e 39 no grupo 4 (TEPCH).  
 
A população apresentava em média 58 anos, com maioria do sexo 
feminino e em classe funcional III pela NYHA (New York Heart Association). 
No grupo de HAP, o principal diagnóstico foi HAP idiopática com 12 casos. 
Os demais diagnósticos foram HAP associadas: à doença veno-oclusiva (2 
pacientes), ao uso de anorexígenos (1 paciente), à doença do tecido 
conectivo (2 pacientes), à comunicação interatrial (3 pacientes), à 
hipertensão portal (2 pacientes) e à anemia falciforme (1 paciente).   
 
 Quando comparamos os grupos HAP e TEPCH encontramos apenas 
diferença significativa na idade e peso. Em relação aos pacientes com HAP, 
os pacientes com TEPCH eram mais velhos e tinham peso discretamente 
maior, conseqüentemente um índice de massa corpórea também maior.  
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Tabela 1. Características clínicas da população. 
 
 
SC: superfície corpórea; IMC: índice de massa corpórea; TC6M: teste de 
caminhada de seis minutos; SvO2: saturação venosa mista; Hb: 
hemoglobina.  
 
       
 
População 
total 
n = 62 
HAP 
n = 23 
TEPCH 
n = 39 P valor 
Idade, anos 58,3 ± 17,2 47,5 ± 17,6 64,6 ± 13,5 
< 
0,001 
SC, m2 1,75 ± 0,21 1,69 ± 0,19 1,79 ± 0,21 0,062 
Peso, Kg 67,9 ± 14,6 62,7 ± 13,9 71,0 ± 14,3 0,029 
Altura, cm 166,5 ± 9,1 166,1 ± 8,2 166,9 ± 9,7 0,735 
IMC 24,3 ± 4,2 22,7 ± 4,6 25,3 ± 3,7 0,015 
Sexo 34 F / 28 M 13 F / 10 M 21 F / 18 M 0,30 
Classe 
funcional 
I e II / III e IV 
11 / 51 6 / 17 5 / 34 1,0 
TC6M, m (n=59) 379,4 ± 113,4 
365,8 ± 
114,3 
387,5 ± 
113,6 
0,48 
SvO2 , % (n=57) 62,0 ± 8,9 63,6 ± 9,6 61,2 ± 8,6 0,336 
Hb, mg/dL 14,6 ± 1,7 14,4 ± 1,7 14,8 ± 1,7 0,352 
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Em relação às medidas hemodinâmicas houve diferença significativa 
entre os dois grupos diagnósticos. A pressão de pulso da artéria pulmonar 
foi maior e conseqüentemente a complacência vascular pulmonar foi menor 
no grupo TEPCH quando comparado com o grupo HAP (Tabela 2). 
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Tabela 2. Características hemodinâmicas da população. 
 
 População Total n = 62 
HAP 
n = 23 
TEPCH 
n = 39 P valor 
FC, bpm 80,8 ± 12,6 83,7 ± 14,4 79,2 ± 11,3 0,191 
PAD, mmHg 6,39 ± 4,6 6,17 ± 4,14 6,52 ± 4,91 0,775 
PAPm, mmHg 46,7 ± 12,3 47,6 ± 15,3 46,2 ± 10,3 0,683 
PAPo, mmHg 7,4 ± 3,1 7,1 ± 2,9 7,6 ± 3,2 0,565 
DC, L/min 4,76 ± 1,48 4,89 ± 1,79 4,67 ± 1,22 0,575 
IC, L/min/m2 2,70 ± 0,74 2,89 ± 0,95 2,59 ± 0,58 0,132 
RVP, UW 9,2 ± 4,2 9,3 ± 4,6 9,1 ± 4,0 0,832 
VS, mL 60,4 ± 19,9 60,1 ± 20,9 60,5 ± 19,5 0,939 
PP, mmHg 52,2 ± 15,1 44,8 ± 12,7 56,6 ± 14,8 0,002 
CVP, ml/mmHg 1,29 ± 0,63 1,56 ± 0,75 1,16 ± 0,51 0,016 
 
FC: freqüência cardíaca; PAD: pressão de átrio direito; PAPm: pressão da 
artéria pulmonar média; PAPo: pressão da artéria pulmonar ocluída; DC: 
débito cardíaco; IC: índice cardíaco; RVP: resistência vascular pulmonar; 
VS: volume sistólico; PP: pressão de pulso; CVP: complacência vascular 
pulmonar.
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4.3. Dados da ressonância cardíaca 
  
Em relação às medidas realizadas pela RMC, houve diferença apenas 
na área diastólica final do VD; o grupo HAP apresentou VD mais dilatado do 
que o grupo de TEP crônico (Tabela 3). 
 
A freqüência cardíaca medida durante a realização do cateterismo 
cardíaco direito e durante a RMC não apresentou variação significativa. 
(80,7 ± 12,7 e 81,5 ± 13,6 respectivamente, p = 0,722). 
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Tabela 3. Dados da ressonância magnética cardíaca. 
 
FEVE: fração de ejeção do ventrículo esquerdo; Tronco AP: tronco da artéria 
pulmonar; Pulsat AP: pulsatilidade da artéria pulmonar; FEVD: fração de 
ejeção do ventrículo direito; VDFVDi: volume diastólico final indexado do 
ventrículo direito; VSFVDi: volume sistólico final indexado do ventrículo 
direito; VSVDi: volume sistólico indexado do ventrículo direito; ADFVDi: área 
diastólica final indexada do ventrículo direito; ASFVDi: área sistólica final 
indexada do ventrículo direito; ADFVEi: área diastólica final do ventrículo 
esquerdo; TAPSE: Tricuspid Annular Plane Systolic Excursion; RVFAC: 
Right Ventricular Fractional Area Change. 
 População total n = 62 
HAP 
n = 23 
TEPCH 
n = 39 P valor 
FEVE, % 61,6 ± 13,3 57,9 ± 16,9 63,6 ± 10,5 0,110 
Tronco AP, mm 33,8 ± 4,8 34,6 ± 5,3 33,4 ± 4,5 0,375 
Pulsat AP, % 17,5 ± 12,8 17,9 ± 12,8 17,3 ± 12,9 0,875 
FEVD, % 30,6 ± 13,8 30,6 ± 15,5 30,6 ± 12,9 0,991 
VDFVDi, mL/m2 109,8 ± 37,1 116,4 ± 38,7 105,9 ± 36,0 0,282 
VSFVDi, mL/m2 78,7 ± 35,9 83,6 ± 39,8 75,8 ± 33,8 0,414 
VSVDi, mL/m2 31,1 ± 14,4 32,8 ± 16,0 30,1 ± 13,4 0,466 
ADFVDi, cm2/m2 18,8 ± 4,6 20,5 ± 5,1 17,8 ± 4,1 0,026 
ASFVDi, cm2/m2 14,2 ± 4,8 15,4 ± 5,5 13,5 ± 4,2 0,133 
ASFVEi, cm2/m2 15,0 ± 3,3 15,3 ± 3,4 14,9 ± 3,2 0,642 
TAPSE, mm 13,7 ± 4,6 14,4 ± 5,2 13,2 ± 4,3 0,359 
RVFAC, % 25,7 ± 11,4 26,3 ± 12,8 25,3 ± 10,7 0,749 
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4.4. Correlações da FEVD com as variáveis hemodinâmicas 
 
A FEVD apresentou correlação fraca tanto com as medidas 
hemodinâmicas que refletem o aumento da pós-carga do VD (PAPm, RVP, 
pressão de átrio direito e complacência vascular pulmonar) como com as 
medidas de função do VD (DC e volume sistólico) (Figura 6). 
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Figura 6. Correlações da FEVD com as variáveis hemodinâmicas. 
  
 
PAPm: pressão da artéria pulmonar média; RVP: resitência vascular 
pulmonar; PAD: pressão de átrio direito; CVP: complacência vascular 
pulmonar; DC: débito cardíaco; Vol Sistólico: volume sistólico; FEVD: fração 
de ejeção do ventrículo direito.  
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4.5. Correlações da FEVD com os volume do ventrículo direito 
 
A FEVD apresentou correlação mais forte com a medida do volume 
sistólico final do que com a medida do volume diastólico final do VD (Figura 
7). 
 
Figura 7. Correlações da FEVD com os volumes do ventrículo direito. 
 
 
VDFVD ind: volume diastólico final indexado do ventrículo direito; VSFVD 
ind: volume sistólico indexado final do ventrículo direito; FEVD: fração de 
ejeção do ventrículo direito. 
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4.6. Correlações entre as áreas e os volumes do ventrículo direito 
 
Apesar das medidas das áreas diastólica e sistólica finais serem 
medidas bidimensionais, elas apresentaram uma forte correlação com as 
medidas dos volumes diastólico e sistólico finais do VD (Figura 8). 
 
Figura 8. Correlações entre as áreas e os volumes do ventrículo direito. 
 
 
 
ADFVD ind: área diastólica final indexada do ventrículo direito; VDFVD ind: 
volume diastólico final indexado do ventrículo direito; ASFVD ind: área 
sistólica final indexada do ventrículo direito; VSFVD ind: volume sistólico final 
indexado do ventrículo direito. 
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4.7. Correlações entre FEVD , RVFAC e TAPSE                                               
 
Quando analisamos a população total, a FEVD apresentou 
associação mais forte com a RVFAC (R2 = 0,65, p < 0,001) do que com o 
TAPSE (R2 = 0,35, p < 0,001) (Figura 9). 
 
Figura 9. Correlações entre FEVD, RVFAC e TAPSE. 
 
 
 
TAPSE: Tricuspid Annular Plane Systolic Excursion; RVFAC: Right 
Ventricular Fractional Area Change; FEVD: fração de ejeção do ventrículo 
direito. 
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4.8. Dados da ressonância cardíaca nos grupos com menor e maior 
gravidade hemodinâmica 
 
Para avaliar o comportamento da função ventricular direita em relação 
à gravidade hemodinâmica, dividimos a população pela mediana da 
resistência vascular pulmonar (8,5 UW) (Tabela 4). 
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Tabela 4. Comparação dos dados da ressonância magnética cardíaca entre 
o grupo com menor e maior gravidade hemodinâmica. 
 
 População total 
RVP < 8,5 
n = 21 
RVP > 8,5 
n = 25 P valor 
FEVE, % 61,6 ± 13,3 64,1 ± 11,7 58,9 ± 14,5 0,131 
Tronco da AP, mm 33,8 ± 4,8 33,6 ± 5,0 34,1 ± 4,6 0,734 
Pulsat AP, % 17,5 ± 12,8 24,2 ± 12,2 10,9 ± 9,5  < 0,001 
FEVD, % 30,6 ± 13,8 37,0 ± 13,9 24,2 ± 10,2 < 0,001 
VDFVDi, mL/m2 109,8 ± 37,1 103,7 ± 43,0 115,8 ± 29,9 0,205 
VSFVDi, mL/m2 78,7 ± 35,9 68,6 ± 39,1 88,7 ± 29,8 0,414 
VSVDi, mL/m2 31,1 ± 14,4 35,2 ± 14,4 20,8 ± 9,3 0,001 
TAPSE, mm 13,7 ± 4,6 15,5 ± 4,8 11,8 ± 3,7 0,001 
RVFAC, % 25,7 ± 11,4 30,6 ± 11,3 20,8 ± 9,3 < 0,001 
 
FEVE: fração de ejeção do ventrículo esquerdo; Tronco AP: tronco da artéria 
pulmonar; Pulsat AP: pulsatilidade da artéria pulmonar; FEVD: fração de 
ejeção do ventrículo direito; VDFVDi: volume diastólico final indexado do 
ventrículo direito; VSFVDi: volume sistólico final indexado do ventrículo 
direito; VSVDi: volume sistólico indexado do ventrículo direito; TAPSE: 
Tricuspid Annular Plane Systolic Excursion; RVFAC: Right Ventricular 
Fractional Area Change. 
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4.9. Correlações entre a FEVD, RVFAC e TAPSE nos grupos com menor 
e maior gravidade hemodinâmica 
 
A RVFAC se relaciona melhor com a FEVD do que o TAPSE nos dois 
grupos (menor e maior gravidade hemodinâmica). No grupo com maior 
gravidade hemodinâmica essa diferença se acentuou, a RVFAC mostrou 
correlação mais de três vezes maior com a FEVD do que o TAPSE (Figura 
10). 
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Figura 10. Correlações entre FEVD, TAPSE e RVFAC nos grupos 
com menor e maior gravidade hemodinâmica. 
 
 
 
 
 
A e B: grupo com menor gravidade hemodinâmica (RVP < 8,5 UW); C e D: 
grupo com maior gravidade hemodinâmica (RVP > 8,5 UW). RVP: 
resistência vascular pulmonar, TAPSE: Tricuspid Annular Plane Systolic 
excursion; RVFAC: Right Ventricular Fractional Area Change; FEVD: fração 
de ejeção do ventrículo direito. 
A B 
C D 
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4.10. Medidas de interdependênca ventricular nos grupos com menor e 
maior gravidade hemodinâmica  
 
Em um subgrupo de 46 pacientes, medidas de interdependência 
ventricular foram analisadas. A relação entre as áreas diastólica finais do VD 
e VE (ADFVD/ADFVE) esteve significativamente aumentada no grupo com 
maior gravidade hemodinâmica. Os índices de excentricidade do VE na 
sístole e na diástole foram significativamente maiores também no grupo com 
maior gravidade hemodinâmica (Tabela 5). 
 
Tabela 5. Medidas de interdependência ventricular nos grupos com maior e 
menor gravidade hemodinâmica. 
 
 n = 46 
RVP < 8,5 
n = 21 
RVP > 8,5 
n = 25 
P valor 
ADFVD, mm2 32,2 ± 7,2 31,1 ± 7,4 33,1 ± 7,1 0,352 
ADFVE, mm2 25,5 ± 5,9 29,1 ± 4,8 22,5 ± 5,1 0,001 
ADFVD/ADFVE 1,32 ± 0,41 1,09 ± 0,32 1,52 ± 0,38 0,001 
IE diástole 1,37 ± 0,25 1,23 ± 0,14 1,49 ± 0,26 < 0,001 
IE sístole 1,39 ± 0,33 1,23 ± 0,19 1,54 ± 0,36 0,001 
   
ADFVD: área diastólica final do ventrículo direito; ADFVE: área diastólica 
final do ventrículo esquerdo; IE: índice de excentricidade do VE.  
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4.11. Comparação entre as curvas ROC para a capacidade da RVFAC e 
do TAPSE em diagnosticar disfunção grave de ventrículo direito 
 
A comparação entre a capacidade desses dois índices em prever 
disfunção grave de VD (FEVD < 35%) através da comparação de curvas 
ROC mostrou que a RVFAC tem melhor performance. (TAPSE: AUC 0,73 e 
RVFAC: AUC 0,93, p = 0,0065) (Figura 11). 
 
Figura 11. Comparação das curvas ROC para a capacidade da RVFAC e do 
TAPSE em diagnosticar disfunção grave do VD. 
 
TAPSE: Tricuspid Annular Plane systolic excursion; RVFAC: Right 
Ventricular Fractional Area Change; FEVD: fração de ejeção do ventrículo 
direito. 
Ο RVFAC 
∆ TAPSE 
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4.12. Correlações entre FEVD, RVFAC e TAPSE em HAP e TEPCH 
 
Analisamos as relações do TAPSE e RVFAC com a FEVD em cada 
um dos grupos diagnósticos (HAP e TEP crônico) separadamente.  
 
No grupo com HAP, a correlação da FEVD com a RVFAC (R2 = 0,80, 
p < 0,001) também foi melhores do que com o TAPSE (R2 = 0,37, p=0,002) e 
no grupo com TEP crônico, os resultados se mantiveram semelhantes 
(TAPSE R2 = 0,34 e RVFAC R2 = 0,54, com p<0,001 para as duas medidas). 
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 Nosso estudo mostrou que a RVFAC é um bom índice para estimar a 
FEVD em pacientes com HP. Nos pacientes com maior gravidade 
hemodinâmica, a RVFAC se correlacionou ainda melhor com a FEVD do que 
o TAPSE e esse achado parece ser relacionado à inclusão do componente 
transversal da contração ventricular na sua medida. A performance da 
RVFAC foi similar nos dois grupos de HP estudados: HAP e TEPCH.  
 
 Com o objetivo de entender melhor as determinantes da FEVD, 
analisamos as correlações da FEVD com as diferentes variáveis 
hemodinâmicas. Observamos que a FEVD apresentou associação apenas 
fraca, tanto com as determinantes de pós-carga (PAPm, RVP, pressão de 
átrio direito e complacência vascular pulmonar) como com as medidas de 
função (volume sistólico e débito cardíaco) do VD. Outro dado interessante 
foi que a FEVD apresentou associação mais forte com o volume sistólico 
final que com o volume diastólico final do VD. Esses achados mostram que 
não é apenas a sobrecarga do VD que determina a FEVD; o componente de 
contração miocárdica tem também papel importante na sua determinação34. 
Em outro estudo preliminar, nosso grupo havia mostrado que esses índices 
clássicos da pós-carga ventricular direita explicavam menos de 40% da 
variabilidade da FEVD35. Desta forma, a FEVD reflete além da sobrecarga 
ventricular, a forma como o VD responde à sobrecarga imposta pela HP, ou 
seja, a forma como ele remodela.  
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Dada a importância do componente miocárdico na determinação da 
FEVD, a melhor compreensão do remodelamento ventricular se faz 
necessária36. Além do estímulo pela sobrecarga volumétrica e de pressão, 
substâncias como a noradrenalina, a endotelina e a angiotensina (que estão 
envolvidas na fisiopatologia da HP) estimulam a hipertrofia miocárdica e 
interferem na apoptose celular. Na hipertrofia, os miócitos apresentam 
alterações no aparato de contração ventricular (mudança no padrão das 
proteínas contráteis), na eficiência energética (redução na síntese de 
adenosina e na absorção de glicose) e aumento do colágeno extracelular37. 
Existe assim, um comprometimento miocárdico independente do 
comprometimento vascular na HP. O fato de a FEVD incluir esse 
comprometimento miocárdico na sua determinação corrobora com o achado 
dela ser um fator prognóstico na HP independente do comprometimento 
hemodinâmico38. Os achados do nosso estudo reforçam o papel do 
comprometimento miocárdico na determinação da FEVD e reforçam o 
achado da FEVD como fator independente do acometimento hemodinâmico, 
como demonstrado por van de Veerdonk M et al.15. O reconhecimento do 
comprometimento miocárdico se torna importante na HP para que novas 
modalidades terapêuticas sejam testadas, já que os tratamentos específicos 
para HP visam apenas a ação nos vasos pulmonares39. Estudos com beta-
bloqueadores, espirinolactona e inibidores da enzima conversora de 
angiotensina vêm sendo realizados em pacientes com HP40-43 e talvez o 
tratamento direcionado ao acometimento cardíaco possa trazer novas 
perspectivas, já que o remodelamento miocárdico pode ser reversível com o 
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tratamento. Reesink et al.44 mostraram que os pacientes com TEPCH 
apresentam redução significativa da massa muscular do VD e do 
abaulamento septal após tromboendarterectomia. 
 
A necessidade de um índice para se estimar a FEVD existe porque o 
seu cálculo é trabalhoso e demorado devido à complexidade anatômica do 
VD45. O TAPSE e a RVFAC são índices classicamente usados na 
ecocardiografia para estimar a função ventricular direita33. Em indivíduos 
livres de sobrecarga do VD, o TAPSE apresenta boa correlação com a 
FEVD o que se justifica pelos achados que o principal componente da 
contração ventricular direita é o encurtamento longitudinal46. Em pacientes 
com HP, o aumento da pós-carga leva à dilatação importante do VD e 
estudos têm mostrado que o componente transversal ganha importância 
nesses casos e que a RVFAC seria um melhor índice da FEVD nesses 
pacientes16,33. Nosso estudo confirma os achados da Mauritz et al.16 e Kind 
et al.30 ao mostrar uma melhor correlação da RVFAC com a FEVD e uma 
melhor capacidade da mesma em diagnosticar disfunção grave do VD do 
que o TAPSE, potencialmente por englobar o componente transversal que 
se torna mais importante na medida em que a disfunção de VD progride.  
 
Para demonstrar isso, optamos por avaliar esses dois índices em 
grupos com diferente gravidade hemodinâmica. Dividimos a população do 
estudo pela mediana da RVP. O grupo com RVP > 8,5 UW apresentou 
FEVD, pulsatilidade da artéria pulmonar e volume sistólico significativamente 
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menores do que o grupo com RVP < 8,5 UW. Esses índices são marcadores 
já estabelecidos de gravidade da HP, confirmando que o grupo com RVP > 
8,5 UW engloba os pacientes mais graves47-49. No grupo com maior 
gravidade hemodinâmica, a associação da RVFAC com a FEVD foi três 
vezes mais forte do que a associação do TAPSE com a FEVD, enquanto no 
grupo com menor gravidade hemodinâmica essa diferença foi apenas duas 
vezes mais forte. Esse achado mostra que em pacientes com maior 
sobrecarga do VD a avaliação da função ventricular direita apenas pelo 
encurtamento longitudinal é insuficiente. Reforçando que o movimento 
transversal ganha importância quando existe aumento da sobrecarga 
ventricular direita. A RVFAC parece ser melhor do que o TAPSE porque ela 
é uma medida bidimensional enquanto o TAPSE é apenas uma medida 
unidimensional. A RVFAC engloba tanto o componente longitudinal quanto 
transversal da contração ventricular e o TAPSE reflete apenas o 
encurtamento longitudinal.  
 
Um achado interessante do nosso estudo foi a forte correlação das 
medidas de área com as medidas de volume, apesar da medida de área ser 
bidimensional apenas e a medida volumétrica ser tridimensional. Esses 
achados justificam o fato da RVFAC apresentar boa correlação com a FEVD.  
 
 A RVFAC medida pela RMC mostrou que é um índice melhor do o 
TAPSE para estimar disfunção grave do VD. A comparação das curvas ROC 
para diagnóstico de FEVD menor do que 35% mostrou performance 
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bastante superior da RVFAC em relação ao TAPSE (TAPSE: AUC 0,73 e 
RVFAC: AUC 0,93, p = 0,0065). Esse achado foi semelhante aos achados 
dos estudos de Mauritz et al.16 e Kind et al.30, reforçando que em pacientes 
com HP a RVFAC é melhor índice da função ventricular direita do que o 
TAPSE quando medida pela RMC. 
 
 O nosso estudo acrescentou uma nova informação ao avaliar esses 
índices nos dois grupos de HP (HAP e TEP crônico) separadamente. 
Quando comparamos as relações de RVFAC e TAPSE com a FEVD nos 
dois grupos observamos que as relações se mantêm semelhantes às 
relações encontradas na população total do estudo. Esse dado mostra que a 
RVFAC é um melhor índice do que o TAPSE independente da causa da HP. 
A análise preliminar do nosso estudo, com 23 pacientes em cada grupo 
diagnóstico, já havia demonstrado não havia diferença significativa nos 
dados da RMC entre esses dois grupos de HP50. Nosso resultado final só 
reforça que não há diferença nos dados de RMC entre os grupos de HAP e 
TEPCH.  
 
 Por considerar o componente transversal, a RVFAC inclui o 
movimento septal, que tem importância fundamental na avaliação da função 
ventricular direita. Mauritz et al.16 mostraram que os pacientes com 
sobrevida menor do que cinco anos evoluíam, no primeiro ano de 
seguimento, com importante redução no movimento transversal. O 
interessante foi que ao analisar os componentes do movimento transversal, 
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a movimentação da parede livre não apresentou diferença significativa. A 
redução no encurtamento transversal se dava pela redução da 
movimentação do septo em direção a parede livre do VD, ou seja, o 
abaulamento do septo em direção ao VE. O septo parece ser a região 
cardíaca que está sujeita a maior estresse mecânico quando ocorre aumento 
da pós-carga. Estudos mostraram que os pontos de inserção do VD no septo 
e a parede septal são os pontos em que existem sinais de fibrose miocárdica 
nos pacientes com HP, por apresentaram realce tardio na RMC51,52. Nessas 
regiões também foram descritas áreas de fibrose em estudos 
anatomopatológicos53 e, em estudos experimentais, estas são as áreas que 
são submetidas a estresse máximo numa contração ventricular normal e 
também são estas áreas as primeiras a produzir peptídeo natriurético do tipo 
A em modelos de HP10. Estudos experimentais em cães já haviam 
demonstrado a interferência do abaulamento septal na função ventricular54. 
Dong et al.55 estudaram o gradiente transseptal (diferença entre a pressão 
do VE e a pressão do VD) e o diâmetro entre o septo e a parede livre do VE 
pela monitorização com ecocardiografia, em cães submetidos a 
garroteamento da artéria pulmonar. Eles mostraram que conforme o 
gradiente transseptal diminuía, o diâmetro do VE reduzia linearmente, 
mostrando que existia relação direta entre o gradiente transseptal e posição 
do septo. Esse estudo avaliou ainda a orientação da contração septal 
usando cristais microtransdutores ultrassônicos e mostrou que o 
abaulamento septal estava associado ao comprometimento da contração do 
mesmo. A mudança na posição do septo e conseqüente mudança na 
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orientação das fibras miocárdicas septais parece comprometer a contração 
septal. Outros estudos realizados também em cães compararam a pressão 
gerada pelo VD antes e após a inativação do septo (por eletrocoagulação 
septal56 ou ligadura da artéria septal57). A inativação septal levou à redução 
significativa na pressão gerada pelo VD56. O volume sistólico do VD 
permanecia inalterado apesar da inativação do septo em condições normais 
de pós-carga do VD, mas em condições de aumento do volume do VD o 
volume sistólico apresentou redução significativa57. Estes achados sugerem 
que o VD consegue manter sua função apesar da inativação do septo se não 
existe sobrecarga do VD, mas em situações de sobrecarga a contração 
septal se torna fundamental para a função ventricular direita. 
 
 O comprometimento da função septal associado ao seu abaulamento 
pode ser um dos motivos pelo qual o encurtamento no eixo longitudinal se 
torna proporcionalmente menos importante em pacientes com sobrecarga 
ventricular direita. A orientação anatômica principal das fibras miocárdicas 
do VD é transversal, assim como a contração da parede livre do VD tem 
também como principal componente a contração no sentido transversal. 
Porém, ao analisar a contração global do VD, a resultante final é o 
encurtamento no eixo longitudinal. O encurtamento no eixo longitudinal está 
associado à presença de feixes de fibra miocárdicas, que tem orientação 
longitudinal no infundíbulo do VD, e também à contração septal. O septo tem 
sua contração principalmente em espiral como o VE com a resultante de 
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contração no sentido longitudinal6. O abaulamento septal e sua conseqüente 
disfunção comprometeriam a contração ventricular direita58.   
 
Em pacientes com HP, estudos mostraram que esses pacientes 
apresentam abaulamento septal levando a redução significativa das medidas 
do diâmetro entre parede septal e a parede livre do VE59-61. Nosso grupo já 
havia demonstrado que a medida o ângulo entre a parede septal e a parede 
livre do VE, que reflete o abaulamento septal, apresentava correlação 
significativa com a PAPm e RVP62. Quanto maior a PAPm e a RVP menor o 
angulo, ou seja, maior a compressão do VE. Nós demonstramos também, 
que a RVP esteve mais fortemente associada à redução da área diastólica 
final do VE do que ao aumento da área diastólica final do VD. Nesse estudo 
mostramos ainda a forte correlação da relação ADFVD/ADFVE com a 
RVP63. Quanto maior era a RVP maior a relação ADFVD/ADFVE, refletindo 
mais uma vez a dilatação do VD e compressão do VE. Marcus et al.63 
mostraram também que o abaulamento septal está relacionado à redução 
significativa do volume diastólico do VE e à disfunção diastólica do mesmo.  
 
Nosso estudo, portanto, reforça o papel do comprometimento septal 
para a avaliação do VD. As medidas que refletem interação interventricular 
foram comparadas entre o grupo com maior e menor gravidade 
hemodinâmica. No grupo com maior gravidade hemodinâmica, a relação 
entre as áreas diastólicas finais do VD e VE foi maior, refletindo dilatação do 
VD e compressão do VE. Os dados mostram ainda que essa relação 
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aumentou às custas da compressão do VE, já que não houve diferença 
significativa entre os grupos com relação à área diastólica final do VD e 
tendo sido a área diastólica final do VE significativamente menor no grupo 
com maior gravidade hemodinâmica. A análise das medidas do VE com o 
índice de excentricidade do VE confirma esse achado. O índice de 
excentricidade esteve significativamente aumentado no grupo com maior 
gravidade. Isso significa que no grupo com maior gravidade o septo esteve 
mais deslocado, comprimindo o VE.  
 
 Nosso estudo apresenta limitações que precisam ser mencionadas. O 
estudo foi conduzido em centro único, o que pode trazer um viés de seleção 
da população estudada. Porém o Hospital Antoine Béclère é o centro 
nacional francês de referência para o tratamento de HP, assim sendo, este 
centro recebe pacientes de todas as regiões da França, tornando a 
população bastante representativa dessa doença neste país. O cateterismo 
cardíaco direito e a ressonância magnética cardíaca não foram realizados ao 
mesmo tempo por questões técnicas. Entretanto, os dois exames foram 
realizados no máximo com três dias de diferença e sem mudanças no 
tratamento nesse período. Nós mostramos que a freqüência cardiaca 
medida durante a realização do cateterismo não apresentou diferença 
significativa em relação à freqüência cardíaca medida durante a realização 
da RMC, reforçando que os pacientes estavam em condições basais 
semelhantes durante a realização dos dois exames. Outra limitação é que 
incluímos apenas pacientes com HAP e TEP crônico, excluindo da análise 
 
 
63 
uma proporção significativa de pacientes com HP associada a outras 
condições, não sendo possível, portanto, extrapolar nossos achados para 
todos os pacientes com HP. Uma limitação importante do estudo é que não 
foi medida a massa ventricular direita. A medida da massa miocárdica 
depende do contorno das bordas endocárdica e epicárdica do ventrículo. 
Como VD tem a parede fina e muito trabeculada este processo se torna 
complexo e demorado e por isso optamos por não mensurá-la.  
 
 Apesar das limitações, acreditamos que estudamos uma população 
homogênea e representativa de pacientes com HP. Mostramos que a 
RVFAC é um bom índice de avaliação da função ventricular direita e que ela 
teve melhor capacidade para estimar a disfunção grave do VD do que o 
TAPSE medido pela RMC. Conseguimos demonstrar ainda que está medida 
tem melhor capacidade para avaliar a função ventricular em pacientes com 
maior gravidade hemodinâmica e que pode ser utilizada para pacientes com 
HAP e TEP crônico. 
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CONCLUSÃO 
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A RVFAC se correlacionou melhor com a FEVD do que o TAPSE 
tanto no grupo com menor como no grupo com maior gravidade 
hemodinâmica, porém de forma ainda mais significativa em pacientes com 
maior gravidade hemodinâmica, não havendo diferenças na performance da 
RVFAC entre os pacientes com HAP e TEPCH. 
 
A RVFAC se correlacionou melhor com a FEVD do que o TAPSE na 
população total do estudo. De forma análoga, a capacidade da RVFAC para 
diagnosticar disfunção grave do VD (FEVD < 35%) também foi maior que a 
do TAPSE. A RVFAC foi um melhor índice da FEVD talvez por incluir o 
movimento transversal da contração ventricular. 
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Figure 1. Surfaces télédiastoliques des ventricules droit (rouge) et gauche (jaune) en 
coupe 4 cavités.
 À gauche : patient sans HTAP (PAPm à 21 mmHg) avec un rapport STDVD/STDVG à 0,66.
 À droite : patient avec HTAP (PAPm à 58 mmHg) avec un rapport STDVD/STDVG à 1,90.
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Apport de l’IRM 
dans l’hypertension artérielle 
pulmonaire précapillaire
Contribution of MRI to precapillary pulmonary arterial 
hypertension
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Le diagnostic d’hypertension artérielle pulmo-naire (HTAP) précapillaire repose sur le cathé-térisme cardiaque droit montrant une pression 
artérielle pulmonaire moyenne de repos ≥ 25 mmHg, 
associée à une pression artérielle occluse ≤ 15 mmHg. 
Dans l’HTAP, la postcharge du ventricule droit est 
chroniquement augmentée, ce qui entraîne une 
dilatation et une hypertrophie des cavités droites. 
Cela conduit à une défaillance ventriculaire droite 
progressive, responsable des signes fonctionnels d’ef-
fort et principale cause de mortalité chez les patients 
qui en sont atteints (1, 2). La valeur pronostique de 
la fonction droite dans l’HTAP justifie son évaluation 
systématique et son suivi régulier sous traitement. La 
morphologie complexe du ventricule droit (forme en 
croissant, trabéculations) et sa position rétrosternale 
rendent difficile son exploration par les techniques 
classiques comme l’échocardiographie.
Pour de multiples raisons, l’imagerie par résonance 
magnétique (IRM) cardiaque (MRI, ou CMRI pour 
Cardiac Magnetic Resonance Imaging) s’est imposée 
ces dernières années comme la technique de réfé-
rence pour l’évaluation non invasive morphologique 
et fonctionnelle du cœur (3-6) : fenêtre d’explo-
ration optimale en raison de l’excellent contraste 
entre la graisse médiastinale, le myocarde et le sang 
contenu dans les cavités cardiaques ; bonne visua-
lisation du cœur dans les 3 plans de coupe usuels ; 
très bonne reproductibilité inter- et intraobserva-
teur ; caractère non irradiant de la technique. L’IRM 
est réalisée avec gating cardiaque et nécessite des 
apnées courtes (environ 20 secondes), bien tolérées 
par le patient.
Les séquences ciné-IRM dans les 3 plans du 
ventricule droit (petit axe, 4 cavités, long axe) 
permettent l’étude morphologique (volume et 
masse) et fonctionnelle (fraction d’éjection) du 
ventricule droit (VD). Les séquences en contraste 
de phase (sans injection) centrées sur l’artère pulmo-
naire (AP) permettent l’étude des flux.
L’injection de gadolinium est parfois réalisée pour 
étudier le rehaussement tardif du myocarde − qui 
visualise les zones avec œdème ou fibrose − et pour 
opacifier les artères pulmonaires lorsqu'on recherche 
du matériel endoluminal chez les patients suspects 
d’emboles.
Les recommandations internationales font à ce jour 
une place très modeste à l’IRM dans l’HTAP (1, 2), 
mais cette technique nous semble particulière-
ment utile et prometteuse dans cette pathologie. 
Les récentes données morphologiques et hémo-
dynamiques obtenues en IRM cardiaque et ayant 
fait l’objet de publications dans l’HTAP précapillaire 
seront détaillées ici.
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Points forts
 » La valeur pronostique de la fonction du ventricule droit (VD) nécessite son évaluation systématique et 
son suivi régulier sous traitement dans l’hypertension artérielle pulmonaire (HTAP).
 » L’imagerie par résonance magnétique (IRM) cardiaque s’est imposée ces dernières années comme la 
technique de référence pour l’évaluation non invasive morphologique et fonctionnelle du VD ; l’IRM est 
également prometteuse dans l’évaluation de l’hémodynamique artérielle pulmonaire.
 » Parmi les variables cardiaques reliées à la sévérité de l’HTAP et à un mauvais pronostic, citons la dimi-
nution de la fraction d’éjection ventriculaire droite (FEVD), la cinétique septale paradoxale et la diminution 
des dimensions du ventricule gauche par rapport à celles du ventricule droit. 
 » Parmi les variables artérielles pulmonaires reliées à la sévérité de l’HTAP et à un mauvais pronostic, 
citons la diminution de la compliance et de la vitesse moyenne du flux. 
Mots-clés
IRM
Hypertension 
artérielle pulmonaire
Ventricule droit
Hémodynamique
Artère pulmonaire
Highlights
 » Right ventr icular  (RV) 
function carries prognostic 
implications in patients with 
pulmonary hypertension (PH), 
and this explains why RV func-
tion must be systematically 
evaluated at baseline and 
during follow-up.
 » Cardiac Magnetic Resonance 
imaging (CMR) is nowadays 
considered as the gold standard 
technique for non-invasively 
evaluating RV morphology and 
function. Pulmonary hemody-
namics may be also successfully 
studied by CMR.   
 » The main CMR-derived 
cardiac variables related to the 
severity and prognosis of PH 
are a lowered RV ejection frac-
tion, paradoxical septal motion 
and decreased left ventricular 
dimension relative to RV. 
 » The main CMR-derived 
pulmonary artery variables 
related to the severity and 
prognosis of PH are a decreased 
compliance and decreased 
mean flow velocity.
 » CMR plays a key role in the 
non-invasive evaluation of RV 
function and pulmonary hemo-
dynamics of PH patients. It is 
likely that CMR will improve 
the rationale evaluation and 
survey of these patients in the 
near future.
Keywords
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Le ventricule droit en IRM
Les valeurs normales de volumes, masse et fraction 
d’éjection ont récemment été définies sur de larges 
populations en IRM pour le ventricule droit. Elles 
sont principalement fonction de la surface corporelle, 
de l’âge et du sexe (6).
Volume ventriculaire droit
Dans l’HTAP précapillaire, l’augmentation des pres-
sions pulmonaires est responsable d’une dilatation du 
ventricule droit, quantifiée en IRM par une augmen-
tation des volumes, de la surface ou des diamètres 
mesurés en télédiastole (figure 1). De nombreux 
travaux ont suggéré qu’un volume télédiastolique 
du ventricule droit (VTDvd) supérieur à 100 ml/m² 
témoignait d’une dilatation VD (3, 6), mais des seuils 
plus élevés ont été rapportés (5). L’anatomie complexe 
du ventricule droit (VD) contribue probablement à 
ces discordances, et cela doit inciter à la prudence 
dans l’application pratique de ces seuils. L’augmen-
tation du VTDvd est un facteur de mauvais pronostic 
en termes de survie (7). Sous traitement, la diminu-
tion du VTDvd a également été rapportée (8-10). 
Il est généralement admis qu’un volume d’éjection 
systolique diminué est de mauvais pronostic (7, 11), 
mais ce n'est pas systématique (12). La dilatation 
ventriculaire droite est également responsable d’une 
sphérisation du ventricule droit expliquant l’appari-
tion d’une insuffisance tricuspide fonctionnelle, bien 
visualisée en IRM (13).
Fonction ventriculaire droite
Elle est généralement appréciée par le calcul de la 
fraction d’éjection ventriculaire droite (FEVD) en 
coupe petit axe, en utilisant la règle de Simpson 
modifiée. Une FEVD inférieure à 45 % est considérée 
comme pathologique ; l’âge et le sexe doivent être 
pris en compte dans l’interprétation des valeurs 
de FEVD comprises entre 45 et 60 % (14). Une 
FEVD inférieure à 35 % signe une défaillance droite 
sévère, dont le rôle pronostique a été démontré dans 
l’HTAP précapillaire et semble prédominer sur celui 
de l’augmentation des résistances vasculaires pulmo-
naires (15, 16).
La fonction ventriculaire droite peut également 
être estimée à l’aide d’autres indices. Les travaux 
en échocardiographie ont popularisé la mesure de 
TAPSE (Tricuspid Annulus Plane Systolic Excursion), 
indice lié à la fonction ventriculaire droite et à la 
survie, et qui peut également être mesuré en IRM, 
avec une moindre précision (17). De même, comme 
en échocardiographie, le pourcentage de raccour-
cissement surfacique du ventricule droit mesuré en 
4 cavités, ou RVFAC (Right Ventricular Fractional Area 
Change), peut être obtenu en IRM pour apprécier la 
fonction droite, une valeur de RVFAC inférieure à 30 % 
étant associée à une FEVD inférieure à 35 % (18, 19).
Septum interventriculaire  
et volumes du ventricule gauche
Dans l’HTAP, la surcharge barométrique et volu-
métrique du ventricule droit est responsable d’un 
bombement du septum interventriculaire dans le 
ventricule gauche, entraînant une compression 
ventriculaire gauche. Le niveau de pression moyenne 
dans l’artère pulmonaire et la surcharge ventriculaire 
droite conditionnent l’importance de ce bombe-
ment (20-22). Il est possible d’apprécier ce signe 
de façon qualitative : septum plat dans les HTAP 
modérées ; bombement septal intraventriculaire 
gauche plus ou moins prononcé dans les HTAP 
sévères (figure 2). Il est aussi possible d’apprécier ce 
bombement septal de façon quantitative (“C-ratio”), 
mais les mesures sont alors plus complexes (20-22), 
et donc plus rarement utilisées. Les zones de fibrose 
myocardique peuvent être visualisées par l’étude du 
rehaussement tardif du myocarde 10 minutes après 
injection de gadolinium. Chez les patients souffrant 
d’HTAP, ces images de rehaussement tardif ont été 
retrouvées au niveau de la jonction (insertion) de la 
paroi libre du ventricule droit sur le septum inter-
ventriculaire, et cela d’autant plus que l’HTAP est 
sévère (23-25).
Toujours par analogie avec l’échocardiographie, 
l’association d’une dilatation ventriculaire droite 
et d’une diminution du volume ventriculaire gauche 
secondaire au déplacement paradoxal du septum est 
 » 5. L’IRM cardiaque devrait s’imposer à l’avenir dans l’évaluation initiale de la fonction ventriculaire 
droite et de l’hémodynamique artérielle pulmonaire dans l’HTAP ; elle pourrait également améliorer 
le suivi non invasif de ces patients. 
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Figure 2. Septum paradoxal. 
 De gauche à droite : septum en position normale, septum aplati et septum bombant 
dans le ventricule droit.
Figure 3. Repérage du plan de coupe perpendiculaire à l’axe valve/bifurcation de l’artère 
pulmonaire déterminé sur une coupe sagittale (image de gauche) et coronale oblique (image 
du milieu) en utilisant le principe de double obliquité. À noter : l’aspect parfaitement 
circulaire de l’artère pulmonaire sur la coupe obtenue ainsi (image de droite).
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quantifi able par la mesure du rapport des surfaces 
télédiastoliques ventriculaire droite/ventriculaire 
gauche en coupe 4 cavités (fi gure 1). L’augmenta-
tion de ce rapport est fortement liée à la sévérité 
de l’HTAP (26, 27).
Masse ventriculaire droite
L’épaisseur normale de la paroi libre du VD est de 2 à 
3 mm (3). Ainsi, pour des raisons techniques (résolu-
tion, contourage imprécis du fait des trabéculations), 
la quantifi cation précise et reproductible de la masse 
ventriculaire droite semble diffi cile, en particulier 
dans les HTAP modérées ou débutantes.
Comme le prédit la loi de Laplace, l’HTAP s’accom-
pagne d’une hypertrophie compensatrice de la paroi 
ventriculaire droite par un mécanisme adaptatif 
visant à normaliser la contrainte ventriculaire droite, 
principal déterminant avec la fréquence cardiaque 
des besoins myocardiques en oxygène. L’index de 
masse ventriculaire (rapport de la masse ventriculaire 
droite divisée par la somme [masse ventriculaire 
gauche + septum]) est augmenté et signifi cativement 
corrélé à la pression artérielle pulmonaire moyenne, 
mais cette relation est faible (28). L’index de masse 
ventriculaire est également lié au pronostic (7), et il 
peut diminuer sous traitement en cas de remodelage 
rapide du ventricule droit (8-10).
Autres
Classiquement, l’épanchement péricardique est un 
facteur de mauvais pronostic, mais c’est un signe 
de gravité souvent tardif (1, 2). Peu de données IRM 
sont disponibles sur la quantifi cation de la dilata-
tion de l’oreillette droite et sur son rôle pronostique 
dans l’HTAP (contrairement à l’échocardiographie). 
L’intérêt de l’évaluation IRM des dimensions et de la 
compliance des veines caves inférieure et supérieure 
a été initialement suggéré (29), mais ces éléments 
sont diffi ciles à mesurer en pratique courante de 
manière fi able et reproductible.
Les artères pulmonaires
Aspects techniques
Chez les patients souffrant d’HTAP précapillaire, 
l’analyse de l’artère pulmonaire en IRM nécessite 
un plan d’étude perpendiculaire au tronc de l’AP, à 
mi-distance de la valve pulmonaire et de la bifur-
cation de l’AP. Ce plan est perpendiculaire à l’axe 
passant par la valve et la bifurcation pulmonaires, 
axe repéré sur 2 plans orthogonaux passant par 
l’artère pulmonaire (fi gure 3). La circularité de l’AP 
est vérifi ée par l’égalité de 2 diamètres perpendicu-
laires. Deux séquences sont ensuite réalisées dans 
ce plan d’étude : une séquence ciné-IRM permet-
tant d’obtenir la surface maximale et minimale de 
l’AP durant un cycle cardiaque (pour le calcul de la 
compliance), et une séquence de fl ux en contraste 
de phase permettant d’obtenir des données hémo-
dynamiques (vitesse, fl ux, temps). Pour limiter les 
artéfacts de battement cardiaque, il a été proposé 
par certains auteurs de calculer la compliance sur 
l’AP droite, mais, dans notre expérience, les images 
obtenues dans le tronc de l’AP sont peu ou pas arté-
factées malgré la faible distance par rapport au cœur.
Surface et diamètre 
de l’artère pulmonaire
Une dilatation du tronc de l’AP est observée dans 
l’HTAP précapillaire, avec augmentation de son 
MISE AU POINT
Figure 4. Estimation de la compliance de l’artère pulmonaire par la détermination de 
la surface maximale (à gauche) et minimale (à droite) du tronc de l’artère pulmonaire 
durant un cycle cardiaque en séquence ciné-IRM. En haut : patient sans HTAP (PAPm à 
21 mmHg) avec une compliance estimée à 36 %. En bas : patient avec HTAP (PAPm à 58 
mmHg) avec une compliance estimée à 7 %.
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diamètre et de sa surface (30-32). Certains ont 
proposé de calculer le rapport entre le diamètre 
du tronc de l’AP et celui du tronc de l’aorte pour 
s’affranchir des différences interindividuelles, 
principalement liées au sexe, à la surface corpo-
relle ou à la pathologie (maladies fibrosantes, par 
exemple). Il a été montré récemment qu’un rapport 
supérieur à 1,1 avait une sensibilité de 80 % et 
une spécificité de 94 % pour identifier les patients 
avec HTAP précapillaire (33). Comme pour les 
cavités droites cependant, cette dilatation n’est 
pas proportionnelle à la sévérité de l’HTAP (obser-
vation personnelle).
Compliance de l’artère pulmonaire
Chez les patients souffrant d’HTAP précapillaire, 
la compliance de l’AP est diminuée, sa rigidité 
étant augmentée (30-32, 34-36), et ce signe 
pourrait constituer l’une des anomalies hémody-
namiques les plus précoces de l’affection (34, 37). 
La compliance artérielle peut être indirectement 
refl étée par la pulsatilité de l’AP (%), calculée comme 
suit : 100 × (surface maximale − surface minimale)/
surface minimale (30, 34, 36) [fi gure 4]. Une pulsa-
tilité de l’AP inférieure à 40 % identifi e les patients 
souffrant d’HTAP précapillaire avec une grande sensi-
bilité (93 %). Une valeur inférieure à 24 % a une 
grande spécifi cité (95 %) [34]. Une valeur inférieure à 
16 % est associée à un mauvais pronostic (36). Il est 
possible de calculer plus précisément la compliance 
de l’AP (exprimée en mm²/mmHg) en couplant les 
données de l’IRM et la pression artérielle pulmo-
naire pulsée obtenue par cathétérisme (PP = pression 
systolique − diastolique). Pour cela, on emploie la 
formule : compliance = (surface maximale − surface 
minimale)/PP (34), avec des résultats essentielle-
ment similaires à ceux de la pulsatilité.
Étude des fl ux, des vitesses 
et des temps en IRM
La vitesse maximale et la vitesse moyenne dans 
l’AP peuvent être calculées à partir de la séquence 
en contraste de phase perpendiculaire au tronc de 
l’AP (fi gure 5). Sur cette séquence, on obtient égale-
ment une courbe de fl ux moyen permettant de déter-
miner le temps d’accélération et la durée d’éjection. 
Pour les vitesses de fl ux, dans l’HTAP, on observe une 
diminution de la vitesse maximale et surtout de la 
vitesse moyenne (30, 32, 38), cette dernière étant 
plus reproductible. La vitesse moyenne, supérieure 
à 15 cm/s chez le sujet normal, est ramenée à une 
valeur comprise entre 14 et 4 cm/s selon la sévé-
rité de l’HTAP (32). Il est par ailleurs possible de 
déterminer le fl ux (débit) moyen passant par l’AP 
durant un cycle cardiaque, qui semble bien corrélé 
au débit cardiaque obtenu par cathétérisme (32, 39). 
La mesure du fl ux moyen en IRM s’affranchit des 
causes d’erreurs liées à la présence d’une insuffi sance 
tricuspide importante ou d’un shunt intracardiaque, 
contrairement aux renseignements fournis par le 
cathétérisme standard. Cet avantage pourrait être 
d’une grande utilité dans la surveillance et l’évalua-
tion du pronostic des HTAP, et il fait actuellement 
l’objet d’études. 
Les différents temps sont déterminés sur la courbe de 
fl ux. Le temps séparant le début de l’éjection du pic 
de fl ux est appelé temps d’accélération (AT [Accele-
ration Time]) [30, 34, 39] (fi gure 6). Dans l’HTAP, le 
pic de fl ux survient plus tôt à mesure que la pression 
AP moyenne augmente, et, en conséquence, l’AT 
est raccourci. Ce raccourcissement d’AT est géné-
ralement attribué au retour précoce de l’onde de 
pression réfl échie, responsable de l’interruption 
précoce du fl ux systolique (Midsystolic Notching). 
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Figure 5. Courbes de vitesse dans le tronc de l’artère pulmonaire permettant d’estimer la vitesse moyenne (Vmoy) au cours d’un cycle cardiaque (séquences 
en contraste de phase perpendiculaire au tronc de l’artère pulmonaire). À gauche : patient sans HTAP (PAPm à 21 mmHg) avec une Vmoy à 22,9 cm/s. 
À droite : patient avec HTAP (PAPm à 58 mmHg) avec une Vmoy à 5,2 cm/s.
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Flux/Temps
AT ET
Figure 6. Courbe de flux obtenue à partir de la séquence en contraste de phase perpen-
diculaire au tronc de l’artère pulmonaire permettant de déterminer le temps d’accéléra-
tion (AT) et le temps d’éjection (ET).
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Les données concernant les variations du temps 
d’éjection (Ejection Time [ET]) dans l’HTAP ne sont 
pas univoques.
Phénomènes de vortex
En cas d’HTAP sévère, on observe souvent un flux 
rétrograde (38-40) contribuant à une image évoca-
trice à type de tourbillons dans le tronc de l’AP : 
c’est le vortex (40). Cette hétérogénéité de flux peut 
être expliquée : par la baisse de compliance limi-
tant la distension radiaire de l’AP ; par la difficulté 
de progression du flux vers la distalité, du fait de 
l’obstruction anatomique ou fonctionnelle (avec 
augmentation des pressions AP moyennes et des 
résistances) ; et par le retour précoce de l’onde de 
pression réfléchie. L’augmentation du pourcentage 
du volume rétrograde (fraction de régurgitation), 
calculé à partir des courbes de vélocité (30, 35, 39), 
pourrait permettre de quantifier indirectement le 
vortex dans l’HTAP.
Sévérité de l’HTAP en IRM :  
vers une hiérarchie des critères ?
La diminution de la FEVD, l’augmentation du 
rapport des surfaces télédiastoliques ventriculaire 
droite/ventriculaire gauche en coupe 4 cavités, la 
diminution de la vitesse moyenne et la diminution 
de la compliance du tronc de l’AP représentent, 
dans notre expérience, les critères les plus liés à la 
sévérité de l’HTAP, et ce sont également les plus 
reproductibles (analyse en inter- et intraobser-
vateur).
MISE AU POINT
La Lettre du Cardiologue ̐ n° 447 - septembre 2011  |  13 
Suivi des patients en IRM
Chez les patients souffrant d’HTAP précapil-
laire et bénéficiant d’un traitement médical par 
époprostenol (8) ou bosentan (10), la distance 
parcourue lors du test de marche de 6 minutes − qui 
sert à quantifier précisément l’amélioration fonction-
nelle − est corrélée à l’augmentation de la fraction 
d’éjection VD et du volume d’éjection systolique 
VD, ainsi qu'à la diminution du VTDvd en IRM. L’IRM 
permet de visualiser une normalisation des volumes 
ventriculaires, de la masse ventriculaire droite et de 
la courbure septale (C-ratio) après thromboendar-
tériectomie chirurgicale, témoignant du caractère 
réversible des phénomènes de remodeling VD (9).
Perspectives
Elles sont nombreuses, et de nouvelles techniques 
IRM sont actuellement en développement (40-43), 
qui reposent par exemple sur l’injection de produit 
de contraste et permettent l’opacification des 
AP (recherche de thrombus) ainsi que la quantifi-
cation de la perfusion pulmonaire, dont la principale 
application sera l’HTAP postembolique.
Conclusion
La tolérance clinique à l’effort et le pronostic vital des 
patients souffrant d’une HTAP précapillaire sont très 
dépendants de la fonction VD. Des travaux IRM récents 
montrent de façon concordante que plusieurs variables 
cardiaques et artérielles pulmonaires sont liées à la 
sévérité de l’HTAP et à un mauvais pronostic (4). Parmi 
les variables cardiaques, citons la diminution de la 
FEVD, la cinétique septale paradoxale et la diminution 
des dimensions du ventricule gauche (par rapport à 
celles du ventricule droit). Pour l’artère pulmonaire, 
citons la diminution de la compliance et de la vitesse 
moyenne du flux. Les recommandations internationales 
font à ce jour une place très modeste à l’IRM, mais cette 
technique de référence, non invasive et reproductible, 
devrait s’imposer à l’avenir dans l’évaluation initiale 
et dans la surveillance des HTAP. ■
Apport de l’IRM dans l’hypertension artérielle pulmonaire précapillaire
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Screening
Patients with complaints of dyspnea on 
exertion and chest pain, with or without 
dizziness, syncope, and signs of right heart failure 
of unknown cause, should be screened for PH. 
Various tests, which present a broad spectrum 
of sensitivity and specificity, can be used for the 
initial evaluation of patients suspected of having 
PH. Chest X-rays and electrocardiography (ECG), 
for instance, are tests that have low accuracy 
for the diagnosis of PH. Nevertheless, due to 
Introduction
Since the latest pulmonary hypertension 
(PH) guidelines were published in this Journal 
in 2005, a new meeting of PH specialists was 
held in Dana Point, California, USA, in 2008, 
and various articles in the field PH have been 
published. Therefore, an update of certain 
aspects of PH diagnosis and treatment is 
necessary. In this article, we review what has 
changed in the diagnosis and treatment of PH 
in recent years.(1,2) 
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Abstract
Over the last five years, knowledge in the field of pulmonary hypertension has grown consistently and significantly. 
On the basis of various clinical studies showing the usefulness of new diagnostic tools, as well as the efficacy 
of new medications and drug combinations, new diagnostic and treatment algorithms have been developed. 
Likewise, in order to simplify the clinical management of patients, the classification of pulmonary hypertension 
has been changed in an attempt to group the various forms of pulmonary hypertension in which the diagnostic 
and therapeutic approaches are similar. The objective of this review was to discuss these modifications, based on 
the 2005 Brazilian guidelines for the management of pulmonary hypertension, emphasizing what has been added 
to the international guidelines.
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Resumo
Ao longo dos últimos cinco anos, o conhecimento na área de hipertensão pulmonar evoluiu de forma consistente e 
significativa. Novos algoritmos diagnósticos e de tratamento foram desenvolvidos com base no resultado de diversos 
estudos clínicos que evidenciaram a utilidade de novas ferramentas, assim como a eficácia de novos medicamentos 
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group of authors found that a PA diameter > 
33.2 mm has a 95% specificity for the diagnosis 
of PH (Figure 2b).(5) 
Echocardiography
Echocardiography is the principal screening 
tool for PH. However, echocardiography is a test 
that has significant limitations, such as the fact 
that it is highly examiner-dependent and that a 
significant proportion of patients present with 
a poor acoustic window. Another limitation of 
echocardiography is that the estimation of PA 
systolic pressure (PASP) depends on the tricuspid 
regurgitant jet and right atrial pressure (RAP). In 
up to 10% of cases, it is impossible to measure 
the tricuspid regurgitant jet velocity and, 
consequently, to estimate PASP. Although some 
studies have shown a significant correlation 
between echocardiography findings and RHC 
values, one group of authors recently reported 
that the RAP and PASP values estimated by 
echocardiography differ significantly from 
those measured by RHC.(6) In that study, 65 
patients referred for PH diagnosis or follow-up 
treatment underwent echocardiography and 
RHC one hour apart, meaning that the basal 
conditions of patients varied minimally. It 
was also shown that cardiac output (Qt) as 
measured by echocardiography is not useful and 
that echocardiography typically overestimates 
pressures. Therefore, PASP values as estimated 
by echocardiography should be used to screen 
for PH, rather than to diagnose it. In addition 
to PASP estimates, dilation and right ventricular 
dysfunction should be considered to constitute 
indirect signs of PH. Despite its limitations, 
echocardiography continues to be the principal 
screening tool for PH because it is a noninvasive 
and readily available test, as well as being useful 
in identifying left heart malformations and 
diseases. 
Because right ventricular function plays a 
significant role in the prognosis of patients with 
PH, it is necessary to measure right ventricular 
function appropriately. The characteristics of 
the right ventricle (RV) are quite different from 
those of the left ventricle (LV). Unlike the LV, 
which has thick, cone-shaped walls, the RV has 
thin, semilunar or crescent-shaped walls, and 
the myocardial mass of the RV is significantly 
lower and more trabecular than is that of the LV. 
The contraction pattern is also different; in the 
their broad availability and low cost, they can be 
employed in PH screening programs. 
ECG
In patients with PH, ECG can show increased P 
wave amplitude (r 2.5 mm in the DII derivation), 
signs of right ventricular hypertrophy, right 
bundle branch block, right QRS axis deviation, 
and repolarization changes (right ventricular 
strain). Although a deviation greater than 
100° has been shown to correlate well with 
hemodynamic measurements, its specificity for 
the diagnosis of PH has been shown to be low. 
Up to 13% of the patients with a diagnosis of 
PH confirmed by right heart catheterization 
(RHC) can initially present with normal ECG 
results (Figure 1).(3) 
Chest X-ray
A chest X-ray reveals hilar enlargement 
that reflects pulmonary artery (PA) dilation 
and cardiomegaly. Chest X-rays also play an 
important role in the diagnosis of other diseases, 
such as those that impair the lung parenchyma 
and can cause dyspnea (Figure 2a). 
Chest CT
Computed angiotomography of the chest 
plays a significant role in the diagnostic 
evaluation of PH. The diameter of the PA trunk 
is significantly larger in patients with PH than in 
normal individuals and correlates well with PA 
pressure measurements.(4) Studies have shown 
that the diameter of the PA ranges from 32.6 
mm to 33.2 mm in normal individuals. One 
Figure 1 - Electrocardiogram of a 24-year-old patient 
with idiopathic pulmonary arterial hypertension. Note 
signs of right ventricular hypertrophy, right QRS axis 
deviation, and repolarization.
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heart have allowed three-dimensional evaluation 
of the RV and detailed tomographic visualization 
of its morphology. Cardiac magnetic resonance 
imaging (CMRI) creates a clear distinction 
between the myocardium and intracavitary 
blood, presenting well-defined myocardial 
and endocardial borders.(8) Because the RV 
presents the aforementioned particularities 
and CMRI allows a more detailed visualization 
of the RV, CMRI is currently considered the 
gold standard for a noninvasive evaluation of 
the RV.(9,10) Studies in which CMRI was used to 
evaluate patients with PH showed that, when 
compared with control group patients, PH 
patients presented with a significant increase in 
end-systolic and end-diastolic volumes, as well as 
in right ventricular muscle mass, together with a 
significant reduction in right ventricular ejection 
fraction. Other studies have shown ventricular 
septal bowing, together with a reduction in the 
LV volume in early diastole, revealing impaired 
left ventricular function associated with right 
ventricular dysfunction.(11) One group of authors 
demonstrated that the position of the septum, 
as determined by calculating its shift toward the 
LV, was accurate in predicting right ventricular 
systolic pressure.(12) Even without the use of 
contrast enhancement, CMRI allows excellent 
visualization of the PA, and it is possible to 
assess PA compliance and flow by means of 
the phase-contrast technique. In patients with 
PH, PA compliance values are significantly 
lower.(13) One study showed that measurements 
of pulsatility (which is related to compliance) 
can also correlate with the response to the NO 
test.(14) The measurement of PA velocity and the 
time it takes to reach the maximum velocity 
RV, longitudinal contraction of the myocardial 
fibers predominates, whereas, in the LV, spiral 
movement predominates. Therefore, it does not 
seem sufficient or appropriate to evaluate right 
ventricular function with the same tools used to 
evaluate left ventricular function. 
New techniques for a better estimation of 
right ventricular function have been studied. 
The determination of tricuspid annular plane 
systolic excursion (TAPSE) has been shown 
to be a useful tool. This technique calculates 
the degree to which the pulmonary valve ring 
is shifted, in relation to the right ventricular 
apex during systole. A study comparing TAPSE 
and RHC measurements for the evaluation 
of right ventricular function showed that the 
measurements correlated well. The authors found 
that a TAPSE < 1.8 cm showed good accuracy 
in detecting right ventricular dysfunction and 
designated it a prognostic marker, because 
survival rates were lower in patients with a 
TAPSE < 1.8 cm than in those with a TAPSE r 
1.8 cm.(7) 
Other techniques for the evaluation of right 
ventricular function, such as the comparison 
between the right ventricular area at systole and 
that at diastole–designated right ventricular 
fractional area change–and the comparison 
between the right ventricular end-diastolic area 
and the left ventricular end-diastolic area, have 
been studied and might prove useful in patients 
with PH. 
Magnetic resonance imaging
Advances in the techniques for acquiring and 
processing magnetic resonance imaging of the 
Figure 2 - In a), chest X-ray of a 30-year-old patient with idiopathic pulmonary arterial hypertension showing 
hilar enlargement. In b), CT scan of the chest of a patient with pulmonary arterial hypertension showing a 
severely dilated pulmonary artery trunk (39 mm). In c), cardiac magnetic resonance imaging of a patient with 
pulmonary hypertension. Image without short-axis contrast showing the right ventricle (on the left) and the 
left ventricle (on the right). Note ventricular septal bowing leading to compression of the left ventricle.
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to perform RHC to confirm the diagnosis of 
PH should be evaluated, because a definitive 
diagnosis of PH can only be established by 
invasive pressure measurements (Figure 3). 
Since the last Brazilian consensus, there have 
been changes in the definition of PH. Before the 
meeting in Dana Point, CA, PH was defined as 
mean PA pressure (MPAP) r 25 mmHg at rest 
or r 30 mmHg during exercise, with pulmonary 
capillary pressure b 15 mmHg. The group of 
specialists who reviewed the data that had been 
published up until the time of the meeting 
concluded that the data collected during exercise 
were extremely heterogeneous regarding the 
load used, the duration of the exercise, and the 
position of the patient during exercise, factors 
that might influence PA pressure measurements. 
Due to this lack of standardization, a decision 
was made to remove exercise-induced PH from 
the definition of PH. This does not mean that 
exercise-induced PH does not exist; it only 
means that the data collected to date are not 
sufficiently robust to provide a definition of 
exercise-induced PH values. This underscores 
the importance of conducting new studies in 
this field in order to provide an appropriate 
definition of exercise-induced PH.(2) 
A review of 47 studies evaluating PA pressure 
in healthy volunteers showed that the MPAP at 
rest was 14.0 ± 3.3 mmHg. When individuals 
from different age brackets were compared, 
there was only a slight, less than significant, 
variation in the MPAP at rest.(19) Normal MPAP 
at rest was then defined as < 20 mmHg. The 
(acceleration time) are reduced in patients 
with PH, and these measurements are related 
to systolic volume as measured by RHC.(15) In 
addition, CMRI plays a role in the follow-up of 
patients with PH. Two studies used CMRI before 
treatment initiation and 6-12 months after 
treatment initiation. In one of the studies, the 
patients received epoprostenol, and in the other, 
they received bosentan.(16,17) In both studies, 
improvement in the six-minute walk test (6MWT) 
was significantly related to improvement in right 
ventricular function parameters, as determined 
by CMRI. In another study, CMRI was used before 
and after pulmonary thromboendarterectomy.
(18) The study showed a significant reduction in 
myocardial mass, right ventricular end-systolic 
volume, and right ventricular end-diastolic 
volume, as well as increased left ventricular 
volumes, reflecting the reversion of ventricular 
remodeling and septal deviation, hemodynamic 
improvement having been achieved with the 
surgical procedure (Figure 2c). 
Although CMRI is not widely available and 
its cost is still high, the role of CMRI in the 
diagnosis and follow-up of patients with PH 
is promising, because the test allows a better 
evaluation of right ventricular function, PA flow, 
and PA behavior. 
Diagnosis
If a patient suspected of having PH has been 
screened and signs consistent with increased 
pressure levels in the pulmonary circulation 
have been detected in the initial tests, the need 
Chart 1 - Hemodynamic definition of pulmonary hypertension.a 
Definition Characteristics Clinical group
PH MPAP r 25 mmHg All
Precapillary PH MPAP r 25 mmHg
PAOP b 15 mmHg
Normal or reduced Qt
1. PAH
3. PH caused by lung disease
4. CTEPH
5. PH with multifactorial mechanism, unknown 
mechanism, or both
Postcapillary PH
 
  
Passive (proportional)
Reactive (disproportional)
MPAP r 25 mmHg
PAOP > 15 mmHg
Normal or reduced Qt
TPG b 12 mmHg
TPG > 12 mmHg 
2. PH caused by left heart disease
PH: pulmonary hypertension; MPAP: mean pulmonary artery pressure; PAOP: pulmonary artery occlusion pressure; Qt: 
cardiac output; PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; and 
TPG: transpulmonary gradient. aAdapted from Badesh et al.(2)
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must be determined. The TPG is calculated 
be the difference between the MPAP and the 
PAOP. When this difference is b 12 mmHg, the 
increase in the MPAP is considered passive, 
which means that the increase in the MPAP is 
caused exclusively by cardiac involvement. If the 
TPG is > 12 mmHg, the increase in the MPAP is 
disproportionate to the increase in left ventricular 
pressure, indicating that there is pulmonary 
vascular remodeling or another associated cause 
of increased MPAP (Chart 1 and Figure 3). 
The acute test with a vasodilator should 
be performed during the initial hemodynamic 
evaluation in patients with precapillary PH. The 
test can be performed with NO, prostacyclin, or 
adenosine. The result is considered positive when 
there is a reduction in the MPAP of r 10 mmHg 
significance of a finding of pressure levels 
ranging from 20 mmHg to 25 mmHg remains 
unclear. Studies involving patients with COPD 
and pulmonary fibrosis showed that patients 
with MPAP > 17 mmHg had a worse prognosis 
than did those with MPAP < 17 mmHg and drew 
attention to the fact that MPAP < 25 mmHg 
might have clinical significance.(20) Values of 
MPAP at rest r 25 mmHg are currently used to 
establish a diagnosis of PH. 
Patients with MPAP r 25 mmHg are 
diagnosed with PH, and, after the diagnosis has 
been established, it must be determined whether 
the PH is precapillary or postcapillary. If the PA 
occlusion pressure (PAOP) is b 15 mmHg, the 
PH is classified as precapillary. If the PAOP is > 
15 mmHg, the transpulmonary gradient (TPG) 
Figure 3 - Flowchart for the diagnosis of pulmonary hypertension (PH). ECG: electrocardiography; Xr: X-ray; 
PFT: pulmonary function test; echo: echocardiogram; TT: transthoracic; PASP: pulmonary artery systolic 
pressure; MPAP: mean pulmonary artery pressure; PCP: pulmonary capillary pressure; and TPG: transpulmonary 
gradient. Adapted from Galiè et al.(27) 
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of the 2003 Venice classification–five principal 
groups and their respective subgroups–was 
maintained, pathologies have been moved from 
one group or subgroup to another. In addition, 
some new groups or subgroups have been 
created, whereas others have been eliminated. 
These changes are described below. The former 
and current classifications are compared in 
Chart 2.(23) 
The first group is still designated “pulmonary 
arterial hypertension” (PAH) and is divided into 
two subgroups: “idiopathic” and “heritable” 
(formerly “familial”). There have been no 
changes in subgroup 1.1, idiopathic PAH (IPAH), 
which still comprises the sporadic cases in which 
no risk factors for PAH are detected or in which 
and when values b 40 mmHg are observed. A 
positive acute test result predicts the clinical 
and hemodynamic response to calcium channel 
blockers.(21,22) 
After the presence of PH and its correct 
hemodynamic classification are confirmed 
by RHC, various tests should be performed in 
order to determine the specific etiology of PH. 
It should be highlighted that idiopathic PH is a 
differential diagnosis, and it is fundamental to 
follow an appropriate flowchart to facilitate the 
diagnostic investigation (Figure 4). 
Classification
There have been various changes in the clinical 
classification of PH. Although the basic structure 
Figure 4 - Flowchart for the diagnosis of the etiology of pulmonary hypertension. CTEPH: chronic 
thromboembolic pulmonary hypertension; PVOD: pulmonary veno-occlusive disease; US: ultrasound; TEE: 
transesophageal echocardiogram; CMRI: cardiac magnetic resonance imaging; and OSAS: obstructive sleep 
apnea syndrome. Adapted from Galiè et al.(27) 
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Chart 2 - Clinical classification of pulmonary hypertension established in Venice, Italy, in 2003, and the current 
classification, established in Dana Point, CA, USA, in 2008.a
Venice, 2003 Dana Point, 2008
1. Pulmonary arterial hypertension
1.1. Idiopathic
1.2. Familial
1.3. Associated with:
1.3.1. Collagen vascular diseases
1.3.2. Congenital systemic-pulmonary shunts
1.3.3. Portal hypertension
1.3.4. Infection with the human immunodeficiency virus
1.3.5. Drugs/toxins
1.3.6. Others (thyroid diseases, hereditary hemorrhagic 
telangiectasia, hemoglobinopathies, Gaucher’s disease, 
myeloproliferative disorders, and splenectomy)
1.4. Associated with significant capillary or venous 
involvement
1.4.1. Pulmonary veno-occlusive disease
1.4.2. Pulmonary capillary hemangiomatosis
1.5. Persistent pulmonary hypertension of the newborn
1. Pulmonary arterial hypertension
1.1. Idiopathic
1.2. Heritable
1.2.1. BMPR2
1.2.2. ALK-1, endoglin (with or without hereditary 
hemorrhagic telangiectasia)
1.2.3. Unknown
1.3. Drug- and toxin-induced
1.4. Associated with
1.4.1. Connective tissue diseases
1.4.2. Human immunodeficiency virus infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis
1.4.6. Chronic hemolytic anemia
1.5. Persistent pulmonary hypertension of the newborn
1’. Pulmonary veno-occlusive disease and/or pulmonary 
capillary hemangiomatosis
2. Pulmonary venous hypertension
2.1. Left ventricular or left atrial heart disease
2.2. Left valvular heart disease
2. Pulmonary hypertension owing to left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. Pulmonary hypertension associated with lung disease, 
hypoxemia, or both
3.1. COPD
3.2. Interstitial lung disease
3.3. Sleep-disordered breathing
3.4. Alveolar hypoventilation
3.5. Chronic exposure to high altitudes
3.6. Developmental abnormalities
3. Pulmonary hypertension owing to lung diseases and/or 
hypoxia
3.1. COPD
3.2. Interstitial lung disease
3.3. Other lung diseases with mixed restrictive and 
obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4. Pulmonary hypertension due to embolic disease, chronic 
thrombotic disease, or both
4.1. Thromboembolic obstruction of proximal pulmonary 
arteries
4.2. Obstruction of distal pulmonary arteries
4.3. Nonthrombotic pulmonary embolism  
(tumor, parasites, foreign body)
4. Chronic thromboembolic pulmonary hypertension
5. Miscellaneous
Sarcoidosis, histiocytosis X, lymphangioleiomyomatosis, 
compression of pulmonary vessels (adenopathy, tumor, and 
fibrosing mediastinitis)
5. Pulmonary hypertension with unclear multifactorial 
mechanisms
5.1. Hematologic disorders: myeloproliferative disorders, 
splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary 
Langerhans cell histiocytosis: lymphangioleiomyomatosis, 
neurofibromatosis, vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher 
disease, thyroid disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, 
chronic renal failure on dialysis
BMPR2: bone morphogenetic protein receptor, type 2; and ALK-1: activin receptor-like kinase-1.aAdapted from 
Simonneau et al.(23)
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demonstrated that the clinical characteristics of 
patients with schistosomiasis and PH are similar 
to those of patients with IPAH.(25) The other study 
demonstrated that 7.7% of the patients with 
hepatosplenic schistosomiasis who were being 
treated at the University of São Paulo School of 
Medicine Hospital das Clínicas, located in the city 
of São Paulo, Brazil, had PH (4.6% of whom had 
precapillary PH).(26) Given the number of patients 
worldwide, schistosomiasis might become the 
leading cause of PH. Therefore, this change in the 
classification has a significant impact on Brazil 
and on all countries in which schistosomiasis is 
endemic. Concluding the changes in group 1, 
subgroup 1’ (read “one prime”) was created. 
This subgroup comprises pulmonary veno-
occlusive disease and pulmonary capillary 
hemangiomatosis, because the histopathological 
features of these two entities have been shown 
to overlap. It is currently believed that they can 
represent different phases of the evolution of 
the same pathology. A decision was made to 
maintain the two entities in the group related 
to primarily arterial involvement, due to their 
degree of clinical response to the treatment with 
PAH-specific drugs, among other reasons. 
Group 2 is designated “[PH] owing to left 
heart disease”, in order to highlight the causal 
relationship between cardiac involvement and 
the development of PH, because this is potentially 
the most common cause of PH. This group was 
subdivided into three subgroups: 2.1–systolic 
dysfunction; 2.2–diastolic dysfunction; and 
2.3–valvular disease. 
In group 3, the term “associated with” 
was changed to “owing to”, reinforcing the 
causal importance of pulmonary involvement. 
Therefore, group 3 is now designated “[PH] 
owing to lung disease and/or hypoxia”, and its 
subgroups are as follows: COPD; interstitial lung 
disease; sleep-disordered breathing; alveolar 
hypoventilation disorders; chronic exposure to 
high altitude; developmental abnormalities; and 
a new subgroup, designated “other pulmonary 
diseases with mixed restrictive and obstructive 
pattern”. The last subgroup comprises chronic 
bronchiectasis, cystic fibrosis, and a recently 
recognized syndrome in which fibrosis 
predominates in the lung bases and emphysema 
predominates in the lung apices. The prevalence 
of PH in patients with this syndrome is nearly 
there is no family history of PAH. Subgroup 
1.2, heritable PAH, is subdivided as follows: 
1.2.1–due to mutations in bone morphogenetic 
protein receptor, type 2 (BMPR2); 1.2.2–due to 
mutations in activin receptor-like kinase-1 or 
endoglin; and 1.2.3–of unknown cause. This new 
subdivision was necessary due to the importance 
of new genes associated with PH and of the 
description of mutations in the BMPR2 gene in 
11-40% of the cases of IPAH; these cases, even 
without a family history of PAH, now characterize 
a subpopulation with hereditary disease, which 
makes the term “familial” inappropriate. 
Subgroup 1.3 is now designated “drug- and 
toxin-induced” PAH. This change resulted from 
recent studies demonstrating the role of certain 
drugs in inducing PAH without changing its 
clinical course, as demonstrated for fenfluramine.
(24) According to the new classification, subgroup 
1.4 comprises conditions associated with the 
pathogenesis of PAH. Subgroup 1.4 subdivisions 
underwent small changes, HIV infection, portal 
hypertension, and persistent PH of the newborn 
remaining as subdivisions of this subgroup. 
The subgroup formerly known as “collagen 
vascular disease” is now designated “connective 
tissue diseases”. The subgroup formerly known 
as “congenital systemic-pulmonary shunts” is 
now designated “congenital heart diseases”. The 
subgroup designated “other” was eliminated 
from the current classification, and two new 
subgroups were created: subgroup 1.4.5, which 
now comprises patients with schistosomiasis; 
and subgroup 1.4.6, which comprises chronic 
hemolytic anemia, because the association 
between these pathologies and PAH has 
been shown to be important. Patients with 
schistosomiasis used to be allocated to the 
group of embolic diseases–group 4, in the 
previous classification–because it was believed 
that the mechanism that led to PH in this 
pathology was associated with the mechanic 
obstruction of pulmonary vessels by eggs of 
the parasite. Anatomic pathology studies have 
demonstrated that the pulmonary involvement 
in schistosomiasis is similar to that found in 
IPAH, being accompanied by the development 
of plexiform lesions and hypertrophy of the 
tunica intima and tunica media, regardless 
of the obstruction by the parasite. Studies 
conducted in Brazil have also contributed to this 
change in the classification. One of these studies 
Diagnosis and treatment of pulmonary hypertension: an update
J Bras Pneumol. 2010;36(6):795-811
803
ideal type of contraception for patients with PH, 
it should be borne in mind that concomitant use 
of bosentan and oral contraceptives can reduce 
the effect of the latter. Patients in functional 
class III or IV, as well as those with hypoxemia 
(PaO2 < 60 mmHg), should use supplemental 
oxygen if flying or visiting areas at altitudes 
above 1,500-2,000 m.(27) 
Supplemental oxygen therapy is indicated 
for patients with hypoxemia (PaO2 < 60 mmHg) 
and can be considered for patients who present 
symptomatic benefit from the correction of 
hypoxemia during physical exertion. The use of 
diuretics is indicated for all patients who present 
with signs of hypervolemia.(27) 
The use of anticoagulants in patients with 
PH is controversial, because there have been no 
randomized controlled studies evaluating the 
effects of anticoagulation in these patients. The 
rationale for the indication of anticoagulation 
for these patients originates from the 
histopathological findings of microvascular 
thrombosis, activation of the coagulation system, 
and platelet dysfunction in patients with IPAH, 
which have led to the assumption that these 
patients present with a prothrombotic state. In a 
meta-analysis of the theme, conducted in 2006, 
the authors concluded that anticoagulation 
should be indicated, given that 5 of the 7 studies 
analyzed demonstrated that anticoagulation was 
beneficial. In the absence of any contraindications, 
the use of oral anticoagulants is indicated 
for patients with PH, with the objective of 
maintaining an international normalized ratio of 
1.5-2.5. Attention should be given to patients 
with liver disease and scleroderma, because 
these patients might be at a higher risk for 
bleeding; likewise, attention should be given 
to the interaction between anticoagulants and 
the PAH-specific treatment. Some studies, for 
instance, have suggested that concomitant use 
of anticoagulants and sitaxsentan can increase 
the risk of bleeding.(28) 
Group 1
Most of the studies of PH treatment were 
conducted in patients with PAH; therefore, 
PH-specific treatment is, for the time being, 
restricted to group 1 patients. However, there 
has been no confirmation that all subgroups 
of patients with PAH respond to the specific 
drugs that are currently available. In general, the 
50%, and it is therefore necessary to emphasize 
this entity in the new classification. 
Group 4, formerly known as “[PH] due 
to embolic disease, chronic thrombotic 
disease, or both”, is now designated “chronic 
thromboembolic pulmonary hypertension” 
(CTEPH). The subdivision of obstruction into 
distal obstruction and proximal obstruction 
was removed from the classification, because 
the definitions of “proximal” and “distal” are 
difficult to standardize and vary among centers, 
making a definitive classification imprecise. 
This change should result in patients diagnosed 
with PH due to CTEPH being immediately 
referred to tertiary-care centers at which there 
are professionals with experience in performing 
thromboendarterectomy, so that operability can 
be determined by a multidisciplinary team. 
Group 5 was changed from “miscellaneous” 
to “[PH] with unclear multifactorial mechanisms” 
and is now divided into four subgroups: 
“hematologic disorders”; “systemic disorders”; 
“metabolic disorders”; and a subgroup designated 
“others”, which comprises a variety of conditions 
associated with PH. 
Treatment
After the diagnosis of PH has been established 
by RHC and the disease has been clinically 
classified, PH treatment can be discussed, because 
the definition of the clinical group determines 
the treatment to be given. The general measures 
and the supportive therapy should be evaluated 
for any patient with PH; however, the largest 
amount of evidence, even regarding the general 
measures, is based on studies of patients with 
PAH, that is, group 1 patients. 
General measures and supportive therapy
All patients diagnosed with PH should receive 
some general instructions. The patients should 
be instructed not to do heavy physical exercise 
and to limit physical activity when experiencing 
mild dyspnea. They should receive influenza 
vaccination and pneumococcal vaccination 
because infection is a major cause of morbidity 
and mortality in these patients. Female patients 
of childbearing age should be instructed to 
use contraceptive methods, because pregnancy 
significantly increases mortality in patients with 
PH. Although there is no consensus regarding the 
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Epoprostenol
In an open randomized study conducted in 
1996, clinical and hemodynamic improvements, 
as well as increased survival, were described in PAH 
patients who used epoprostenol in combination 
with conventional therapy (anticoagulation, 
diuretics, and oxygen therapy), when compared 
with those who used the conventional therapy in 
isolation.(29) Although other studies have shown 
functional and hemodynamic improvements, 
the improvement in survival described in the 
aforementioned study has not been described 
elsewhere. Epoprostenol should be administered 
intravenously, through a tunneled catheter, 
and continuously, through a portable infusion 
pump, due to its short half-life. The most 
common side effects are jaw pain, flushing, 
diarrhea, nausea, and vomiting. Catheter-related 
complications, such as infection and thrombosis, 
as well as those related to the functioning of the 
equipment, have often been reported. Although 
epoprostenol is unavailable for use in Brazil, it 
is the only drug for functional class IV patients 
that has a grade of recommendation of A. 
Treprostinil
Treprostinil is a prostacyclin analogue whose 
half-life is longer than is that of epoprostenol, 
which allows treprostinil to be administered 
subcutaneously. In a randomized, placebo-
controlled study, there was improvement in 
the symptoms, as well as slight but significant 
functional and hemodynamic improvements. 
Treprostinil has the advantage of not requiring 
an indwelling catheter, which avoids catheter-
related complications. However, subcutaneous 
administration of treprostinil has been associated 
with pain at the injection site in 85% of the 
patients receiving the drug, and discontinuation 
of the drug is necessary in 8% of the cases. 
The speed at which the dose of the drug was 
increased was the principal causative factor 
for this side effect. Therefore, the dose should 
be increased slowly and progressively, and the 
site of injection should be changed every three 
days, in order to reduce this problem. The other 
side effects associated with epoprostenol can 
also occur in patients treated with treprostinil.
(30) In one study, sustained hemodynamic and 
symptomatic improvements were observed 
during a mean follow-up period of 26 months.
evidence discussed here is restricted to patients 
with IPAH, heritable PAH, drug-induced PAH, 
PAH associated with connective tissue diseases, 
or PAH associated with congenital heart 
diseases. There is also some evidence for patients 
with HIV infection. However, for patients with 
portopulmonary hypertension, schistosomiasis, 
or hemolytic anemia, it is still impossible to 
indicate the use of the same drugs, and clinical 
studies specifically designed to investigate those 
indications are needed. 
If the patient presents pulmonary 
vasoreactivity, as assessed by the acute test, 
treatment with a calcium channel blocker 
should be initiated, and, if there is a sustained 
clinical response, the drug should be maintained, 
together with supportive treatment. The survival 
rates in patients who respond to the use of 
a calcium channel blocker are significantly 
higher than in those who do not respond well 
to the drug.(22) However, the use of calcium 
channel blockers in patients who do not present 
pulmonary vasoreactivity, as assessed by the 
acute test, can lead to a reduction in Qt and 
systemic vascular resistance without a reduction 
in the MPAP or pulmonary vascular resistance 
(PVR). Therefore, the use of a calcium channel 
blocker is contraindicated for patients who do 
not present pulmonary vasoreactivity or those 
who have not undergone the acute test, due to 
the risk of clinical deterioration. The calcium 
channel blocker to be used can be nifedipine, 
diltiazem, or amlodipine. However, in patients 
with high heart rates, diltiazem is the drug 
of choice. The treatment should be initiated 
with low doses, which should be progressively 
increased in accordance with the tolerance limit 
of the patient. 
The classes of specific drugs that are approved 
for use in PAH patients, that is, in group 1 
patients, are as follows: prostacyclin analogues; 
phosphodiesterase-5 inhibitors; and endothelin 
receptor antagonists. 
Prostacyclin analogues
Prostacyclin analogues constitute the first 
class of drugs to be approved for PH-specific 
treatment. Prostacyclin analogues can be 
administered intravenously, subcutaneously, 
orally, or by inhalation. 
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antiproliferative and pro-apoptotic effects, and 
seems to have a positive inotropic effect on the 
RV.(33) Phosphodiesterase-5 inhibitors reduce 
PVR and lead to an increase in Qt, and the use 
of these drugs has been associated with clinical 
and functional improvement in patients with 
PH.(34,35) Two phosphodiesterase-5 inhibitors 
have been approved for use in patients with 
PH: sildenafil, approved in 2005; and tadalafil, 
approved in 2009. One study compared the use 
of increasing doses of sildenafil (20, 40, and 80 
mg), administered three times a day, with the use 
of placebo. The study showed a significant but 
not dose-dependent increase in the 6MWD, as 
well as a significant, dose-dependent reduction 
in PVR.(36) The benefits of tadalafil have been 
demonstrated in another study, in which 
increasing doses of the drug were also compared 
with placebo. Only the 40-mg dose correlated 
with a significant increase in the 6MWD, an 
improvement in the markers of quality of life, 
and a slight increase in the time to clinical 
worsening.(37) Phosphodiesterase inhibitors are 
relatively safe and well tolerated. Tadalafil has 
the advantage of being administered only once 
daily. The major side effects of the drugs are 
headache, nasal congestion, dyspepsia, flushing, 
muscle pain, and epistaxis. Phosphodiesterase 
inhibitors are metabolized in the liver, and the 
use of protease inhibitors, such as ritonavir and 
saquinavir, can increase their bioavailability, and 
care should therefore be taken when prescribing 
this class of drugs to HIV-infected patients. Visual 
disorders, such as blurred vision, color changes, 
and photosensitivity, have been described, 
principally in patients with diabetic neuropathy 
or anterior ischemic optic neuropathy. Dilated 
eye examination is recommended before starting 
the treatment with this type of medication.(27) 
Endothelin receptor antagonists
Endothelin-1 levels are elevated in the lung 
tissue and plasma of patients with PAH and 
scleroderma. Endothelin-1 acts by binding 
to endothelin receptors (ETA and ETB), 
promoting vasoconstriction and smooth muscle 
cell proliferation. Bosentan is a nonselective 
endothelin receptor antagonist, meaning that 
it blocks types A and B, and has been shown 
to be beneficial for patients with IPAH and for 
those with PAH associated with collagen disease, 
leading to an increase in exercise capacity and 
(27) Treprostinil is also currently unavailable for 
use in Brazil. The administration of the drug 
through inhalation and continuous intravenous 
administration is currently being evaluated. 
Iloprost
Iloprost is the prostacyclin analogue that 
is administered through inhalation. This route 
of administration has the advantage of acting 
on the pulmonary arteries that are in contact 
with ventilated regions; however, the drug must 
be inhaled 6-9 times a day and is commonly 
associated with the development of dry cough. 
Other side effects observed are the same as those 
of other prostacyclin analogues. A randomized, 
placebo-controlled study involving patients 
with PAH and CTEPH showed significant clinical 
improvement in a combined outcome that 
included physical exercise capacity, functional 
class in accordance with the New York Heart 
Association, and clinical deterioration for the 
group of patients treated with iloprost, who also 
presented hemodynamic stability during the 
study period.(31) Although it has been registered 
for use in Brazil, iloprost is not yet commercially 
available in the country. 
Beraprost
Beraprost is the only prostacyclin analogue 
that is available for oral administration. Although 
two studies have demonstrated an improvement 
in the six-minute walk distance (6MWD), this 
response was not sustained, and there was no 
hemodynamic response. The side effects of the 
drug are the same as those of other prostacyclin 
analogues.(28) In an open, uncontrolled study 
conducted in Japan, long-acting beraprost 
(a preparation designated TRK-100STP) was 
reported to produce clinical, functional, and 
hemodynamic improvement, its future use being 
therefore promising.(32) Beraprost is also currently 
unavailable for use in Brazil. 
Phosphodiesterase-5 inhibitors
Increased phosphodiesterase-5 in pulmonary 
arterioles and right ventricular myocytes has 
been demonstrated in patients with PH. The 
inhibition of this enzyme leads to an increase 
in the concentration of cyclic guanosine 
monophosphate, which promotes vasodilation, 
inhibits pulmonary artery remodeling due to its 
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also has the advantage of being administered 
only once daily. Another characteristic of the 
use of ambrisentan is the low interaction with 
other drugs, specifically with dicumarol and 
its derivatives, which allows safer concomitant 
use.(43) 
However, it should be highlighted that there 
have been no controlled studies to determine 
which of the endothelin receptor antagonists, if 
any, is the most effective. 
Combination therapy
Although the therapeutic armamentarium for 
the treatment of PH has expanded greatly in recent 
years, a significant proportion of patients show 
no improvement or present clinical worsening 
during monotherapy. Until recently, there had 
been no studies confirming that the clinical 
response to combination therapy was effective or 
reporting that such therapy was well tolerated, 
although the concept of targeting different 
pathophysiological pathways was deemed logical 
in theory. Case reports and uncontrolled studies 
showed clinical improvement with and tolerance 
to the use of combination therapy. Consequently, 
randomized, placebo-controlled studies were 
conducted. Concomitant use of sildenafil in 
patients receiving epoprostenol was found to 
provide greater functional and hemodynamic 
improvement, as well as greater improvement in 
quality of life, together with an increase in the 
time to clinical worsening.(44) Patients treated 
with the bosentan-epoprostenol combination 
showed a trend toward significant hemodynamic 
improvement, as well as good tolerance to the 
concomitant use of the two drugs. The lack of 
statistical significance is likely attributable to 
the small number of patients studied. The only 
symptom that was more common in the group 
of patients treated with combination therapy 
was edema of the lower limbs, which was not 
attributed to right ventricular dysfunction, 
because the combination therapy produced a 
reduction in RAP. It is of note that there was 
a reduction in the side effects secondary to 
epoprostenol in the group of patients who also 
received bosentan, possibly due to the inhibition 
of the activation of the sympathetic system, 
which is characteristic of the use of epoprostenol, 
by bosentan.(45) Concomitant use of iloprost was 
well tolerated in patients receiving bosentan, 
who showed a trend toward an increase in 
in the time to clinical worsening.(38) Other 
studies have reinforced the beneficial effects of 
bosentan, as well as showing hemodynamic and 
functional improvements.(27,39) One study showed 
that the use of bosentan in functional class lI 
patients is also beneficial.(40) The use of bosentan 
in these patients, who are less symptomatic, was 
shown to produce hemodynamic improvement 
and prevent clinical worsening.(40) The drug is 
generally well tolerated, and its principal side 
effect is an increase in hepatic enzyme levels, 
which requires that liver function be monitored 
throughout the treatment. The treatment should 
be initiated at a dose of 62.5 mg, twice daily, 
and, if the drug is well tolerated, the dose should 
be increased to 125 mg, twice daily. Monitoring 
through blood workup is also indicated, due to a 
report of anemia associated with the use of the 
drug.(27) Retrospective studies have also shown 
a reduction in the mortality associated with the 
use of endothelin receptor antagonists. 
Another endothelin receptor antagonist 
is sitaxsentan, which is a specific inhibitor of 
the ETA receptor and has also been associated 
with better quality of life and functional 
capacity in patients with PH.(41) An open study 
comparing patients receiving sitaxsentan with 
those receiving bosentan demonstrated that 
the patients receiving sitaxsentan showed 
a trend toward reduced clinical worsening 
and better tolerance, with a lower increase in 
hepatic enzyme levels. A subgroup analysis has 
suggested that patients with PAH associated with 
connective tissue disease benefit significantly 
more from sitaxsentan than from bosentan.(42) 
The use of sitaxsentan significantly increases 
serum levels of dicumarol, requiring even closer 
monitoring of the coagulation profile during 
the treatment. This characteristic, together with 
case reports of complications related to the use 
of sitaxsentan, is what prevents this medication 
from being universally approved by the agencies 
that regulate the use of medications. 
Yet another endothelin receptor antagonist 
is ambrisentan, which is also a selective ETA 
receptor antagonist and has been shown to 
produce a significant increase in the 6MWD 
and in the time to clinical worsening, as well as 
improving dyspnea and quality of life scores. It 
is of note that none of the patients who received 
treatment with ambrisentan presented with 
increased hepatic enzyme levels, and the drug 
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those with TPG r 12 mmHg, should be included 
in studies designed to that end. 
Group 3
Patients with parenchymal disease or 
hypoxemia should be primarily treated with 
oxygen therapy, and the treatment of the 
underlying disease should be optimized. The 
effectiveness of PH-specific drugs in this group of 
patients has yet to be confirmed, and the use of 
such drugs is currently contraindicated for these 
patients. When the MPAP is disproportionately 
high, that is, when parenchymal or functional 
involvement does not explain the degree of 
dyspnea and the MPAP at rest is higher than 40-45 
mmHg, patients should be referred to a tertiary-
care center, and the inclusion of such patients 
in studies is encouraged. However, PH-specific 
treatment should not be prescribed. It should 
be borne in mind that a finding of diastolic 
left ventricular dysfunction is not uncommon 
in these patients and might constitute another 
factor related to the pathogenesis of PH. 
Group 4
In all patients with PH, CTEPH should be ruled 
out. A ventilation/perfusion lung scintigraphy 
should always be performed, as seen in the 
diagnostic algorithm, and, if the result is normal, 
CTEPH can be ruled out. Angiotomography of the 
chest is useful for the evaluation of pulmonary 
circulation; however, it should not be used as 
an isolated tool for determining the operability 
of CTEPH. Patients with a diagnosis of CTEPH 
should receive anticoagulants and be referred 
the 6MWD, significantly improving functional 
parameters and increasing the time to clinical 
worsening.(46) 
The use of combination therapy was therefore 
shown to be safe and effective. In cases in which 
the clinical response is inadequate or in which 
there is deterioration during monotherapy, 
concomitant use of another class of drugs 
should be indicated. Combination therapy can 
be initiated at the beginning of the treatment 
in cases in which the initial presentation is 
extremely severe. However, further studies are 
needed in order to confirm the true benefit of 
this approach. 
Group 2
The treatment of patients with PH caused by 
left heart disease should focus on compensating 
for the underlying heart disease, and the use of 
PH-specific treatment is therefore contraindicated 
for these patients. Studies involving the use of 
bosentan and epoprostenol in this group of 
patients were terminated earlier than intended 
because the number of events observed in the 
groups of patients who received treatment was 
greater than was that observed in the placebo 
group. In addition, only one small-scale study 
has shown that the use of sildenafil is beneficial 
for the functional capacity of patients treated 
with the drug. These results therefore require 
corroboration from other studies, which might 
determine the true effectiveness and safety 
of the drugs that are currently available for 
this specific group of patients. Patients with a 
disproportionate increase in the MPAP, that is, 
Chart 3 - Parameters for the evaluation of the clinical severity of pulmonary arterial hypertension, as well as 
prognosis of the disease.a 
Better prognosis Determinants Worse prognosis
No Clinical evidence of right ventricular failure Yes
I or II Functional class IV
No Syncope Yes
Slow Symptom progression speed Rapid
> 500 m 6MWD < 300 m
Normal or stable BNP High or increased
Without pericardial effusion Echocardiography With pericardial effusion
TAPSE > 15 mm TAPSE < 15 mm
RAP < 8 mmHg Hemodynamic function RAP > 15 mmHg
CI r 2.5 L/min/m2 CI b 2.0 L/min/m2
6MWD: six-minute walk distance; BNP: brain natriuretic peptide; TAPSE: tricuspid annular plane systolic excursion; 
RAP: right atrial pressure; and CI: cardiac index. aAdapted from Galiè et al.(27)
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and involving 104 patients showed good patient 
tolerance to the drug and a reduction in PVR, 
as well as improved function and 6MWD.(49) A 
small-scale but placebo-controlled study showed 
improved quality of life, as well as hemodynamic 
and functional improvement, in patients with 
residual PH after thromboendarterectomy or 
with distal CTEPH.(50) The decision to use specific 
medication in patients with CTEPH who cannot 
undergo surgery or who present with residual 
PH after surgical intervention should be made 
after an adequate evaluation of the case in a 
referral center, in order to rule out the hypothesis 
that these patients will benefit from the surgical 
approach. In addition, these patients should 
remain under close clinical monitoring. 
to a tertiary-care center for the evaluation of 
the possibility of surgery. If the obstruction 
is operable, such patients should be referred 
for thromboendarterectomy. When a surgical 
intervention is contraindicated or cannot be 
performed, or when the patient presents with 
PH after thromboendarterectomy, the use of 
specific treatment seems beneficial. 
A recent randomized controlled study 
demonstrated the hemodynamic benefit of the 
use of bosentan in patients with inoperable 
CTEPH, although the effect of the drug on 
functional capacity was not significant.(47) The 
use of sildenafil in patients with CTEPH for 
whom surgery is contraindicated has previously 
been described in a case series.(48) In addition, 
an open uncontrolled study conducted in 2007 
Figure 5 - Treatment algorithm. FC: functional class. Adapted from Barst et al.(55)
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optimized clinical treatment should be referred 
for an evaluation for lung transplantation 
(Figure 5).(55) 
Future perspectives 
There have been significant advances in 
recent years, and existing concepts, the levels 
of evidence of which had not been sufficient 
to allow further extrapolations, have been 
consolidated, making it possible to construct 
new diagnostic and therapeutic algorithms. The 
prospect of effective therapeutic alternatives 
for the various PH groups is excellent, and new 
pathophysiological pathways with therapeutic 
potential have been discovered, providing the 
spark for the development of new classes of drugs 
that might be added to the existing therapeutic 
armamentarium. This development has always 
been based on research, of increasing quality, 
which generates increasingly robust evidence. In 
the coming years, the expectation is that this 
characteristic will be increasingly present in the 
field of PH.(56) 
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The association between resting and mild-
to-moderate exercise pulmonary artery
pressure
K. Whyte*,#, S. Hoette*,", P. Herve+, D. Montani*,",1, X. Jaı¨s", F. Parent", L. Savale*,",
D. Natali*,", D.S. O’Callaghan", G. Garcia*,1,e, O. Sitbon*,",1, G. Simonneau*,",1,
M. Humbert*,",1 and D. Chemlae,**
ABSTRACT: The mean pulmonary artery pressure (P¯pa) achieved on mild-to-moderate exercise is
age related and its haemodynamic correlates remain to be documented in patients free of
pulmonary hypertension (PH).
Our retrospective study involved patients free of PH investigated in our centre for possible
pulmonary vascular disease between January 1, 2007 and October 31, 2009 who underwent right
heart catheterisation at rest and during supine exercise up to 60 W. The 38 out of 99 patients aged
,50 yrs were included and a P¯pa of 30 mmHg was considered the upper limit of normal on exercise.
The 24 subjects who developed P¯pa.30 mmHg on exercise had higher resting P¯pa (19¡3
versus 15¡4 mmHg) and indexed pulmonary vascular resistance (PVRi; 3.4¡1.5 versus
2.2¡1.1 WU?m2; p,0.05) than the remaining 14 subjects. Resting P¯pa .15 mmHg predicted
exercise P¯pa .30 mmHg with 88% sensitivity and 57% specificity. The eight patients with resting
P¯pa 22–24 mmHg all had exercise P¯pa .30 mmHg.
In subjects aged ,50 yrs investigated for possible pulmonary vascular disease and free of PH,
patients with mild-to-moderate exercise P¯pa .30 mmHg had higher resting PVRi and higher
resting P¯pa, although there was no resting P¯pa threshold value that could predict normal response
on mild-to-moderate exercise. The clinical relevance of such findings deserves further long-term
follow-up studies.
KEYWORDS: Cardiac output, pulmonary hypertension, pulmonary vascular disease, right heart
catheterisation
F
or the last 30 yrs, the diagnosis of pulmon-
ary hypertension (PH) depended on either a
resting mean pulmonary artery pressure
(P¯pa) of .25 mmHg or an increase in P¯pa on exer-
cise to .30 mmHg, with the pulmonary capillary
wedge pressure f15 mmHg in the subgroup of
pre-capillary PH. Since the 4th World Conference
on PH, new guidelines have recommended that the
exercise criterion should be eliminated [1, 2], given
both the marked age-dependency of ‘‘normal’’ P¯pa
threshold on exercise [3] and the paucity of robust
data supporting its clinical relevance [1, 2]. The age-
dependency of P¯pa is much less at rest [3–7], such
that a common 20.6 mmHg upper limit of normal
(ULN)was suggested in supine healthy subjects [3].
Though a P¯pa ofo21 mmHg is beyond the normal
range (mean +2 standard deviations) and may be
suspicious of pulmonary vascular disease, a small
but significant proportion of apparently normal
individuals will have a P¯pa o21 mmHg and they
will outnumber the previously documented pro-
portion of patients with PH [3]. As a result, new
guidelines have defined pulmonary hypertension
by a P¯pa at rest o25 mmHg (mean +3 standard
deviations), and have also highlighted the fact that
studies focusing on patients with resting P¯pa of 21–
24 mmHg are especially needed [1–3].
Numerous studies have documented the high
percentage of patients at high risk for PH exhibit-
ing elevation of P¯pa on exercise .30 mmHg while
their P¯pa was normal at rest [8–16], and this may be
considered as an early manifestation of pulmonary
vasculopathy [12, 14, 17, 18]. Most of these studies
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c
had been carried out in middle-aged patients, at a time when
normal P¯pa values during exercise have not yet been defined.
Recently, the review of the range of pulmonary haemodynamic
responses to exercise in normal subjects by KOVACS et al. [3] was
timely in alerting the community to the huge amount of avai-
lable data supporting the ‘‘classical’’ definition of exercise
induced PH in patients aged ,50 yrs, while the ULN of
30 mmHg was not always supported by the available data in
older patients. Thus, the precise relationship between resting P¯pa
and the age-related P¯pa responses during mild-to-moderate
exercise still deserve further studies in patients free of PH, and
this may have implications for improving our understanding of
PH pathophysiology.
The present study examined the range of haemodynamic respon-
ses in individuals aged ,50 yrs with resting P¯pa ,25 mmHg
being investigated for possible pulmonary vascular disease in our
institution who underwent measurement of pulmonary haemo-
dynamic responses to mild-to-moderate exercise while supine.
METHODS
This was a retrospective study. We extracted the catheter
laboratory records of all patients who underwent diagnostic
right heart catheterisation at the Centre National de Re´fe´rence
de l’Hypertension Pulmonaire Se´ve`re, Hoˆpital Antoine Be´cle`re,
Assistance Publique Hoˆpitaux de Paris, Universite´ Paris-Sud,
Paris, France over a 34-month period (January 1, 2007–October
31, 2009).
We included patients with a P¯pa at rest of ,25 mmHg and a
pulmonary artery occlusion pressure (Ppao) f15 mmHg who
underwent progressive supine exercise test during the right
heart catheterisation procedure. Patients with unexplained
exertional dyspnoea or an abnormal screening echocardiogram
P¯pa were included, as well as patients with a history of
probable or possible pulmonary thromboembolic disease being
investigated for chronic thromboembolic pulmonary hyperten-
sion. As our aim was to examine a ‘‘real life’’ patient
population undergoing diagnostic right heart catheterisation,
we did not exclude patients with significant comorbidities,
including diseases known to carry a risk of PH [1, 2]. We also
excluded patients in whom acceptable quality Ppao could not
be obtained. On exercise, Ppao .20 mmHg was considered as
abnormal but the corresponding patients were not excluded a
posteriori. The 6-min walking distance and respiratory and
biological tests were obtained according to our routine
protocol. Our retrospective study was compliant with require-
ments of the French Commission Nationale de l’Informatique
et des Liberte´s (CNIL), and right heart catheterisation with
exercise is part of the usual care at our institute.
Amongst the 99 eligible patients, only patients aged ,50 yrs
(n538) were included in our final analysis and 30 mmHg was
considered the ULN on mild-to-moderate exercise [3]. Patients
aged o50 yrs were excluded, given that KOVACS et al. [3] have
suggested that an upper limit of 30 mmHg could not be
supported by the available data in such subjects. The main risk
factors and comorbidities were a previous history of thrombo-
embolic pulmonary disease (n514, 37%), connective tissue
disease (n58, 21%; namely two lupus and six systemic
sclerosis) and anorexigens intake (n55, 13%) (table 1).
TABLE 1 Characteristics of the study population
Overall population P¯pa,exf30 mmHg P¯pa,ex .30 mmHg p-value
Subjects n 38 14 24
Demographic and clinical data
Females 30 (80) 10 (71) 20 (83) NS
Age yrs 40¡8 40¡8 40¡8 NS
BSA m2 1.72¡0.22 1.86¡0.22 1.63¡0.18 ,0.01
SAP mmHg 118¡17 123¡18 116¡16 NS
DAP mmHg 76¡10 77¡9 75¡10 NS
fC bpm 76¡11 74¡12 78¡10 NS
Haemoglobin g?dL-1 13.3¡2.0 13.7¡1.7 13.2¡2.1 NS
BNP pg?mL-1 31¡21 30¡8 32¡24 NS
6MWD m 505¡104 550¡100 478¡99 0.062
FEV1 % pred 86¡22 98¡20 81¡21 0.048
FVC % pred 85¡21 94¡19 80¡21 0.110
DL,CO % pred 62¡20 74¡18 56¡19 0.030
Risk factors and comorbidities n
History of thromboembolic disease 14 6 8
CTD 8 1 7
Anorexigens 5 5 0
Miscellaneous 7 1 6
None 4 1 3
Data are presented as n (%) or mean¡SD, unless otherwise stated. P¯pa,ex: exercising mean pulmonary arterial pressure; BSA: body surface area. SAP: systolic arterial
pressure. DAP: diastolic arterial pressure; fC: cardiac frequency; BNP: brain natriuretic peptide; 6MWD: 6-min walking distance; FEV1: forced expiratory volume in 1 s;
% pred: % predicted; FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; CTD: connective tissue diseases; NS: not significant.
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Patients had baseline haemodynamic measurements showing
resting P¯pa,25 mmHg and Ppaof15 mmHg. They then carried
out supine bicycle exercise ergometry [19, 20], including baseline
measurements with feet in the pedals but no dynamic exercise
followed by a stepwise increase of load. The number of steps and
the pattern of increase in load were determined for each
individual by the operator’s judgement based on the patient’s
age, comorbidities and clinical response to initial load. As we
have concentrated on examining the haemodynamic response at
mild-to-moderate exercise, we examined the data obtained
,60 W [3]. As our standard protocol was developed before the
new guidelines from the 4th World Conference on PH [1, 2], the
exercise was terminated in cases where the P¯pa was noted to be
.30 mmHg. In patients whose exercise was terminated prior to
60 W, either due to symptoms or reaching a P¯pa.30 mmHg, we
analysed their response at their highest workload.
Statistics
Data are presented as mean¡SD. Comparisons at baseline (rest)
wereperformedbyusingone-wayANOVAfollowedbyunpaired
t-test. The haemodynamic effects of exercise were compared
between patients with normal and abnormal P¯pa on mild-to-
moderate exercise by using a two-way ANOVA (group 6 time
interaction). Correlations were tested by using the least squares
method. Frequency distribution of both sex and P¯pa responses
between subgroups were compared using the Chi-squared test.
Receiver operating characteristic (ROC) curves (with 95% con-
fidence interval) were constructed for testing the ability of the
resting P¯pa to predict mild-to-moderate exercise P¯pa.30 mmHg.
A p-value ,0.05 was considered statistically significant. The
statistical analysis was performed using StatView 512 software
(Abacus concepts, Berkeley, CA, USA), except for ROC curves
analysis which was performed by using MedCalc8.1.0.0 software
(Mariakerke, Belgium).
RESULTS
The study population (n538) comprised 30 females and eight
males (age540¡8 yrs); their clinical characteristics are listed in
table 1. Median workload was 40 W (mean¡SD 41¡16 W).
Overall, 24 out of 38 (63%) of patients developed P¯pa
.30 mmHg on mild-to-moderate exercise. As compared with
the remaining 14 subjects, the 24 patients who developed
P¯pa.30 mmHg on mild-to-moderate exercise had lower body
surface area, lower forced expiratory volume in 1 s, and lower
diffusing capacity of the lung for carbon monoxide (table 1).
Differences in risk factors and comorbidities were also observed
between the two groups (table 1). The two groups had similar
sex ratio, age, systolic and diastolic arterial pressure, cardiac
frequency and haemoglobin and brain natriuretic peptide blood
content. The 6-min walking distance was 478¡99 m in the 24
patients who developed P¯pa.30 mmHg and 550¡100 m in the
remaining 14 patients (p50.062) (table 1).
The haemodynamic characteristics of the study population are
listed in table 2. Individual haemodynamic data are presented as
online supplementary material. The 24 patients who developed
P¯pa.30 mmHg onmild-to-moderate exercise had higher resting
P¯pa (19¡3 versus 15¡4 mmHg; p,0.01) and higher indexed
pulmonary vascular resistance (PVRi) at rest (3.4¡1.5 versus 2.2
¡1.1 WU?m-2; p,0.05) compared with the remaining 14 sub-
jects, (table 2). They also had similar Ppao and cardiac index at
rest (table 2), and similar right atrial pressure at rest (4¡3 versus
5¡3 mmHg; p5NS).
In the overall study population, there was a weak positive
relationship between resting P¯pa and mild-to-moderate exercise
P¯pa (r250.44; p,0.001) (fig. 1). Therewas no relationship between
age and either resting P¯pa or mild-to-moderate exercise P¯pa.
Haemodynamic responses to mild-to-moderate exercise in the
two subgroups are detailed in table 3 and individual P¯pa, Ppao
and cardiac index values are presented as online supplementary
material. Cardiac index increased in a similar way and PVRi
remained unchanged in the two subgroups (table 3). Mild-to-
moderate differences in Ppao changes (p50.047) were documen-
ted between the two subgroups. On exercising, two patients had
Ppao.20 mmHg (25 and 21 mmHg, see online supplementary
material) with .12 mmHg transpulmonary pressure gradient
(24 and 13 mmHg, respectively), and both had P¯pa .30 mmHg.
Exercising P¯pa exceeded 30 mmHg in 15 out of 27 (55%) of the
patients with resting P¯pa,21 mmHg and in nine out of 11 (82%)
of the patients with resting P¯pa between 21 and 24 mmHg (p5NS)
(table 4). The eight patients with resting P¯pa 22–24 mmHg all had
TABLE 2 Haemodynamics at rest and at mild-to-moderate
exercise in the study population#
Rest Mild-to-moderate exercise"
Pra mmHg 4¡3 Not recorded
P¯pa mmHg 18¡4 31¡8
Ppao mmHg 8¡3 12¡5
TPG mmHg 10¡5 19¡7
CI L?min-1?m-2 3.49¡0.54 6.34¡1.13
PVRi WU?m2 2.9¡1.5 3.1¡1.5+
Data are presented as mean¡SD. Pra: right atrial pressure; P¯pa: mean pulmonary
arterial pressure; Ppao: pulmonary arterial occlusion pressure; TPG: transpulmon-
ary pressure gradient; CI: cardiac index; PVRi: pulmonary vascular resistance
index. #: n538; ": p,0.001 in each case except where indicated; +: not significant.
n538.
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FIGURE 1. Linear relationship between mean pulmonary arterial pressure
whilst exercising (P¯pa,ex) and at rest (P¯pa,rest). n538; r250.44; p,0.001.
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an exercising P¯pa .30 mmHg. ROC curve analysis (fig. 2)
indicated that a resting P¯pa .15 mmHg predicted an exercising
P¯pa .30 mmHg with 88% sensitivity (95% CI 68–97%) and 57%
specificity (95% CI 29–82%).
DISCUSSION
Our retrospective study was performed in 38 patients aged
,50 yrs, free of PH (resting P¯pa,25 mmHg), being investigated
in our centre for possible vascular disease between January 1,
2007 and October 31, 2009. The main results were as follows: 1)
patients with mild-to-moderate exercise P¯pa .30 mmHg had
higher resting PVRi and higher resting P¯pa; 2) it was not possible
to reliably set a lower limit of resting P¯pa that guarantees normal
P¯pa at mild-to-moderate exercise loads; and 3) all eight patients
with resting P¯pa 22–24 mmHg had exercising P¯pa .30 mmHg.
The clinical relevance of such findings deserves further long-
term follow-up studies.
The present study was undertaken following recent articles and
editorials that stressed the necessity of further research in the
area of haemodynamics in patients with pulmonary vascular
diseases, with special focus on the potential link between resting
and exercising pulmonary haemodynamics and on the sig-
nificance of resting P¯pa 21–24 mmHg [1–3, 12, 17, 18]. Numerous
studies [8–16] have documented the so-called ‘‘exercise-induced
pulmonary hypertension’’ [12, 13, 15, 17] frequently observed in
various populations carrying a high risk of PH while their P¯pa
was normal at rest. To the best of our knowledge, our study is
the first to take into account the recent recommendations made
by KOVACS et al. [3], namely that the 30 mmHg ULN for the P¯pa
achieved on mild-to-moderate exercise fairly applies only in
patients aged ,50 yrs. Thus elderly patients (61 out of 99) were
not included in our final analysis, given that an ULN of
30 mmHg could not be supported by the available data in such
patients [3].
Our study focused on mild-to-moderate exercise only, and this
was based on the following rationale. First, the literature review
made it possible to define reliable ULN for P¯pa during mild-to-
moderate exercise [3, 5]. Secondly, reliable and consistent P¯pa,
Ppao and cardiac output data have been published during mild-
to-moderate exercise [4, 5, 21], thus allowing pathophysiological
interpretation of our data. Finally, light exercise may reflect the
daily life physiological stress put on the pulmonary circulation
and right ventricle more accurately than maximal exercise [1, 2].
In healthy subjects aged ,50 yrs, the resting P¯pa is ,14 mmHg
on average [1–3], and the haemodynamic changes on mild-to-
TABLE 3 Haemodynamic data at rest and while exercising according to the normal/abnormal response of mean pulmonary
arterial pressure on mild-to-moderate exercise (P¯pa,ex)
P¯pa,ex f30 mmHg P¯pa,ex .30 mmHg Two-way ANOVA p-value
Rest Exercise Rest Exercise
Subjects n 14 24
P¯pa mmHg 15¡4 23¡5 19¡3** 36¡5 0.0001
Ppao mmHg 8¡4 10¡4 8¡3# 13¡5 0.047
TPG mmHg 8¡4 13¡5 11¡4* 22¡6 0.0001
CI L?min-1?m-2 3.62¡0.56 6.26¡1.24 3.41¡0.52# 6.38¡1.09 0.30
PVRi WU?m2 2.2¡1.1 2.1¡1.0 3.4¡1.5* 3.7¡1.5 0.25
Data are presented as mean¡SD, unless otherwise stated. P¯pa: mean pulmonary arterial pressure; Ppao: pulmonary arterial occlusion pressure; TPG: transpulmonary
pressure gradient; CI: cardiac index; PVRi: pulmonary vascular resistance index. #: not significant. *: p,0.05; **: p,0.01 versus resting values in the P¯pa,exf30 mmHg
subgroup.
TABLE 4 Summary of resting mean pulmonary arterial
pressure (P¯pa,rest) versus exercising P¯pa (P¯pa,ex)
in the 38 patients
P¯pa,ex P¯pa,rest
,21 mmHg
P¯pa,rest
21–24 mmHg
Total
f30 mmHg 12 2 14
.30 mmHg 15 9 24
Total 27 11 38
Data are presented as n.
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FIGURE 2. Receiver operating characteristic curve showing mean pulmonary
arterial pressure at rest (P¯pa,rest) .15 mmHg and predicted exercise P¯pa
.30 mmHg with 88% sensitivity (95% CI 68–97%) and 57% specificity (95% CI
29–82%).
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moderate exercise while supine slightly differ according to the
research team, with either unchanged PVR [5, 22], or slightly
decreased PVR [23]. Pulmonary capillary pressure may increase
slightly [3, 5, 6, 24], although other studies and reference
textbooks often indicate unchanged pulmonary capillary pres-
sure during exercise. The 18 mmHg resting P¯pa value docu-
mented in our study (table 2) is consistent with that previously
reported in populations similar to ours [12–15] and reflects the
fact that patients were investigated in our centre for possible
vascular disease. It has been suggested that age, sex and resting
systolic blood pressure significantly influence P¯pa responses to
exercise, but all were similar in the two groups (table 1). The
underlying risk factors and comorbidities (table 1) may con-
tribute, at least in part, to explaining the high percentage (24 out
of 38; 63%) of patients exhibiting abnormal P¯pa responses [8–16].
The stress put on the right ventricle is minimal at rest and this
may in part explain why resting pulmonary haemodynamics do
not correlate highly with exercise pulmonary haemodynamics in
patients with established PH [6, 8, 12, 19, 20, 25, 26]. In our
patients at risk for PH and exhibiting normal P¯pa at rest, ROC
curve analysis indicated that resting P¯pa .15 mmHg predicted
exercise P¯pa.30 mmHgwith 88% sensitivity and 57% specificity.
Interestingly, SAGGAR et al. [15] have suggested that resting P¯pa
o14 mmHg was associated with abnormal P¯pa responses on
exercise in patients with systemic sclerosis. However, in our
study, it was not possible to reliably set a lower limit of resting P¯pa
that guarantees normal P¯pa at mild-to-moderate exercise loads
As far as the upper limit that guarantees abnormal P¯pa at mild-
to-moderate exercise loads is concerned, it may be expected that
the closer the resting P¯pa lies to the ULN on exercise (30 mmHg)
the more likely the exercise P¯pa threshold is to be breached.
Resting P¯pa was consistently higher in the 24 patients who
developed P¯pa .30 mmHg on mild-to-moderate exercise, and
this was explained by the 55% higher levels for resting PVRi as
compared with the remaining 14 patients who did not develop
P¯pa .30 mmHg on mild-to-moderate exercise (table 3). This
could also explain why exercise P¯pa was .30 mmHg in 82%
(nine out of 11) of the patients with resting P¯pa 21–24 mmHg
and in all eight patients with resting P¯pa of 22–24 mmHg.
Significant differences in Ppao changes were also documented
and contributed to explaining differences in exercising P¯pa in
the two subgroups (table 3). Amongst the 24 patients with P¯pa
.30 mmHg on exercise, two (8%) had an exercising Ppao of
.20 mmHg (see online supplementary material), thus con-
firming that acute left ventricular dysfunction could also
contribute to the rise in P¯pa, e.g. diastolic dysfunction [27, 28].
Conversely, similar cardiac output responses on exercise were
documented in the two subgroups and gave similar PVRi
responses (table 3). In summary, in patients aged ,50 yrs and
free of PH, the increased PVRi at rest resulting in higher
resting P¯pa was the main factor likely to explain abnormally
high P¯pa on mild-to-moderate exercise. Additionally, further
exercise-related increases in capillary wedge pressure also
played a role.
Our study did not involve healthy subjects, but patients with
symptoms and a certain risk of PH. Accordingly, the results
cannot be used to create novel thresholds of physiological
changes during exercise and may not be compared with studies
examining healthy individuals. The clinical heterogeneity of the
study group reflects the current ‘‘real-life’’ experience of a
reference PH centre. Other limitations include the retrospective
study design and the lack of extensive assessment of left
ventricular function at rest (e.g. detailed echocardiography to
detect diastolic and/or systolic dysfunction). The intrinsic
limitations related to the exercise protocol must also be discussed.
We have examined P¯pa responses on mild-to-moderate exercise
as best as we could, with the understanding that we do not
measure oxygen consumption during our right heart studies. We
could not determine the slope and pressure axis intercept of the
P¯pa–cardiac output relationship, as the number of data points and
pattern of exercise varied between individuals. The determina-
tion of multipoint P¯pa–cardiac output plots provides a more
accurate insight into the nature of PVR than the single-point PVR,
as the intercept may be higher than pulmonary capillary pressure
[6, 7, 19, 20, 29, 30]. Thus, the observed pattern of increased
transpulmonary pressure gradient and increased cardiac output
together with unchanged or decreased single-point PVR does not
necessarily reflect unchanged or decreased resistive properties of
the pulmonary circulation [7, 20, 29, 30]. Similarly, we cannot
exclude the possibility that our results reflect averaging patients
with various patterns of P¯pa–cardiac output relationship on
exercise [20]. The two patients with exercise Ppao .20 mmHg
were included in our final analysis as our aim was to study the
relationship between resting and mild-to-moderate exercise P¯pa
in patients at risk of PH but free of PH at rest (P¯pa ,25 mmHg)
and with normal filling pressure at rest (Ppao f15 mmHg).
Finally, elderly subjects could not be studied for the above-
mentioned reasons and further studies focusing on this popula-
tion are thus needed.
The implications of our study must be carefully considered.
First of all, we wish to emphasise the fact that our study did not
intend to challenge the 4th World Conference proposal that
exercise testing must be abandoned in the definition of PH [1, 2].
However, we remain concerned by the fact that the new
consensus does sometimes leave clinicians faced with a patients
that have symptoms suggestive of pulmonary vascular disease
but with resting P¯pa ,25 mmHg [12, 14, 18]. Interestingly, our
study pointed to a major redundancy between resting and mild-
to-moderate exercise P¯pa values in the subgroup of patients
,50 yrs with a resting P¯pa of 22–24 mmHg. The 22–24 mmHg
range of resting P¯pa may help clinicians to recognise patterns
consistent with abnormal haemodynamic responses on mild-to-
moderate exercise. Elsewhere, our study demonstrates a lack of
tight correlation between resting and exercise haemodynamics
in non-PH patients. In other words, our data would suggest that
it is not possible to reliably set a lower limit of resting P¯pa that
guarantees that pulmonary haemodynamic responses to exer-
cise will be normal at mild-to-moderate exercise loads in
patients ,50 yrs.
In conclusion, in subjects aged ,50 yrs and free of PH, patients
with mild-to-moderate exercise P¯pa .30 mmHg had higher
resting PVRi and higher resting P¯pa. Although all patients with
resting P¯pa 22–24 mmHg had an exercising P¯pa .30 mmHg,
there was no resting P¯pa threshold value that could reasonably
predict normal/abnormal response on mild-to-moderate exer-
cise. The clinical relevance of such findings deserves further
long-term follow-up studies.
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 Pulmonary arterial hypertension (PAH) is a life-threatening disease that may occur either in idio-
pathic form or in the setting of different associated 
medical conditions. PAH is characterized by a marked 
and sustained elevation of pulmonary vascular resis-
tance, leading to an increase in pulmonary artery pres-
sure, right ventricular failure, and ultimately death. 1 
Nevertheless, despite its severity, in the last 20 years 
advances in the therapeutic management of the disease 
have changed the natural history of PAH. 2,3 In modern 
days, patients with idiopathic pulmonary arterial hyper-
tension (IPAH), connective tissue disease-associated 
PAH, or congenital heart disease-associated PAH 
benefi t from prostanoids, endothelin receptor antag-
onists (ERAs), and phosphodiesterase-5 inhibitors, 
improving clinical and hemodynamic function as well 
as quality of life and even survival. 4,5 Other etiologies 
in group 1 of the pulmonary hypertension classifi cation 
also have demonstrated some benefi t with specifi c 
PAH treatment. 6-9 However, there is no evidence in 
medical literature about clinical effi cacy of specifi c 
PAH treatment for one of the pivotal causes of PAH, 
the disease associated with schistosomiasis. 
 Background:  Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) may be one 
of the most prevalent forms of pulmonary arterial hypertension (PAH) worldwide. However, the 
clinical and hemodynamical response to specifi c PAH therapy in Sch-PAH is not known. 
 Methods:  We retrospectively analyzed the charts of all patients with Sch-PAH who initiated spe-
cifi c PAH treatment between June 2003 and June 2010 in a single PAH reference center in 
São Paulo, Brazil. Clinical and hemodynamical data were retrospectively collected and evaluated 
in two periods: baseline and posttreatment. 
 Results:  The study population consisted of 12 patients with Sch-PAH. They were treated with 
phosphodiseterase-5 inhibitors (seven patients), endothelin receptor antagonists (four patients), 
or combination therapy (one patient). Mean treatment period was 34.9  ! 15.5 months. Patients 
with Sch-PAH presented signifi cant improvements in terms of functional class, 6-min walk test 
distance (439  ! 85 to 492  ! 79 m,  P  5 .032), cardiac index (2.66  ! 0.59 to 3.08  ! 0.68 L/min/m 2 , 
 P  5 .028), and indexed pulmonary vascular resistance (20.7  ! 11.6 to 15.9  ! 9 W/m 2 ,  P  5 .038) with 
the introduction of specifi c PAH treatment. 
 Conclusions:  We conclude that specifi c PAH therapy may be of benefi t to patients with Sch-PAH, 
considering clinical, functional, and hemodynamic parameters.   CHEST 2012; 141(4):923–928 
 Abbreviations: 6MWT  5 6-min walk test; ERA  5 endothelin receptor antagonist; IPAH  5 idiopathic pulmonary arterial 
hypertension; NYAH  5 New York Heart Association; PAH  5 pulmonary arterial hypertension; PoPH  5 portopulmonary 
hypertension; Sch-PAH  5 schistosomiasis-associated pulmonary arterial hypertension 
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hemodynamic reevaluation were performed in all patients at dif-
ferent follow-up intervals as dictated by the patient clinical status. 
 Treatment 
 In the absence of any contraindication (eg, high risk of gastro-
intestinal bleeding or presence of esophageal varices), patients 
received oral anticoagulation; diuretics and oxygen were pre-
scribed as needed during the whole observational period. Patients 
with Sch-PAH do not receive PAH-specifi c therapy as a routine in 
our center due to the absence of controlled clinical data support-
ing this indication. Also, in Brazil specifi c PAH treatments are 
systematically available only for IPAH, connective tissue disease-
related PAH, and PAH related to congenital heart disease. Never-
theless, all patients enrolled in this study received specifi c PAH 
treatment as rescue therapy due to progressive right ventricular 
dysfunction, following current recommendations for IPAH 17 as a 
guideline. Patients in functional class III or IV received fi rst-line 
therapy with either an ERA or a phosphodiesterase-5 inhibitor. The 
choice between the agents was based merely on drug availability. 
One patient presenting in NYHA functional class IV with rapidly 
progressive disease and worsening symptoms received combina-
tion therapy with agents from both classes as fi rst-line therapy. 
 Statistical Analysis 
 Analysis was performed using the SPSS 15 statistical package 
(SPSS, Inc). All continuous variables are expressed as mean  ! SD; 
categorical data are presented as proportions. For comparison 
between baseline and posttreatment clinical and hemodynamic 
characteristics, a paired  t test was used. A  P value  , .05 was con-
sidered statistically signifi cant. 18,19 
 Results 
 The study population consisted of 12 patients 
with Sch-PAH. All patients had endemic exposure to 
schistosomiasis and highly suggestive liver ultrasono-
graphic fi ndings; additionally, four patients examined 
also had positive stool at the time of diagnostic inves-
tigation. Specifi c treatment was predominantly based 
on use of phosphodiseterase-5 inhibitors (n  5 7, 
58.3%). ERAs were used in four patients (33.3%) and 
fi rst-line combination therapy in one patient (8.4%). 
 Baseline and posttreatment clinical, functional, and 
hemodynamic data are shown in  Table 1 and  Figure 1 . 
The mean period of treatment between baseline and 
posttreatment evaluations was 34.9  ! 15.5 months. 
The majority of patients with Sch-PAH improved 
functional class with the introduction of specifi c PAH 
treatment (nine of 12 patients) ( Fig 1A ). 6MWT dis-
tance ( Fig 1B ), cardiac index, and indexed pulmonary 
vascular resistance ( Table 1 ) also improved with the 
therapy. No difference was found in mean pulmo-
nary arterial pressure (mPAP) as a consequence of 
treatment. 
 Discussion 
 The present study demonstrated that patients with 
Sch-PAH may have signifi cant clinical, functional, and 
 In the setting of pulmonary hypertension, the rele-
vance of schistosomiasis-associated PAH (Sch-PAH) 
has been better recognized in recent years. It is 
believed that approximately 5% of patients diagnosed 
with hepatosplenic  Schistosomiasis mansoni may also 
present themselves with PAH, 10 suggesting that Sch-
PAH is potentially the most prevalent cause of PAH 
worldwide. Its importance might be even greater in 
endemic regions for schistosomiasis. Indeed, it is esti-
mated that up to 30% of all pulmonary hypertension 
patients followed at reference centers in Brazil have 
Sch-PAH. 11 In the updated classifi cation of PAH, 12 
following the better understanding of the mechanisms 
involved in Sch-PAH as well as its hemodynamic fea-
tures, Sch-PAH has been reclassifi ed within group 1 
(PAH), the group that generates the biggest interest 
in the area, as well as the most researched of all fi ve 
groups. 
 Mortality rates associated with Sch-PAH were 
recently described in a Brazilian cohort and may reach 
up to 15% in 3 years. 13 Despite being less severe than 
IPAH, Sch-PAH affects a young population (between 
the fourth and fi fth decades of life), and its described 
prognosis justifi es the need of specifi c therapies for 
this setting. Nevertheless, no information about the 
hemodynamic and/or clinical response to target PAH 
therapies in Sch-PAH is available. The objective of 
this study was to evaluate the clinical, functional, and 
hemodynamic responses of patients with Sch-PAH 
followed at a PAH reference center in Brazil who 
received specifi c PAH treatment. 
 Materials and Methods 
 Patient Population 
 All patients with Sch-PAH who initiated specifi c PAH treat-
ment between June 2003 and June 2010 in a single PAH refer-
ence center in São Paulo, Brazil, were included in this study. The 
study was approved by the ethics board of the institution, approval 
1359/06. Clinical and hemodynamic data were retrospectively 
collected. 
 PAH was defi ned by a mean pulmonary artery pressure 
(mPAP)  . 25 mm Hg with a normal pulmonary artery occlusion 
pressure   , 15 mm Hg. Patients were classifi ed as having Sch-PAH 
when the presence of PAH was associated with liver ultrasono-
graphic fi ndings highly suggestive of mansonic schistosomiasis 
(left lobe enlargement and/or periportal fi brosis 14 ) and at least one 
of the following features: (1) exposure to endemic region for 
schistosomiasis, (2) previous treatment of schistosomiasis, and 
(3) presence of  S mansoni eggs in stool examination or rectal biopsy. 
 Functional and Hemodynamic Evaluations 
 Baseline evaluation included demographics, medical history, phys-
ical examination, New York Heart Association (NYHA) functional 
class assessment, routine laboratory testing, a nonencouraged 6-min 
walk test (6MWT), as previously described, 15 and right-sided heart 
catheterization using standard techniques. 16 Both clinical and 
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empirically use already available classes of medica-
tions for PAH to these patients, provided that they 
also present themselves with dyspnea on exertion 
and/or symptoms of right ventricular insuffi ciency. 
However, there are signifi cant differences between 
IPAH and Sch-PAH: The hemodynamic profi le at 
diagnosis is markedly better in Sch-PAH, as com-
pared with IPAH and survival in Sch-PAH seems 
to be better that in other PAH forms. These fi ndings 
need to be accounted for when designing appropriate 
controlled studies in this specifi c subset of patients. 
 Considering the high prevalence of schistosomi-
asis worldwide (200 million patients, 8.5 million 
with hepatoesplenic disease, 24 potentially more than 
400,000 patients with Sch-PAH 10 ) when compared 
with the other relatively rare etiologies of PAH, 
including IPAH (about 170,000 patients worldwide 25 ), 
the 15% 3-year mortality described in Sch-PAH 13 is 
of absolute relevance. Moreover, although Sch-PAH 
seems to have a slower progression, eventually patients 
dete riorate in a similar fashion to IPAH. Thus, one 
might speculate that specifi c PAH therapy to Sch-
PAH may obey the same general principles of IPAH 
treatment. 17 
 Additionally, the magnitude of response to specifi c 
PAH therapy found in patients with Sch-PAH in this 
study is encouraging. Despite the long time interval 
between evaluations, an increase of 16% in CI was 
observed. In the same direction, the 6MWT increased 
by 12%, and most patients improved the functional 
class. Even after 35 months, patients with Sch-PAH 
still demonstrated clear signs of clinical and hemody-
namic improvement. 
 There are several proposed mechanisms of disease 
for Sch-PAH: (1) embolic disease by egg impact in 
the pulmonary circulation and mechanical obstruc-
tion 26 ; (2) passage of the worm or the egg by the lungs, 
inducing endothelial dysfunction by infl ammatory 
mediator release and abnormal scarring 27,28 ; and 
(3) like portopulmonary hypertension (PoPH), the pul-
monary overfl ow caused by the opening of porto-
caval shunts in the presence of portal hypertension 
induces endothelial dysfunction and PAH. 29 Based on 
the last mechanism, it is tempting to correlate the 
known benefi ts of the specifi c PAH therapy in the 
setting of PoPH 6 to Sch-PAH. Nevertheless, it is clear 
today that PoPH and Sch-PAH are not the same 
disease; while 1% to 2% of portal hypertension 
patients develop PAH, 30 approximately 5% of schisto-
somotic hepatosplenic patients present PAH, 10 sug-
gesting that different mechanisms might be involved 
in PAH genesis. A published cohort of PoPH patients 
showed that the outcome of these patients is infl u-
enced by the degree of liver insuffi ciency and by 
cardiac function, 31 but it is important to emphasize 
that patients with Sch-PAH do not routinely present 
hemodynamic improvements in response to specifi c 
PAH treatments. To the best of our knowledge, this 
is the fi rst time that such an observation has been 
reported. 
 Schistosomiasis is a disease directly correlated to 
poverty and lack of sanitation, with a characteristic 
geographical distribution. 20,21 Nevertheless, there is 
an insurgence of new cases in developed countries, 
following migratory practices and modern tourist 
habits. According to the US Centers for Disease Con-
trol and Prevention, schistosomiasis is one of the 10 
leading causes of morbidity among travelers. 22 Pul-
monary hypertension represents one of the most 
severe complications of chronic schistosomiasis, with 
a prevalence of 5% in patients with mansonic hepa-
tosplenic disease, and it may take years after the 
initial infestation by the worm to develop. 10 It is 
probable that, in a few years, other PAH reference 
centers, beyond the traditional geographic borders 
of the disease, will have to deal with this etiology of 
PAH. 
 Clinical data about presentation of Sch-PAH dem-
onstrate that the disease is similar to IPAH in several 
aspects, such as mean age and functional class at 
diagnosis, as well as baseline 6MWT. 13 Furthermore, 
pathology studies have shown similarities between 
IPAH and Sch-PAH regarding the histology of small 
lung arteries and the presence of plexiform lesions in 
both groups. 23 Therefore, it seems reasonable to 
 Table 1— Clinical and Hemodynamical Data at 
Baseline and Post-Specifi c PAH Treatment for 
Patients With Sch-PAH (N  5 12) 
Parameter Baseline Posttreatment  P Value
Age, y 46.2  ! 9.8 … …
NYHA functional class
 I 0 5 (41.6) .002
 II 0 5 (41.6) …
 III 9 (75) 2 (16.8) …
 IV 3 (25) 0 …
6MWT, m 439  ! 85 492  ! 79 .032
Hemodynamics
 RAP, mmHg 11.0  ! 5.9 10.8  ! 3.8 .65
 mPAP, mmHg 64.0  ! 19.1 58.7  ! 17.1 .13
 CI, L/min/m 2 2.7  ! 0.6 3.1  ! 0.7 .028
 PAOP, mmHg 12.1  ! 3 13.7  ! 4.4 .24
 PVR, International Units 12  ! 6.5 9.1  ! 4.8 .038
First-line treatment
PDE-5 inhibitor 0 7 (58.3) …
ERA 0 4 (33.3) …
Combined therapy 0 1 (8.4) …
Data are given as mean  ! SD or No. (%). Mean period between 
evaluations: 34.9  ! 15.5 mo. 6MWT  5 distance on nonencouraged 
6-min walk test; CI  5 cardiac index; ERA  5 endothelin receptor antag-
onist; mPAP  5 mean pulmonary artery pressure; PAOP  5 pulmonary 
artery occlusion pressure; PDE-5  5 phosphodiesterase-5 inhibitor; 
PVR  5 pulmonary vascular resistance; RAP  5 right atrial pressure; 
Sch-PAH  5 schistosomiasis-associated pulmonary arterial hypertension.
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point with regard to the absence of a consensus on 
the value of 6MWD in non-IPAH PAH. 
 Recent data demonstrated no acute response to 
vasodilator test in Sch-PAH, therefore there would 
be no indication of a high dose of calcium-channel 
blockers as primary therapy in this group. 13 The 
choice between ERA and the phosphodiesterase-5 
inhibitor in this study was made mainly by the avail-
ability of the drug in our center at the moment of 
therapy initiation. There was no signifi cant side effect 
in the seven patients using the phosphodiesterase-5 
inhibitor, the four patients using ERAs, or the one 
using combined therapy. Particular attention was 
paid to the patients with Sch-PAH using ERAs and 
the one with combined therapy because patients with 
hepatosplenic schistosomiasis have hepatic blood 
fl ow impaired due to portal hypertension, generating 
some degree of relative ischemia and possibly ampli-
fying vulnerability to the potential hepatoxicity of this 
class of drugs. Nevertheless, no signifi cant abnormal 
levels of liver enzymes were identifi ed during the 
course of study (data not shown). In fact, some drugs 
of this class, such as bosentan, have been safely 
used in PoPH in several reports. 6 Cases of favor-
able responses with the use of sildenafi l in Sch-PAH 
have been previously reported, 32 but without hemo-
dynamic confi rmation of PAH diagnosis and post-
treatment control. 
 Other forms of specifi c treatment in Sch-PAH also 
should be considered. Being an infectious disease for 
which a single dose treatment is widely available, the 
need for implementing the antiparasitic treatment to 
this population—even with the purposes of discon-
tinuing the chronic infection, and avoiding both 
re-infection and infestation of other patients—is quite 
obvious. Nevertheless, there is a possible role of anti-
parasitic treatment on pulmonary arteriopathy as 
well. It is known that, in hepatosplenic disease, this 
modality of treatment may improve the tissue archi-
tectural destruction induced by the disease, sometimes 
even promoting complete resolution of the granulo-
matous process. 33 Despite the fact that this effect 
has never been specifi cally studied in the pulmonary 
circulation, at least one case report has been pub-
lished showing signifi cant improvement in pulmo-
nary hemodynamics after treatment of  Schistosoma 
hematobium . 34 Nevertheless, all of our patients with 
Sch-PAH received adequate treatment of  S mansoni 
at the time of diagnosis, therefore, before any specifi c 
PAH treatment was initiated. 
 Our study has several limitations that have to be 
taken into consideration before any extrapolation of 
our data. It is a retrospective case series with a limited 
number of patients followed at a single tertiary cen-
ter. It should be solely considered as an exploratory 
hypothesis generating study. Not all patients with 
liver dysfunction in association with portal hyperten-
sion. Nonetheless, data regarding use of specifi c PAH 
therapy in patients with PoPH, as in patients with 
IPAH, should not be directly extrapolated to other 
groups such as Sch-PAH. 
 When the data of patients with Sch-PAH is ana-
lyzed considering previous information obtained in 
patients with IPAH, some issues may be noted. Three 
patients with Sch-PAH had functional class IV at 
diagnosis while the others had functional class III. 
However, this does not match with a quite high base-
line walking distance (440 m). This kind of discrep-
ancy between functional class and 6MWT has been 
described in other forms of PAH, such as in PoPH. 
Considering the comorbidities present in chronic 
schistosomiasis, it might be expected that other fac-
tors may infl uence dyspnea besides the hemodynamic 
limitation. However, it is important to emphasize that 
the high variability of 6MWT may also prevent fur-
ther speculation in this case series, reinforcing the 
 Figure 1. Clinical data at baseline and post-specifi c pulmo-
nary arterial hypertension (PAH) treatment for patients with 
schistosomiasis-associated pulmonary arterial hypertension. A, 
Proportion of patients in respective New York Heart Association 
(NYHA) FC. B, Length in 6MWT. * P  , .05; ** P  , .01. 6MWT  5 non-
encouraged 6-min walk test; FC  5 functional class. 
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Sch-PAH were treated, and this surely led to selec-
tion bias, minimized by the fact that the comparison 
was done to the patient him or herself and not to a 
control subject. It would have been extremely valu-
able if a larger number of patients could have been 
treated with targeted therapies; however, the limited 
drug availability imposes a major limitation in this 
matter. Therefore, it is particularly important to 
gather data that support the use of specifi c therapies 
in Sch-PAH. Nevertheless, this is a fi rst step in estab-
lishing the clinical response to specifi c PAH therapy 
to patients with Sch-PAH, and also the fi rst report 
to provide evidence of potential effi cacy of target 
therapies in the setting of Sch-PAH, enabling and 
reinforcing the need for controlled trials. We con-
clude that specifi c PAH therapy may be of benefi t 
to patients with Sch-PAH, considering clinical, func-
tional, and hemodynamical parameters. 
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REVIEW
Implementing the ESC/ERS pulmonary
hypertension guidelines: real-life cases
from a national referral centre
D. Montani*,#,",+, D.S. O’Callaghan*,#,",+, X. Jaı¨s*,#,", L. Savale*,#,", D. Natali*,#,",
A. Redzepi*,#,", S. Hoette*,#,", F. Parent*,#,", O. Sitbon*,#,",
G. Simonneau*,#," and M. Humbert*,#,"
ABSTRACT: Pulmonary hypertension (PH) comprises a heterogeneous group of disorders
characterised by increased pulmonary vascular resistance that results in progressive right
ventricular failure. In order to translate current evidence into routine clinical practice, the
European Society of Cardiology (ESC) and the European Respiratory Society (ERS) have recently
jointly proposed evidence-based guidelines for the optimal management of different PH patient
groups. This article describes a series of clinical cases of PH due to various aetiologies that were
referred to a large national PH expert referral centre. In each case, the assessment and
therapeutic approach undertaken is described in the context of the new ECS/ERS guidelines. The
routine diagnostic work-up of suspected idiopathic pulmonary arterial hypertension (PAH) and
recommended treatments for patients with functional class II, III and IV disease is emphasised.
Familial screening and management of heritable PAH is discussed. Appropriate investigation and
therapeutic strategies for patients with chronic thromboembolic disease and PH that is
associated with congenital heart disease, pulmonary veno-occlusive disease and systemic
sclerosis are also highlighted.
T
he term pulmonary hypertension (PH)
describes a group of devastating and life-
limiting diseases, defined by a mean pul-
monary artery pressure (P¯pa) o25 mmHg at rest
[1–8]. PH remains poorly characterised as it is a
rare disorder and because there is an incomplete
understanding of the diverse underlying patho-
genic conditions and mechanisms. Furthermore,
effective treatment approaches available to clin-
icians have traditionally been limited. However,
the past decade has witnessed a significant
increase in our knowledge base, leading to novel
medical, surgical and supportive therapeutic
options for patients. In addition, international
collaborative efforts have directly led to the
development of regularly updated proceedings
and guidelines [1, 2, 9]. The recent publication of
the joint European Society of Cardiology (ESC) and
European Respiratory Society (ERS) guidelines is a
major event in our community and it thus
appeared timely to comment on these guidelines
with real-life cases managed according to this
approach [1, 2]. Indeed, it is essential to implement
these guidelines in day-to-day care of this fragile
patient population [4, 10]. This article describes a
number of real-life clinical cases and focuses on the
management approaches employed at a large
national pulmonary vascular disease referral cen-
tre. The level of evidence and the strength of
recommendation of particular treatment options
are weighed and graded according to pre-defined
scales, as presented in tables 1 and 2.
CASE 1: DIAGNOSTIC WORK-UP IN
IDIOPATHIC PULMONARY ARTERIAL
HYPERTENSION
Case report
A 30-yr-old female presented with progressive
dyspnoea associated with intermittent episodes of
dizziness. She was a nonsmoker and had no
history of venous thromboembolism, Raynaud’s
phenomenon or exposure to anorexigens. Family
history was noncontributory. At initial assessment
after referral to a PH expert centre she was deemed
to be in World Health Organization (WHO)
functional class III. Physical examination was
remarkable only for a loud second heart sound
over the pulmonic valve. There was no clinical
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evidence of connective tissue disease (CTD). Transthoracic
echocardiography revealed dilated right heart chambers, mod-
erate impairment of right ventricular contractility and a systolic
Ppa estimated to be 70 mmHg.Her 6-minwalk distance (6MWD)
was 310 m. Pulmonary function tests (PFTs) and arterial blood
gas analysis were within normal limits. The only abnormality
observed on high-resolution computed tomography (HRCT)
was mild dilatation of the pulmonary arteries. Ventilation/
perfusion lung scintigraphy demonstrated some subsegmental
mismatched defects but findings were not consistent with a
diagnosis of chronic thromboembolic PH (CTEPH). Testing for
infection with hepatitis B, hepatitis C and HIV was negative and
liver function tests were normal. Portal hypertension was
excluded by abdominal ultrasound. The patient proceeded to
diagnostic right heart catheterisation (RHC), which confirmed
severe pre-capillary PH (P¯pa 55 mmHg, pulmonary capillary
wedge pressure (Ppcw) 8 mmHg, cardiac index (CI)
2.88 L?min-1?m-2 and pulmonary vascular resistance (PVR)
694 dyn?s?cm-5). Acute vasodilator testing with inhaled nitric
oxide was negative. As no identifiable underlying cause was
revealed by the various investigations performed for the work-
up of PH in this patient, a diagnosis of idiopathic pulmonary
arterial hypertension (PAH) was established and endothelin
receptor antagonist therapy was instituted. Oral anticoagulation
for a target international normalised ratio (INR) of 2–3 was
initiated, and the patient was advised on effective contraception
measures as well as avoidance of excessive physical activity. A
clinical and haemodynamic re-evaluation after 4 months was
scheduled.
Commentary: relevance to ESC/ERS guidelines
PH has been defined as an increase in P¯pao25 mmHg at rest,
as assessed by RHC.
The definition of PH on exercise as a P¯pa o30 mmHg is not
supported by published data and healthy individuals can reach
much higher values. Thus no definition for PH on exercise as
assessed by RHC can be provided at the present time.
According to various combinations of values of Ppcw, PVR and
cardiac output (CO), different haemodynamic definitions of
PH are shown in table 3.
To avoid possible confusion among the terms PH and PAH,
the specific definitions have been included in table 4.
Compared with the previous version of the clinical classifica-
tion, a number of changes have been made (table 5). 1) In
group 1, corresponding to PAH, the term familial PAH has
been replaced by heritable PAH that includes clinically
sporadic idiopathic PAH with germline mutations and clinical
familial cases with or without identified germline mutations.
2) Associated PAH includes conditions that can have a similar
clinical presentation to that seen in idiopathic PAH with
identical histological findings, and accounts for approximately
half of all PAH patients. Schistosomiasis and chronic haemo-
lytic anaemia have been now included among the associated
PAH forms. 3) A group 19 has been created, which includes
pulmonary veno-occlusive disease (PVOD) and pulmonary
capillary haemangiomatosis (PCH), as these disorders share
some characteristics with idiopathic PAH but also demonstrate
a number of differences.
TABLE 1 ESC/ERS guidelines: classes of recommendations
Definition
Class I Evidence and/or general agreement that a given treatment
or procedure is beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion
about the usefulness/efficacy of the given
treatment or procedure.
Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well established by evidence/opinion.
Class III Evidence or general agreement that the given treatment or
procedure is not useful/effective, and in some cases
may be harmful.
Reproduced from [1] with permission from the publisher.
TABLE 2 ESC/ERS guidelines: levels of evidence
Level of evidence A Data derived from multiple randomised clinical
trials# or meta-analyses.
Level of evidence B Data derived from multiple randomised clinical
trials# or large nonrandomised studies.
Level of evidence C Consensus of opinion of the experts and/or small
studies, retrospective studies, registries.
#: or large accuracy or outcome trial(s) in the case of diagnostic tests or
strategies. Reproduced from [1] with permission from the publisher.
TABLE 3 ESC/ERS guidelines: haemodynamic definitions of
pulmonary hypertension (PH)#
Definition Characteristics Clinical group(s)"
PH P¯pao25 mmHg All
Pre-capillary PH P¯pa o25 mmHg 1. Pulmonary arterial
hypertension
Ppcw f15 mmHg 3. PH due to lung diseases
CO normal or
reduced+
4. Chronic thromboembolic PH
5. PH with unclear and/or
multifactorial mechanisms
Post-capillary PH P¯pa o25 mmHg 2. PH due to left heart disease
Ppcw .15 mmHg
CO normal or
reduced+
Passive TPG f12 mmHg
Reactive (out of
proportion)
TPG .12 mmHg
P¯pa: mean pulmonary arterial pressure; Ppcw: pulmonary capillary wedge
pressure; CO: cardiac output; TPG: transpulmonary pressure gradient
(P¯pa-P¯pcw). #: all values measured at rest; ": according to table 5; +: high CO
can be present in cases of hyperkinetic conditions such as systemic-to-
pulmonary shunts (only in the pulmonary circulation), anaemia, hyperthyroid-
ism, etc. Reproduced from [1] with permission from the publisher.
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The evaluation process of a patient with suspected PH requires
a series of investigations intended to confirm the diagnosis,
clarify the clinical group of PH and the specific aetiology
within the PAH group, and evaluate the functional and
haemodynamic impairment.
Since PAH, and particularly idiopathic PAH, is a diagnosis of
exclusion, a diagnostic algorithm may be useful as a starting
point in any case of suspected PH (fig. 1), as follows:
1) The symptoms of PAH are nonspecific and include breath-
lessness, fatigue, weakness, angina, syncope and abdominal
distension. In 90% of patients with idiopathic PAH the chest
radiograph is abnormal at the time of diagnosis. The ECG may
provide suggestive or supportive evidence of PH by demon-
strating right ventricular hypertrophy and strain, and right
atrial dilatation.
2) Transthoracic echocardiography provides several variables
that correlate with right heart haemodynamics, including Ppa,
and should always be performed in the case of suspected PH.
The estimation of Ppa during echocardiography is based on the
peak velocity of the jet of tricuspid regurgitation. Other
echocardiographic variables that might reinforce suspicion of
PH include an increased velocity of pulmonic valve regurgita-
tion, short acceleration time of right ventricular ejection into
the pulmonary artery, increased dimensions of right heart
chambers, abnormal shape and function of the interventricular
septum, increased right ventricular wall thickness, and
dilatation of the main pulmonary artery.
3) PFTs and arterial blood gases will identify the contribution
of underlying airway or parenchymal lung disease. Patients
with PAH usually have decreased diffusion capacity for
carbon monoxide (DL,CO) and mild to moderate reduction of
lung volumes.
4) The ventilation/perfusion lung scan should be performed in
patients with PH to look for potentially treatable CTEPH. The
ventilation/perfusion scan remains the screening method of
choice for CTEPH and a normal or low probability effectively
excludes CTEPH with a sensitivity .90% and a specificity
.94%.
5) HRCT facilitates the diagnosis of interstitial lung disease
and emphysema and may be very helpful where there is a
suspicion of PVOD or PCH.
6) Liver cirrhosis and/or portal hypertension can be reliably
excluded by the use of abdominal ultrasound.
7) Routine biochemistry, haematology and thyroid function
tests are required in all patients, as well as a number of other
essential blood tests. Serological testing is important to detect
underlying CTD, HIV and hepatitis.
RHC is required to confirm the diagnosis of PAH, to assess the
severity of the haemodynamic impairment and to test the
TABLE 4 ESC/ERS guidelines: important definitions
PH is a haemodynamic and pathophysiological condition defined as an
increase in P¯pa o25 mmHg at rest as assessed by right heart catheter-
isation (table 3). PH can be found in multiple clinical conditions (table 5).
The definition of PH on exercise as a P¯pa .30 mmHg as assessed by right
heart catheterisation is not supported by published data.
PAH (group 1) is a clinical condition characterised by the presence of pre-
capillary PH (table 3) in the absence of other causes of pre-capillary PH
such as PH due to lung diseases, chronic thromboembolic PH, or other
rare diseases (table 5). PAH includes different forms that share a similar
clinical picture and virtually identical pathological changes of the lung
microcirculation (table 5).
PH: pulmonary hypertension; P¯pa: mean pulmonary arterial pressure; PAH:
pulmonary arterial hypertension. Reproduced from [1] with permission from the
publisher.
TABLE 5 ESC/ERS guidelines: updated clinical
classification of pulmonary hypertension (PH)
1 PAH
1.1 Idiopathic
1.2 Heritable
1.2.1 BMPR2
1.2.2 ALK-1, endoglin (with or without hereditary haemorrhagic telangiectasia)
1.2.3 Unknown
1.3 Drugs and toxins induced
1.4 Associated with (APAH)
1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.4.6 Chronic haemolytic anaemia
1.5 Persistent pulmonary hypertension of the newborn
19 Pulmonary veno-occlusive disease and/or pulmonary capillary
haemangiomatosis
2 PH due to left heart disease
2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
3 PH due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
4 Chronic thromboembolic PH
5 PH with unclear and/or multifactorial mechanisms
5.1 Haematological disorders: myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell
histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease,
thyroid disorders
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal
failure on dialysis
PAH: pulmonary arterial hypertension; BMPR2: bone morphogenetic protein
receptor, type 2; ALK-1: activin receptor-like kinase 1; APAH: associated
pulmonary arterial hypertension. Reproduced from [11] with permission from
the publisher.
REVIEW: PULMONARY HYPERTENSION GUIDELINES D. MONTANI ET AL.
274 VOLUME 18 NUMBER 114 EUROPEAN RESPIRATORY REVIEW
vasoreactivity of the pulmonary circulation. The following
variables must be recorded during RHC. 1) Ppa (systolic,
diastolic and mean), right atrial pressure, Ppcw and right
ventricular pressure. CO must be measured in triplicate,
preferably by thermodilution or by the Fick method. 2)
Adequate recording of Ppcw is required for the differential
diagnosis of PH due to left heart disease.
Special awareness should be directed towards patients with
associated conditions and/or risk factors for development of
PAH, such as family history, CTD, congenital heart disease
(CHD), HIV infection, portal hypertension, haemolytic anae-
mia or a history of intake of drugs and toxins known to induce
PAH. If noninvasive assessment is compatible with PH, clinical
history, symptoms, signs, ECG, chest radiograph, transthoracic
Symptoms/signs/history suggestive of PH
Noninvasive assessment compatible with PH?
Search for
other causes and/or
re-check
Group 3: lung diseases
and/or hypoxia?
Yes
"out of proportion" PH
Search for
other causes
Schistosomiasis,
other group 5
Consider common causes of PH
Group 2 or 3: diagnosis confirmed
Perform V '/Q ' scan
Segmental perfusion defects
Consider other uncommon causes
Perform RHC
(PAH probability#)
Specific diagnostic tests
History, symptoms, signs
ECG, chest radiograph
TTE, PFT, HRCT
YES
YES
YES
NO
NO
NO
NO
Chronic
haemolysis
Porto-
pulmonary
BMPR2, ALK-1,
endoglin (HHT), 
family history
Idiopathic or heritable PAH
HIV CHD
CTD
Drugs,
toxins
PVOD
PCH
Consider
PVOD/PCH
Consider group 4:
CTEPH
Treat underlying disease and 
check for progression
Yes
PH "proportionate" to severity
Group 2: left heart disease?
Ppa ≥25 mmHg
Ppcw ≤15 mmHg
Physical,
US,
LFT
TTE,
TEE,
CMR
HIV
test
Clinical signs
HRCT,
ANA Physical,
analysis
laboratory
History
FIGURE 1. Diagnostic algorithm. ALK-1: activin-receptor-like kinase; ANA: antinuclear antibodies; BMPR2: bone morphogenetic protein receptor 2; CHD: congenital
heart disease; CMR: cardiac magnetic resonance; CTD: connective tissue disease; CTEPH: chronic thromboembolic pulmonary hypertension; HHT: hereditary haemorrhagic
telangiectasia; HRCT: high-resolution computed tomography; LFT: liver function tests; P¯pa: mean pulmonary arterial pressure; PAH: pulmonary arterial hypertension; PCH:
pulmonary capillary haemangiomatosis; Ppcw: pulmonary capillary wedge pressure; PFT: pulmonary function test; PH: pulmonary hypertension; PVOD: pulmonary veno-
occlusive disease; RHC: right heart catheterisation; TEE: trans-oesophageal echocardiography; TTE: transthoracic echocardiography; US: ultrasonography; V9/Q9 scan:
ventilation/perfusion lung scan. #: refer also to table 9. Reproduced from [1] with permission from the publisher.
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echocardiogram, PFTs and HRCT of the chest are requested to
identify the presence of group 2 left heart disease or group 3
lung diseases. If a ventilation/perfusion scan shows multiple
segmental perfusion defects, a diagnosis of group 4 CTEPH
should be suspected. The final diagnosis of CTEPH (and the
assessment of suitability for pulmonary endarterectomy) will
require computed tomography (CT) angiography, RHC and
selective pulmonary angiography.
The clinical assessment of the patient has a pivotal role in the
choice of the initial treatment, the evaluation of the response to
therapy, and the possible escalation of therapy if needed.
Despite large interobserver variation in themeasurement, WHO
functional class (table 6) remains a powerful predictor of
survival. In untreated patients with idiopathic or heritable
PAH, historical data showed a median survival of 6 months for
WHO functional class IV, 2.5 yrs for WHO functional class III,
and 6 yrs for WHO functional classes I and II.
CASE 2: SYSTEMIC SCLEROSIS-ASSOCIATED PAH
Case report
A 37-yr-old female with limited systemic sclerosis (LSSc) was
referred by her rheumatologist for assessment of increasing
exercise intolerance associated with effort-induced chest
discomfort and dizziness. Physical examination was remark-
able for an accentuated pulmonic component of the second
heart sound, a parasternal heave and mucocutaneous features
consistent with LSSc. Auscultation of the lungs was unremark-
able and there was no clinical evidence of right heart failure.
Transthoracic echocardiography revealed a left ventricle
compromised by markedly dilated right heart chambers with
associated paradoxical motion of the interventricular septum
and a 1-cm circumferential noncompressive pericardial effu-
sion. Spirometry and lung volume measurements were normal
and there was no evidence of interstitial lung disease on HRCT
of the chest. RHC confirmed severe pre-capillary PH (P¯pa
TABLE 6 ESC/ERS guidelines: functional classification of
pulmonary hypertension modified after the New
York Heart Association functional classification
according to the World Health Organization
Class I Patients with pulmonary hypertension but without resulting
limitation of physical activity. Ordinary physical activity does not
cause undue dyspnoea or fatigue, chest pain, or near syncope.
Class II Patients with pulmonary hypertension resulting in slight limitation
of physical activity. They are comfortable at rest. Ordinary
physical activity causes undue dyspnoea or fatigue, chest pain,
or near syncope.
Class III Patients with pulmonary hypertension resulting in marked
limitation of physical activity. They are comfortable at rest.
Less than ordinary activity causes undue dyspnoea or fatigue,
chest pain, or near syncope.
Class IV Patients with pulmonary hypertension with inability to carry out any
physical activity without symptoms. These patients manifest signs
of right heart failure. Dyspnoea and/or fatigue may even be
present at rest. Discomfort is increased by any physical activity.
Reproduced from [12] with permission from the publishers.
TABLE 7 ESC/ERS guidelines: recommendations for
pulmonary arterial hypertension (PAH) associated
with connective tissue disease (CTD)
Statement Class# Level"
In patients with PAH associated with CTD the same
treatment algorithm as in patients with idiopathic
PAH is recommended
I A
Echocardiographic screening for the detection of
PH is recommended in symptomatic patients with
scleroderma spectrum of diseases
I B
Echocardiographic screening for the detection of
PH is recommended in symptomatic patients with
all other CTDs
I C
RHC is indicated in all cases of suspected PAH
associated with CTD, in particular if specific drug
therapy is considered
I C
Oral anticoagulation should be considered on an
individual basis
IIa C
Echocardiographic screening for the detection of
PH may be considered in asymptomatic patients with
the scleroderma spectrum of disease
IIb C
PH: pulmonary hypertension; RHC: right heart catheterisation. #: class of
recommendation; ": level of evidence. Reproduced from [1] with permission
from the publishers.
TABLE 8 ESC/ERS guidelines: arbitrary criteria for
estimating the presence of pulmonary
hypertension (PH) based on tricuspid regurgitation
peak velocity and Doppler-calculated systolic
pulmonary arterial pressure (Ppa) at rest (assuming
a normal right atrial pressure of 5 mmHg) and on
additional echocardiographic variables suggestive
of PH
Criteria Class# Level"
Echocardiographic diagnosis: PH unlikely
Tricuspid regurgitation velocity f2.8 m?s-1, systolic Ppa
f36 mmHg and no additional echocardiographic variables
suggestive of PH
I B
Echocardiographic diagnosis: PH possible
Tricuspid regurgitation velocity f2.8 m?s-1, systolic Ppa
f36 mmHg, but presence of additional
echocardiographic variables suggestive of PH
IIa C
Tricuspid regurgitation velocity 2.9–3.4 m?s-1, systolic
Ppa 37–50 mmHg with/without additional
echocardiographic variables suggestive of PH
IIa C
Echocardiographic diagnosis: PH likely
Tricuspid regurgitation velocity .3.4 m?s-1, systolic Ppa
.50 mmHg, with/without additional echocardiographic
variables suggestive of PH
I B
Exercise Doppler echocardiography is not recommended
for screening of PH
III C
#: class of recommendation; ": level of evidence. Reproduced from [1] with
permission from the publisher.
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73 mmHg, PVR 1,950 dyn?s?cm-5 and Ppcw 10 mmHg) with
evidence of volume overload (right atrial pressure 20 mmHg)
and no acute vasodilator response to inhaled nitric oxide. The
patient was deemed to be in WHO functional class III and was
commenced on treatment with oral endothelin receptor
antagonist. In addition, diuretics and anticoagulation with a
target INR of 2.0–3.0 were initiated. Monthly surveillance of
liver transaminases was advised and effective contraceptive
measures suggested. At re-evaluation after 4 months of
therapy, the patient reported a symptomatic improvement
and her 6MWD increased to 365 m from a baseline of 250 m.
There was also a modest improvement in the pulmonary
haemodynamic profile at repeat RHC (P¯pa 65 mmHg, PVR
1,800 dyn?s?cm-5 and right atrial pressure 15 mmHg).
Commentary: relevance to ESC/ERS guidelines
PAH is a well-known complication of CTD such as systemic
sclerosis, systemic lupus erythematosus, mixed CTD and, to a
lesser extent, rheumatoid arthritis, dermatomyositis and
Sjo¨gren’s syndrome. PAH associated with CTD is the second
most prevalent type of PAH after idiopathic PAH.
Systemic sclerosis, particularly in its limited variant, represents
the main CTD associated with PAH. The prevalence of
haemodynamically proven PAH in large cohorts of patients
with systemic sclerosis is between 7% and 12%. Compared with
idiopathic PAH, patients with CTD and PAH are mainly
females (female to male ratio 4:1), are older (mean age at
diagnosis 66 yrs), may present concomitant disorders (pulmon-
ary fibrosis and left heart disease) and have shorter survival.
Echocardiographic screening for the detection of PH has been
recommended annually in asymptomatic patients with the
scleroderma spectrum of diseases but only in the presence of
symptoms in other CTD (table 7).
The reliability of several tricuspid regurgitation velocity cut-off
values, using RHC as reference, has been assessed in two large
screening studies. A trial evaluating the reliability of prospective
screening of patients with scleroderma, based on tricuspid
regurgitation velocity .2.5 m?s-1 in symptomatic patients or
.3.0 m?s-1 irrespective of symptoms, found that 45% of cases of
echocardiographic diagnoses of PH were falsely positive.
Another trial selected a tricuspid regurgitation pressure gradient
.40 mmHg (tricuspid regurgitation velocity .3.2 m?s-1) with an
assumed right atrial pressure of 10 mmHg as the cut-off value for
diagnosis of PH. Those criteria were recently prospectively
applied in systemic sclerosis patients.
In tables 8 and 9, the ESC/ERS task force suggests arbitrary
criteria for detecting the presence of PH based on tricuspid
regurgitation peak velocity and Doppler-calculated systolic Ppa
at rest (assuming a normal right atrial pressure of 5 mmHg)
and additional echocardiographic variables suggestive of PH.
CASE 3: SYSTEMIC SCLEROSIS-ASSOCIATED POST-
CAPILLARY PH
Case report
A 67-yr-old female in whom LSSc was diagnosed 11 yrs
previously was referred for assessment of PH. She reported
worsening dyspnoea on exertion over the preceding several
TABLE 9 ESC/ERS guidelines: probability of pulmonary
arterial hypertension (PAH) diagnosis and
suggested management according to the
echocardiographic diagnosis of pulmonary
hypertension (PH) (table 8), symptoms and
additional clinical information
Low probability for PAH diagnosis Class# Level"
Echocardiographic diagnosis of ‘‘PH unlikely’’,
no symptoms: no additional work-up is recommended
I C
Echocardiographic diagnosis of ‘‘PH unlikely’’,
presence of symptoms and of associated conditions
or risk factors for group 1–PAH: echocardiographic
follow-up is recommended
I C
Echocardiographic diagnosis of ‘‘PH unlikely’’,
presence of symptoms and absence of associated
conditions or risk factors for group 1–PAH: evaluation of
other causes for the symptoms is recommended
I C
Intermediate probability for PAH
Echocardiographic diagnosis of ‘‘PH possible’’,
no symptoms and absence of associated conditions
or risk factors for group 1–PAH: echo-
cardiographic follow-up is recommended
I C
Echocardiographic diagnosis of ‘‘PH possible’’,
presence of symptoms and of associated conditions
or risk factors for group 1–PAH: RHC
may be considered
IIb C
Echocardiographic diagnosis of ‘‘PH possible’’,
presence of symptoms and absence of associated
conditions or risk factors for group 1–PAH: alternative
diagnosis and echocardiographic follow-up may be
considered. If symptoms at least moderate RHC
may be considered
IIb C
High probability for PAH
Echocardiographic diagnosis of ‘‘PH likely’’, with symptoms
and presence/absence of associated conditions or risk
factors for group 1–PAH: RHC is recommended
I C
Echocardiographic diagnosis of ‘‘PH likely’’,
without symptoms and presence/absence of
associated conditions or risks factors for group 1–PAH:
RHC should be considered
IIa C
RHC: right heart catheterisation. #: class of recommendation; ": level of
evidence. Reproduced from [1] with permission from the publisher.
TABLE 10 Case 3: invasive pulmonary haemodynamics
Baseline After 500 mL fluid challenge
Pra mmHg 7 13
P¯pa mmHg 26 33
Ppcw mmHg 8 21
CO L?min-1 4.82 5.43
CI L?min-1?m-2 2.71 3.02
PVR dyn?s?cm-5 299 177
Pra: right atrial pressure; P¯pa: mean pulmonary arterial pressure; Ppcw:
pulmonary capillary wedge pressure; CO: cardiac output; CI: cardiac index;
PVR: pulmonary vascular resistance.
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months associated with intermittent episodes of chest discomfort
and mild leg swelling, in addition to severe Raynaud’s phen-
omenon and gastro-oesophageal reflux symptoms. Physical
examination was remarkable for severe calcinosis involving both
hands and extensive telangiectasia. She was normotensive and
there was no clinical evidence of cardiac failure. PFTs revealed
normal spirometry and lung volume measurements and a DL,CO
of 60% predicted. She was referred to an expert centre for
evaluation of suspected PAH as transthoracic echocardiography
demonstrated enlarged right heart chambers and an estimated
systolic Ppa of 50 mmHg with normal left ventricular function,
mild left atrial enlargement, normal valvular structure and a
normal pericardium. At review, she was inWHO functional class
III with a 6MWDof 320 m.HRCT showedmild bibasal interstitial
infiltrates. Liver function tests, blood gas analysis, lung scinti-
graphy, abdominal ultrasound and polysomnography were
normal and HIV test was negative. RHC was performed and
confirmed mild PH (P¯pa 26 mmHg) with normal Ppcw (table 10).
Because of the strong suspicion of underlying left heart disease, a
fluid challenge (500 mL saline over 10 min) was administered
and repeat measurements of pulmonary haemodynamics were
made, revealing a profile consistent with post-capillary PH in the
context of diastolic left heart disease associated with scleroderma
(table 10).
Commentary: relevance to ESC/ERS guidelines
The diagnostic approach to PH due to left heart disease is
similar to that for PAH, doppler echocardiography being the
best tool for screening purposes.
Left ventricle diastolic dysfunction should be suspected in the
presence of a dilated left atrium, atrial fibrillation, character-
istic changes in mitral flow profile, pulmonary venous flow
profile, and mitral annulus tissue Doppler signals and left
ventricle hypertrophy. Characteristic clinical and echocardio-
graphic features of PH associated with left ventricle diastolic
dysfunction are listed in table 11.
TABLE 11 ESC/ERS guidelines: factors favouring diagnosis
of left ventricular diastolic dysfunction in the
presence of pulmonary hypertension as
assessed by Doppler echocardiography
Clinical features
Age .65 yrs
Elevated systolic blood pressure
Elevated pulse pressure
Obesity, metabolic syndrome
Hypertension
Coronary artery disease
Diabetes mellitus
Atrial fibrillation
Echocardiography
Left atrial enlargement
Concentric remodelling of the LV (relative wall thickness .0.45)
LV hypertrophy
Presence of echocardiographic indicators of elevated LV filling
pressure [13, 14]
Interim evaluation (after echocardiography)
Symptomatic response to diuretics
Exaggerated increase in systolic blood pressure with exercise
Re-evaluation of chest radiograph consistent with heart failure [14]
LV: left ventricle. Modified from [15] with permission from the publisher.
TABLE 12 ESC/ERS guidelines: recommendations for
pulmonary hypertension (PH) due to left heart
disease
Statement Class# Level"
The optimal treatment of the underlying left heart
disease is recommended in patients with PH due to
left heart disease
I C
Patients with ‘‘out of proportion’’ PH due to left
heart disease (table 3) should be enrolled in
RCTs targeting PH specific drugs
IIa C
Increased left-sided filling pressures may be
estimated by Doppler echocardiography
IIb C
Invasive measurements of Ppcw or LV end-diastolic
pressure may be required to confirm the diagnosis
of PH due to left heart disease
IIb C
RHC may be considered in patients with
echocardiographic signs suggesting severe
PH in patients with left heart disease
IIb C
The use of PAH specific drug therapy is not
recommended in patients with PH due to
left heart disease
III C
RCT: randomised controlled trial; Ppcw: pulmonary capillary wedge pressure;
LV: left ventricular; RHC: right heart catheterisation; PAH: pulmonary arterial
hypertension. #: class of recommendation; ": level of evidence. Reproduced
from [1] with permission from the publisher.
FIGURE 2. Chest radiograph showing markedly dilated pulmonary arteries
(arrows).
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Adequate recording of Ppcw is required for the differential
diagnosis of PH due to left heart disease. In rare cases, left
heart catheterisation may be required for direct assessment of
left ventricular end-diastolic pressure.
A Ppcw .15 mmHg excludes the diagnosis of pre-capillary
PAH.
One of the most challenging differential diagnoses of PAH is
heart failure with normal left ventricular ejection fraction and
diastolic dysfunction. In this population, Ppcw may be mildly
elevated or at the higher end of the normal range at rest. Ppcw
and left ventricular end-diastolic pressure can be ‘‘pseudo-
normal’’, especially when patients have been treated with
diuretics. In this setting, exercise haemodynamic volume
challenge has been proposed to identify left ventricular
dysfunction, but these diagnostic tools require further stand-
ardisation.
An elevated transpulmonary gradient (P¯pa-P¯pcw) .12 mmHg
is suggestive of intrinsic changes in the pulmonary circulation
overriding the passive increase in Ppcw.
Recommendations for PH due to left heart disease are
summarised in table 12.
CASE 4: PAH AND CONGENITAL HEART DISEASE
Case report
A 24-yr-old female was referred for assessment of suspected PH.
Except for mild asthma treatedwith a short-acting b2-adrenergic
agonist, she had no significant personal or familial medical
history and denied illicit drug or appetite suppressant intake.
2 months before admission, a chest radiograph was performed
for tuberculosis contact screening and revealed markedly
dilated pulmonary arteries (fig. 2). She reported mild dyspnoea
on exertion (WHO functional class II) over the preceding several
months. Physical examination revealed an accentuated second
heart sound over the pulmonic valve but was otherwise normal.
ECG showed right ventricular hypertrophy and an incomplete
right bundle branch block pattern. 6MWD was 505 m, during
which a decrease in arterial oxygen saturation to 87% was
recorded. Echocardiography demonstrated a large atrial septal
defect of the posterior ostium secundum (15615 mm) asso-
ciated with a bi-directional shunt that was predominantly right
to left. Significant tricuspid regurgitation was also noted and
systolic Ppa was estimated at 55 mmHg. Systemic and pulmon-
ary venous returns were normal. Contrast-enhanced chest CT
was remarkable for massive dilatation of the pulmonary arteries
associated with marked right ventricular hypertrophy and
dilatation (fig. 3). RHC confirmed PAH with a pre-capillary
pattern: P¯pa 57 mmHg, Ppcw 3 mmHg, and PVR 880 dyn?s?cm-5.
The pressures in right and left atria were equivalent at 3 mmHg.
The pulmonary CI measured by the Fick method was
3.2 L?min-1?m-2 and the systemic CI was 2.6 L?min-1?m-2, result-
ing in a pulmonary to systemic CI ratio of 1.22. Because of the
high level of PVR and the presence of right-to-left shunt, repair
surgery was not performed. Instead, oral specific PAH therapy
with an endothelin receptor antagonist was initiated. After
6 months, the patient remained in WHO functional class II with
a moderate clinical and haemodynamic improvement (70 m
increase in 6MWD and 25% reduction in PVR). Repeat
echocardiography confirmed persistence of the right-to-left
shunt. Specific PAH therapy was therefore maintained and
repair surgery was definitively contraindicated.
Commentary: relevance to ESC/ERS guidelines
PAH associated with CHD is included in group 1 of the PH
clinical classification. A specific clinical classification (table 13)
and an anatomical–pathophysiological classification (table 14)
are useful to better define each individual patient with PAH
associated with CHD.
!
!
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FIGURE 3. Contrast-enhanced computed tomography of the chest of a patient
with pulmonary arterial hypertension associated with congenital heart disease (large
atrial septal defect). Massive dilatation of the pulmonary arterial trunk and branches
(#). The ratio of the diameter of aorta (Ao) to the diameter of main pulmonary artery
(PA) is .1.5.
TABLE 13 ESC/ERS guidelines: clinical classification of
congenital, systemic-to-pulmonary shunts
associated with pulmonary arterial hypertension
(PAH)
A. Eisenmenger’s syndrome
Eisenmenger’s syndrome includes all systemic-to-pulmonary shunts due
to large defects leading to a severe increase in PVR and resulting in a
reversed (pulmonary-to-systemic) or bidirectional shunt. Cyanosis,
erythrocytosis and multiple organ involvement are present.
B. PAH associated with systemic-to-pulmonary shunts
In these patients with moderate-to-large defects, the increase in PVR is
mild to moderate, systemic-to-pulmonary shunt is still largely present, and
no cyanosis is present at rest.
C. PAH with small# defects
In cases with small defects (usually ventricular septal defects, 1 cm and
atrial septal defects, 2 cm of effective diameter assessed by echocardio-
graphy) the clinical picture is very similar to idiopathic PAH.
D. PAH after corrective cardiac surgery
In these cases, congenital heart disease has been corrected but PAH is
either still present immediately after surgery or has recurred several months
or years after surgery in the absence of significant post-operative residual
congenital lesions or defects that originate as a sequela to previous surgery.
PVR: pulmonary vascular resistance. #: the size applies to adult patients. Repro-
duced from [1] with permission from the publisher.
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The persistent exposure of the pulmonary vasculature to
increased blood flow due to systemic-to-pulmonary shunts as
well as increased pressure may result in a typical pulmonary
obstructive arteriopathy that leads to the increase of PVR.
If PVR approaches or exceeds systemic vascular resistance, the
shunt is reversed (Eisenmenger’s syndrome).
In patients listed for lung or heart–lung transplantation when
no medical treatment was available, Eisenmenger’s syndrome
had better survival compared with idiopathic PAH, with a 3-yr
survival rate of 77% compared with 35% for untreated
idiopathic PAH.
Recommendations for PAH associated with congenital cardiac
shunts are summarised in table 15.
CASE 5: HERITABLE PAH
Case report
A 10-yr-old male presented with a 2-month history of
progressive dyspnoea on exertion. Clinical examination
revealed an accentuated second heart sound over the pulmonic
valve. Although the child had no medical history, a strong
familial history of PAH had previously been established (fig. 4).
10 yrs earlier, the patient’s father had been diagnosed with
severe PAH at age 30 yrs that was initially deemed idiopathic
given the absence of familial history at time of diagnosis.
However, 2 yrs thereafter, the patient’s paternal grandmother
was also diagnosed with severe PAH. She had developed
symptoms at age 52 yrs, presenting in WHO functional class III
with marked haemodynamic impairment. A screening of point
mutations and large rearrangements of bone morphogenetic
protein receptor type 2 (BMPR2) gene found a c.418+3A.T
mutation (a defect that affects a putative spicing regulatory
element in intron 3), thereby confirming the diagnosis of
heritable PAH. Genetic counselling sessions were conducted
with family members in order to provide information on the
risks of developing PAH and to inform them of disease
symptoms and signs. These interventions helped facilitate the
early referral of the child to a PAH referral centre in order to
expedite a diagnostic work-up. RHC confirmed severe PAH
(P¯pa 73 mmHg, CI 2.71 L?min-1?m-2 and PVR 1,510 dyn?s?cm-5)
and endothelin receptor antagonist therapy was initiated.
However, after 6 months of treatment there was only a modest
TABLE 14 ESC/ERS guidelines: anatomical–
pathophysiological classification of congenital
systemic-to-pulmonary shunts associated with
pulmonary arterial hypertension
1 Type
1.1 Simple pre-tricuspid shunts
1.1.1 ASD
1.1.1.1 Ostium secundum
1.1.1.2 Sinus venosus
1.1.1.3 Ostium primum
1.1.2 Total or partial unobstructed anomalous pulmonary venous return
1.2 Simple post-tricuspid shunts
1.2.1 VSD
1.2.2 Patent ductus arteriosus
1.3 Combined shunts
Describe combination and define predominant defect
1.4 Complex congenital heart disease
1.4.1 Complete atrioventricular septal defect
1.4.2 Truncus arteriosus
1.4.3 Single ventricle physiology with unobstructed pulmonary blood flow
1.4.4 Transposition of the great arteries with VSD (without pulmonary
stenosis) and/or patent ductus arteriosus
1.4.5 Other
2 Dimension (specify for each defect if more than one congenital heart
defect exists)
2.1 Haemodynamic (specify Qp/Qs)#
2.1.1 Restrictive (pressure gradient across the defect)
2.1.2 Nonrestrictive
2.2 Anatomical"
2.2.1 Small to moderate (ASD f2.0 cm and VSD f1.0 cm)
2.2.2 Large (ASD .2.0 cm and VSD .1.0 cm)
3 Direction of shunt
3.1 Predominantly systemic-to-pulmonary
3.2 Predominantly pulmonary-to-systemic
3.3 Bidirectional
4 Associated cardiac and extracardiac abnormalities
5 Repair status
5.1 Unoperated
5.2 Palliated (specify type of operation(s), age at surgery)
5.3 Repaired (specify type of operation(s), age at surgery)
ASD: atrial septal defect; VSD: ventricular septal defect. #: ratio of pulmonary
(Qp) to systemic (Qs) blood flow; ": the size applies to adult patients. Modified
from [16] with permission from the publisher.
TABLE 15 ESC/ERS guidelines: recommendations for
pulmonary arterial hypertension associated with
congenital cardiac shunts
Statement Class# Level"
The ERA bosentan is indicated in WHO FC III
patients with Eisenmenger’s syndrome
I B
Other ERAs, phosphodiesterase type-5 inhibitors,
and prostanoids should be considered in patients
with Eisenmenger’s syndrome
IIa C
In the absence of significant haemoptysis, oral
anticoagulant treatment should be considered
in patients with PA thrombosis or signs of heart failure
IIa C
The use of supplemental O2 therapy should be
considered in cases in which it produces a
consistent increase in arterial oxygen
saturation and reduces symptoms
IIa C
If symptoms of hyperviscosity are present,
phlebotomy with isovolumic replacement
should be considered usually when the
haematocrit is .65%
IIa C
Combination therapy may be considered in
patients with Eisenmenger’s syndrome
IIb C
The use of CCBs is not recommended in patients
with Eisenmenger’s syndrome
III C
ERA: endothelin receptor antagonist; WHO FC: World Health Organization
functional class; PA: pulmonary arterial; CCB: calcium channel blockers. #: class
of recommendation; ": level of evidence. Reproduced from [1] with permission
from the publisher.
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clinical and haemodynamic improvement, justifying the addi-
tion of a phosphodiesterase-5 (PDE-5) inhibitor.
Commentary: relevance to ESC/ERS guidelines
When PAH occurs in a familial context, germline mutations in
the BMPR2 gene are detected in o70% of cases.
Mutations of this gene can also be detected in 11–40% of
apparently sporadic cases, thus representing the major genetic
predisposing factor for PAH.
The BMPR2 gene encodes a type 2 receptor for bone
morphogenetic proteins, which belong to the transforming
growth factor-b superfamily, involved in the control of
vascular cell proliferation.
Mutations of other receptors for these substances, such as
activin receptor-like kinase 1 (ALK-1 or ACVRL-1) and endoglin,
have been identified mostly in PAH patients with a personal or
family history of hereditary haemorrhagic telangiectasia
(Osler–Weber–Rendu syndrome).
CASE 6: CHRONIC THROMBOEMBOLIC PULMONARY
HYPERTENSION
Case report
A 21-yr-old male professional soccer player presented with a 1-
yr history of exercise intolerance and intermittent pleuritic
chest pain. He was a cigarette smoker (2 pack-yrs) but
otherwise had no significant past medical history, denied
previous illicit or performance-enhancing drug intake and had
no personal or family history of venous thromboembolism.
Initial chest radiograph, PFTs and echocardiography were
negative and no further exams were performed. The patient
represented 18 months later with worsening of breathlessness.
Repeat echocardiography showed moderately dilated right
heart chambers with an estimated systolic Ppa of 55 mmHg. A
working diagnosis of pulmonary embolism was made; how-
ever, both CT pulmonary angiography and lower limb
compression ultrasonography were normal. 1 month later, he
represented with severe pleuritic chest pain. On this occasion,
ventilation/perfusion lung scintigraphy confirmed bilateral
pulmonary emboli and compression ultrasonography identi-
fied a left leg deep vein thrombosis. Anticoagulation therapy
was therefore initiated. 4 months thereafter, the patient had
persistent WHO functional class II symptoms. Repeat echo-
cardiography demonstrated persistent PH (systolic Ppa
60 mmHg). 6MWD was 540 m. Thrombophilia screening was
negative. RHC confirmed mild PH at rest with a significant
increase in P¯pa with exercise at 100 W (table 16). Repeat CTPA
and formal pulmonary angiography confirmed the presence of
chronic thromboembolic disease in a proximal distribution
(fig. 5a and b) and treatment by pulmonary thromboendarter-
ectomy (PEA) was proposed. However, the patient declined
surgery, though agreed to continue oral anticoagulation.
18 months later, he was readmitted with increasing breath-
lessness. The patient was in WHO functional class III and
6MWD was 477 m (decrease of 63 m from baseline).
Haemodynamic reassessment confirmed worsening PH
(table 16) while progressive occlusive vasculopathy was noted
%&'()*#+,
-&'()*#+,
./'()*#+,
01(23#45
$"67
FIGURE 4. Genealogical tree of heritable pulmonary arterial hypertension
(PAH) with BMPR2 mutation, demonstrating the phenomenon of genetic anticipa-
tion. PAH in the first generation was diagnosed at age 52 yrs, then at age 30 yrs in
the second generation and at age 10 yrs for the last generation.
TABLE 16 Case 6: clinical data
First evaluation After 18 months of
evolution without PEA
6 months after PEA
At rest Exercise (100 W)
WHO functional class II III I
6MWD m 540 477 748
Pra mmHg 2 NA 6 4
P¯pa mmHg 31 69 43 18
Ppcw mmHg 2 NA 4 6
CO L?min-1 4.6 12.3 4.7 5.8
TPR dyn?s?cm-5 539 449 732 248
SV,O2 % 68 27 63 73
Decision for therapy VKA VKA VKA
Patient declined PEA Patient accepted PEA
PEA: pulmonary thromboendarterectomy; WHO: World Health Organization; 6MWD: 6-min walk distance; Pra: right atrial pressure; P¯pa: mean pulmonary arterial pressure;
Ppcw: pulmonary capillary wedge pressure; CO: cardiac output; TPR: total pulmonary resistance; SV,O2: mixed venous oxygen saturation; VKA: oral vitamin K antagonist
anticoagulation.
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on repeat imaging studies (fig. 5c and d). On this occasion, the
patient proceeded to PEA during which obstructing material
was successfully removed from all major pulmonary artery
branches. His post-operative course was unremarkable and
oral anticoagulation was recommenced. At follow-up
6 months later, he was asymptomatic and repeat RHC
confirmed normal pulmonary haemodynamics (table 16).
Commentary: relevance to ESC/ERS guidelines
CTEPH is one of the most prevalent forms of PH. Nevertheless,
it is almost impossible to determine the overall prevalence of
CTEPH since not all of these patients have a history of acute
pulmonary embolism.
Any patient with unexplained PH should be evaluated for the
presence of CTEPH. 1) A normal ventilation/perfusion scan
rules out CTEPH. 2) Multi-row CT angiography is indicated
when the ventilation/perfusion lung scan is indeterminate or
reveals perfusion defects. Even in the era of modern multi-row
CT scanners, there is not yet enough evidence to suggest that a
normal CT angiography excludes the presence of operable
CTEPH.
Once ventilation/perfusion scanning and/or CT angiogram
show signs compatible with CTEPH, the patient should be
referred to a centre with expertise in the medical and surgical
management of these patients.
To determine the appropriate therapeutic strategy, invasive
tools, including RHC and traditional pulmonary angiography,
are usually required. The final diagnosis of CTEPH is based on
the presence of pre-capillary PH in patients with multiple
chronic/organised occlusive thrombi/emboli in the elastic
pulmonary arteries (main, lobar, segmental and subsegmental).
The decision on how to treat patients with CTEPH should be
made at an experienced centre based upon interdisciplinary
discussion among internists, radiologists, and expert surgeons:
1) PEA is the treatment of choice for patients with CTEPH, as it
is a potentially curative option; 2) patients with CTEPH should
receive life-long anticoagulation, usually with vitamin K
antagonists adjusted to a target INR of 2.0–3.0.
Recommendations for PH due to CTEPH are summarised in
table 17.
CASE 7: ACUTE VASOREACTIVITY TEST RESPONDER
Case report
A 69-yr-old female presented with a 3-month history of
dyspnoea and exercise intolerance. Her past medical history
was significant for breast cancer diagnosed 2 yrs previously
treated by surgery and adjuvant combination cytotoxic therapy
with cyclophosphamide, 5-fluoro-uracil and farmorubicin. At
the time of initial referral, she was in WHO functional class III.
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FIGURE 5. Case 6. a) Computed tomography pulmonary angiography and b) formal pulmonary angiography confirmed the presence of chronic thromboembolic
disease. c) and d) Progressive occlusive vasculopathy was noted on repeat imaging studies.
TABLE 17 ESC/ERS guidelines: recommendations for
chronic thromboembolic pulmonary
hypertension (CTEPH)
Statement Class# Level"
The diagnosis of CTEPH is based on the presence
of pre-capillary PH (P¯pa o25 mmHg, Ppcw
f15 mmHg, PVR.2 Wood units) in patients with
multiple chronic/organised occlusive thrombi/
emboli in the elastic pulmonary arteries (main,
lobar, segmental, subsegmental)
I C
In patients with CTEPH lifelong anticoagulation
is indicated
I C
Surgical pulmonary endarterectomy is the
recommended treatment for patients with CTEPH
I C
Once perfusion scanning and/or CT
angiography show signs compatible with
CTEPH, the patient should be referred to a
centre with expertise in surgical
pulmonary endarterectomy
IIa C
The selection of patients for surgery should be
based on the extent and location of the
organised thrombi, on the degree of PH, and
on the presence of comorbidities
IIa C
PAH-specific drug therapy may be indicated in
selected CTEPH patients such as patients not
candidates for surgery or patients with residual
PH after pulmonary endarterectomy
IIb C
PH: pulmonary hypertension; P¯pa: mean pulmonary arterial pressure; Ppcw:
pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance; CT:
computed tomography; PAH: pulmonary arterial hypertension. #: class of
recommendation; ": level of evidence. Reproduced from [1] with permission
from the publisher.
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Clinical examination revealed an accentuated second heart
sound over the pulmonic valve without evidence of cardiac
failure. Transthoracic echocardiography estimated systolic Ppa
62 mmHg. Additional routine diagnostic testing for an under-
lying cause of PH was negative. The patient proceeded to RHC
in order to confirm the diagnosis and assess severity of
haemodynamic impairment. This revealed severe pre-capillary
PH (P¯pa 52 mmHg and PVR 509 dyn?s?cm-5) with a preserved
CO and no evidence of hypervolaemia (table 18). An acute
vasodilator challenge testing using inhaled nitric oxide at a
dose of 10 ppm was then performed to assess for vasoreactiv-
ity. This showed a significant acute vasodilator response with
near normalisation of P¯pa, reduction in PVR and an associated
increase in CI (table 18). A treatment with high-dose oral
calcium channel antagonist (CCB) therapy was therefore
initiated and titrated up to the maximum tolerated dose, in
conjunction with oral anticoagulation. At haemodynamic
reassessment 12 months later, the patient had improved to
WHO functional class II and had increased her 6MWD from
210 m to 310 m. Subsequent RHC confirmed a sustained
favourable pulmonary haemodynamic response and the dose
of oral CCB was increased because of persistence of an acute
vasoreactivity to inhaled nitric oxide.
Commentary: relevance to ESC/ERS guidelines
In PAH, vasoreactivity testing should be performed at the time
of diagnostic RHC to identify patients who may benefit from
long-term therapy with CCBs.
Acute vasodilator challenge should only be performed with
short-acting, safe and easy to administer drugs with no or
limited systemic effects. Currently the agent most used in acute
testing is nitric oxide based on previous experience; i.v.
epoprostenol or i.v. adenosine may also be used as an
alternative (but with a risk of systemic vasodilator effects)
(table 19). Due to the risk of potentially life-threatening
complications, the use of CCBs given orally or i.v. as an acute
test is discouraged.
A positive acute response (positive acute responder) is defined
as a reduction of P¯pao10 mmHg to reach an absolute value of
P¯pa f40 mmHg with an increased or unchanged CO. Only
10% of patients with idiopathic PAH will meet these criteria
(table 20).
Positive acute responders are most likely to show a sustained
response to long-term treatment with high doses of CCBs and
they are the only patients that can safely be treated with this
type of therapy. About half of idiopathic PAH-positive acute
responders are also positive long-term responders to CCBs and
only in these cases is the continuation of a CCB as a single
treatment warranted.
The usefulness of acute vasoreactivity tests and long-term
treatment with CCBs in patients with other PAH types, such as
heritable PAH, CTD, and HIV patients is less clear than in
idiopathic PAH. Nevertheless, experts recommend performing
acute vasoreactivity studies in these patients and to look for a
long-term response to CCBs in those in whom the test is positive.
TABLE 18 Case 7: clinical characteristics
First evaluation After 12 months of high-dose CCB
At rest Acute vasodilator testing At rest Acute vasodilator testing
WHO functional class III II
6MWD m 210 310
Pra mmHg 6 5 6 6
P¯pa mmHg 52 25 31 23
Ppcw mmHg 10 6 11 9
CO L?min-1 6.6 7.3 7.0 6.8
PVR dyn?s?cm-5 509 208 286 200
CCB: calcium channel blockers; WHO: World Health Organization; 6MWD: 6-min walk distance; Pra: right atrial pressure; P¯pa: mean pulmonary arterial pressure; Ppcw:
pulmonary capillary wedge pressure; CO: cardiac output; PVR: pulmonary vascular resistance.
TABLE 19 ESC/ERS guidelines: route of administration, half-life, dose ranges, increments and duration of administration of the
most commonly used agents for pulmonary vasoreactivity tests
Drug Route Half-life Dose range# Increments" Duration+
Epoprostenol Intravenous 3 min 2–12 ng?kg-1?min-1 2 ng?kg-1?min-1 10 min
Adenosine Intravenous 5–10 s 50–350 mg?kg-1?min-1 50 mg?kg-1?min-1 2 min
Nitric oxide Inhaled 15–30 s 10–20 ppm 5 min1
#: initial dose and maximal tolerated dose suggested (maximal dose limited by side-effects such as hypotension, headache, flushing, etc.); ": increments of dose by each
step; +: duration of administration on each step; 1: for nitric oxide, a single step within the dose range is suggested. Reproduced from [1] with permission from the publisher.
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The CCBs that have been predominantly used in reported
studies are nifedipine, diltiazem, and amlodipine, with
particular emphasis on the first two. The choice of CCB is
based upon the patient’s heart rate at baseline, with a relative
bradycardia favouring nifedipine and amlodipine and a
relative tachycardia favouring diltiazem. The daily doses of
these drugs that have shown efficacy in idiopathic PAH are
relatively high, 120–240 mg for nifedipine, 240–720 mg for
diltiazem, and up to 20 mg for amlodipine.
Patients with idiopathic PAH who meet the criteria for a
positive vasodilator response and are treated with a CCB
should be followed closely for both safety and efficacy with an
initial reassessment after 3–4 months of therapy including
RHC. If the patient does not show an adequate response,
defined as being in WHO functional class I or II and with a
marked haemodynamic improvement, additional PAH ther-
apy should be instituted.
Patients who have not undergone a vasoreactivity study or
those with a negative study should not be started on a CCB
because of potential severe side-effects.
CASE 8: IDIOPATHIC PAH WITH WHO FUNCTIONAL
CLASS II SYMPTOMS
Case report
A 48-yr-old male was referred for evaluation of breathlessness
associated with effort-associated palpitations and chest dis-
comfort. He reported that his symptoms occurred with
moderate exertion and was therefore deemed to be in WHO
functional class II. He denied dizziness, syncope or ankle
swelling. The only positive sign elicited on physical examina-
tion was an accentuated pulmonary component to the second
heart sound. Baseline 6MWD was 450 m. RHC confirmed pre-
capillary PH of moderate severity without associated acute
vasodilator response (right atrial pressure 2 mmHg, P¯pa
35 mmHg, Ppcw 5 mmHg, PVR 260 dyn?s?cm-5 and CI
5.6 L?min-1?m-2). Routine testing to assess for underlying
causes of PH was negative and a diagnosis of idiopathic
PAH was made. He was commenced on PAH-specific therapy
with an endothelin antagonist in addition to oral anticoagula-
tion. At reassessment after 6 months of treatment, he remained
in WHO functional class II, had a 6MWD of 466 m and showed
a stable pulmonary haemodynamic profile (right atrial
pressure 7 mmHg; P¯pa 39 mmHg; Ppcw 8 mmHg; PVR
238 dyn?s?cm-5 and CI 5.8 L?min-1?m-2). He was reassessed
thereafter on a 6-monthly basis. On each occasion, he was
TABLE 20 ESC/ERS guidelines: recommendations for right
heart catheterisation (RHC) (A) and vasoreactivity
testing (B)
Class# Level"
A. RHC
RHC is indicated in all patients with PAH to confirm
the diagnosis, to evaluate the severity and when PAH
specific drug therapy is considered
I C
RHC should be performed for confirmation of
efficacy of PAH-specific drug therapy
IIa C
RHC should be performed for confirmation of
clinical deterioration and as baseline for the evaluation
of the effect of treatment escalation and/or combination
therapy
IIa C
B. Vasoreactivity testing
Vasoreactivity testing is indicated in patients with IPAH,
heritable PAH and PAH associated with anorexigen
use to detect patients who can be treated with high
doses of a CCB
I C
A positive response to vasoreactivity testing is
defined as a reduction of P¯pa o10 mmHg to
reach an absolute value of P¯pa f40 mmHg
with an increased or unchanged CO
I C
Vasoreactivity testing should be performed
only in referral centres
IIa C
Vasoreactivity testing should be performed using
nitric oxide as vasodilator
IIa C
Vasoreactivity testing may be performed
in other types of PAH
IIb C
Vasoreactivity testing may be performed using
i.v. epoprostenol or i.v. adenosine
IIb C
The use of an oral or i.v. CCB in acute
vasoreactivity testing is not recommended
III C
Vasoreactivity testing to detect patients who can
be safely treated with high doses of a CCB is not
recommended in patients with other PH groups
(groups 2, 3, 4 and 5)
III C
PAH: pulmonary arterial hypertension; IPAH: idiopathic pulmonary arterial
hypertension; CCB: calcium channel blocker; P¯pa: mean pulmonary arterial
pressure; CO: cardiac output; PH: pulmonary hypertension. #: class of
recommendation; ": level of evidence. Reproduced from [1] with permission
from the publisher.
TABLE 21 ESC/ERS guidelines: recommendations for
general measures
Statement Class# Level"
It is recommended to avoid pregnancy in patients
with PAH
I C
Immunisation of PAH patients against influenza
and pneumococcal infection is recommended
I C
Physically deconditioned PAH patients should be
considered for supervised exercise rehabilitation
IIa B
Psychosocial support should be considered in
patients with PAH
IIa C
In-flight O2 administration should be considered
for patients in WHO FC III and IV and those with
arterial blood O2 pressure consistently
,8 kPa (60 mmHg)
IIa C
Epidural anaesthesia instead of general
anaesthesia should be utilised, if possible, for
elective surgery
IIa C
Excessive physical activity that leads to distressing
symptoms is not recommended in patients with PAH
III C
PAH: pulmonary arterial hypertension; WHO FC: World Health Organization
functional class. #: class of recommendation; ": level of evidence. Reproduced
from [1] with permission from the publisher.
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noted to be in WHO functional class II and had stable exercise
capacity, as evidenced by 6MWD consistently in the 475–500 m
range. Treatment was therefore continued without modifica-
tion. Since diagnosis of PAH 5 yrs ago, the patient has shown
no evidence of clinical or haemodynamic deterioration.
Commentary: relevance to ESC/ERS guidelines
The management of PAH patients includes general and
supportive measures, as follows. 1) Patients should avoid
excessive physical activity that leads to distressing symptoms,
but when physically deconditioned may undertake supervised
exercise rehabilitation. 2) Pregnancy is associated with 30–50%
mortality in patients with PAH and, as a consequence,
pregnancy is contraindicated in PAH. There is less consensus
relating to the most appropriate methods of birth control.
Barrier contraceptive methods are safe and progesterone-only
preparations are effective approaches to contraception and
avoid potential issues of oestrogens. 3) Patients should avoid
going to altitudes above 1,500–2,000 m without supplemental
oxygen. 4) It is recommended to vaccinate against influenza
and pneumococcal pneumonia.
Recommendations for general measures are summarised in
table 21.
Advice regarding the target INR in patients with idiopathic
PAH varies from 1.5–2.5 in most centres of North America to
2.0–3.0 in European centres.
Diuretic treatment is indicated in PAH patients with signs of
right ventricular failure and fluid retention.
When arterial blood oxygen pressure is consistently ,8 kPa
(60 mmHg) patients are advised to take oxygen to achieve a
arterial blood oxygen pressure of.8 kPa for o15 h?day-1.
Recommendations for general measures are summarised in
table 22.
TABLE 22 ESC/ERS guidelines: recommendations for
supportive therapy
Statement Class# Level"
Diuretic treatment is indicated in PAH patients
with signs of RV failure and fluid retention
I C
Continuous long-term O2 therapy is indicated
in PAH patients when arterial blood O2 pressure
is consistently ,8 kPa (60 mmHg)+
I C
Oral anticoagulant treatment should be
considered in patients with IPAH, heritable
PAH and PAH due to use of anorexigens
IIa C
Oral anticoagulant treatment may be
considered in patients with APAH
IIb C
Digoxin may be considered in patients with
PAH who develop atrial tachyarrhythmias to
slow ventricular rate
IIb C
PAH: pulmonary arterial hypertension; RV: right ventricular; IPAH: idiopathic
PAH; APAH: associated PAH. #: class of recommendation; ": level of evidence;
+: see also recommendations for PAH associated with congenital cardiac
shunts (table 15). Reproduced from [1] with permission from the publisher.
TABLE 23 ESC/ERS guidelines: recommendations for efficacy of specific drug therapy, balloon atrial septostomy and lung
transplantation for pulmonary arterial hypertension (group 1) according to World Health Organization functional class
(WHO FC)
Measure/treatment Classes of recommendation–level of evidence
WHO FC II WHO FC III WHO FC IV
Calcium channel blockers I–C# I–C# –
Endothelin receptor antagonists Ambrisentan I–A I–A IIa–C
Bosentan I–A I–A IIa–C
Sitaxentan IIa–C I–A IIa–C
Phosphodiesterase type-5 inhibitors Sildenafil I–A I–A IIa–C
Tadalafil" I–B I–B IIa–C
Prostanoids Beraprost – IIb–B –
Epoprostenol (intravenous) – I–A I–A
Iloprost (inhaled) – I–A IIa–C
Iloprost (intravenous) – IIa–C IIa–C
Treprostinil (subcutaneous) – I–B IIa–C
Treprostinil (intravenous) – IIa–C IIa–C
Treprostinil (inhaled)" – I–B IIa–C
Initial drugs combination therapy – – IIa–C
Sequential drugs combination therapy IIa–C IIa–B Iia–B
Balloon atrial septostomy – I–C I–C
Lung transplantation – I–C I–C
#: only in responders to acute vasoreactivity tests, I for idiopathic pulmonary arterial hypertension (PAH), heritable PAH and PAH due to anorexigens; IIa for associated
PAH conditions; ": under regulatory review in the European Union. Reproduced from [1] with permission from the publisher.
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As head-to-head comparisons among different compounds are
not available, no evidence-based first-line treatment can be
proposed. In this case the choice of the drug is dependent on a
variety of factors, including the approval status, the route of
administration, the side-effect profile, patients’ preferences
and physicians’ experience.
Classes of recommendations and level of evidence for first-line
therapy in PAH patients (group 1) depends on the WHO
functional class (table 23). Nonresponders to acute vasoreac-
tivity testing who are in WHO functional class II should be
treated with an endothelin receptor agonist or a PDE-5
inhibitor.
CASE 9: IDIOPATHIC PAH WITH WHO FUNCTIONAL
CLASS IV SYMPTOMS TREATED BY FIRST-LINE
COMBINATION THERAPY
Case report
A 27-yr-old female with previously well-controlled asthma since
childhood was referred for evaluation of a 1-month history of
progressive dyspnoea unresponsive to augmentation of inhaled
corticosteroids. There was no family history of pulmonary
vascular disease. At presentation she was in WHO functional
class IV, being breathless on minimal exertion and having
experienced several pre-syncopal episodes. Physical examination
revealed a loud pulmonic component to the second heart sound
and a soft pansystolic murmur over the tricuspid valve without
General measures and
supportive therapy
Avoid pregnancy (I-C)
Influenza and pneumococcal
immunisation (I-C)
Supervised rehabilitation (IIa-B)
Psycho-social support (IIa-C)
Avoid excessive physical activity (III-C)
Diuretics (I-C)
Oxygen# (I-C)
Oral anticoagulants:
  IPAH, heritable PAH and PAH
  due to anorexigens (IIa-C)
  APAH (IIb-C)
Digoxin (IIb-C)
Acute vasoreactivity test
(I-C for IPAH)
(IIb-C for APAH)
Expert referral (I-C)
NonvasoreactiveVasoreactive
WHO FC I-III
CCB (I-C)
Sustained response
(WHO FC I-II)
Continue CCB
Inadequate clinical
response Inadequate clinical
response
Sequential combination therapy (IIa-B)+
ERA
Prostanoids PDE-5 I
++
+
BAS (I-C) and/or
lung transplantation
(I-C)
Initial therapy
Epoprostenol i.v.Ambrisentan, bosentan,
sitaxentan, sildenafil
epoprostenol i.v.,
iloprost inhaled
Ambrisentan,
bosentan,
sildenafil
Tadalafil¶
Treprostinil s.c., inhaled¶
Tadalafil¶
Iloprost i.v., treprostinil i.v.Sitaxentan
I-A
Recommendation-
evidence
WHO FC
II
WHO FC
III
WHO FC
IV
I-B
IIa-C
Yes No
IIb-B Beraprost
Ambrisentan, bosentan,
sitaxentan, sildenafil, tadalafil¶,
iloprost inhaled, and i.v.
treprostinil s.c., i.v., inhaled¶,
initial combination therapy
FIGURE 6. Evidence-based treatment algorithm for pulmonary arterial hypertension patients (PAH; for group 1 patients only). APAH: associated PAH; BAS: balloon atrial
septostomy; CCB: calcium channel blocker; ERA: endothelin receptor antagonist; IPAH: idiopathic PAH; PDE-5I: phosphodiesterase type-5 inhibitor; WHO FC: World Health
Organization functional class. #: to maintain arterial blood O2 pressure .8 kPa (60 mmHg);
": under regulatory review in the European Union; +: IIa-C for WHO FC II.
Reproduced from [1] with permission from the publisher.
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jugular venous distension or peripheral oedema. Chest radio-
graph demonstrated an enlarged heart and clear lung fields.
Transthoracic echocardiography revealed a systolic Ppa
.100 mmHg and associated dilated right heart chambers with-
out evidence of intracardiac shunt. Arterial blood gas analysis
showed a respiratory alkalosis pattern and hypoxaemia.
Antinuclear antibody, anti-double-stranded DNA, rheumatoid
factor and HIV test were negative. Abdominal ultrasound
showed no evidence of portal hypertension. PFTs demonstrated
normal airway function and lung volumes, but a DL,CO of 60%
pred. Lung scintigraphywas unremarkable. The patient’s 6MWD
was 150 m, during which an oxygen desaturation to 81% was
recorded, despite the use of supplementary oxygen. RHC
confirmed severe pre-capillary PH with P¯pa 74 mmHg, PVR
1,450 dyn?s?cm-5, CI 1.9 L?min-1?m-2 and a mixed venous oxygen
saturation of 57%. Acute vasodilator testing with nitric oxide was
negative. Because of the severity of the patient’s symptoms,
advanced functional class, marked limitation of exercise capacity
and significant haemodynamic impairment, a decision was made
to initiate a dual targeted therapy regimen with combination
continuous i.v. prostacyclin and oral endothelin antagonist.
Commentary: relevance to ESC/ERS guidelines
The treatment algorithm (fig. 6) does not apply to patients in
other clinical groups, and in particular not to patients with PH
associated with group 2 (left heart disease) or with group 3
(lung diseases). In addition, the different treatments have been
evaluated by randomised controlled trials mainly in idiopathic
PAH, heritable PAH, PAH due to anorexigen drugs, and in
PAH associated with CTD or with CHD (surgically corrected
or not). The grades of recommendation and levels of evidence
for the other PAH subgroups are lower.
The suggested initial approach after the diagnosis of PAH is
the adoption of the general measures, the initiation of the
supportive therapy and referral to an expert centre. Acute
vasoreactivity testing should be performed in all patients with
group 1 PAH. Vasoreactive patients should be treated with
optimally tolerated doses of CCBs.
Nonresponders to acute vasoreactivity testing, or responders
who remain in (or progress to) WHO functional class III should
be considered candidates for treatment with an endothelin
receptor agonist, a PDE-5 inhibitor, or a prostanoid.
TABLE 24 Case 10: clinical characteristics
Treatment at evaluation None ERA (for 4 months) ERA and PDE-5I (for 5 months) ERA, PDE-5I and i.v.
prostacyclin (for 4 months)
WHO functional class III III III II
6MWD m 519 525 441 601
Pra mmHg 7 8 8 3
P¯pa mmHg 55 60 65 47
CI L?min-1?m-2 2.01 2.5 2.09 3.35
PVR dyn?s?cm-5 1248 1066 1368 649
BNP pg?mL-1 217 360 62
Modification of specific PAH therapy Initiation of ERA Addition of PDE5-I Addition of i.v. prostacyclin No change
ERA: endothelin receptor agonist; PDE5-I: phosphodiesterase type-5 inhibitor; WHO: World Health Organization; 6MWD: 6-min walk distance; Pra: right atrial pressure;
P¯pa: mean pulmonary arterial pressure; CI: cardiac index; PVR: pulmonary vascular resistance; BNP: brain natriuretic peptide; PAH: pulmonary arterial hypertension.
TABLE 25 ESC/ERS guidelines: parameters with established importance for assessing disease severity, stability and prognosis in
pulmonary arterial hypertension
Better prognosis Determinants of prognosis Worse prognosis
No Clinical evidence of RV failure Yes
Slow Rate of progression of symptoms Rapid
No Syncope Yes
I, II WHO FC IV
Longer (.500 m)# 6MWT Shorter (,300 m)
Peak O2 consumption .15 mL?min
-1?kg-1 Cardiopulmonary exercise testing Peak O2 consumption ,12 mL?min
-1?kg-1
Normal or near-normal BNP/NT-proBNP plasma levels Very elevated and rising
No pericardial effusion TAPSE" .2.0 cm Echocardiographic findings" Pericardial effusion TAPSE" ,1.5 cm
Pra ,8 mmHg and CI o2.5 L?min-1?m-2 Haemodynamics Pra .15 mmHg or CI f2.0 L?min-1?m-2
RV: right ventricular; WHO FC: World Health Organization functional class; 6MWT: 6-min walk test; BNP: brain natriuretic peptide; NT-proBNP: N-terminal proBNP;
TAPSE: tricuspid annular plane systolic excursion; Pra: right atrial pressure; CI: cardiac index. #: depending on age; ": TAPSE and pericardial effusion have been selected
because they can be measured in the majority of the patients. Reproduced from [17] with permission from the publisher.
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Continuous i.v. epoprostenol is recommended as first-line
therapy for WHO functional class IV PAH patients, because of
the survival benefit in this subset. In WHO functional class IV
patients, initial combination therapy should also be considered.
CASE 10: INADEQUATE RESPONSE TO PAH THERAPY
Case report
A previously healthy 39-yr-old female presented to her local
hospital with a 1-month history of progressive dyspnoea
associated with exercise-induced palpitations. She reported
that her symptoms had begun approximately 1 month after the
birth of her third child. Initial transthoracic echocardiography
demonstrated enlarged right heart chambers with estimated
systolic Ppa 100 mmHg without evidence of intracardiac shunt.
She was referred to an expert centre for further evaluation.
Initial RHC confirmed severe pre-capillary PH (P¯pa 55 mmHg,
PVR 1,250 dyn?s?cm-5, CI 2.0 L?min-1?m-2; table 24) without
acute vasodilator response. A diagnosis of idiopathic PAH was
made after additional investigations for associated causes of
PH were negative. As she was deemed to be in functional class
III, with a baseline 6MWD of 519 m, oral endothelin antagonist
therapy was initiated.
When the patient was reassessed after 4 months of treatment,
she was still in functional class III with a similar 6MWD and
haemodynamic profile that showed only a modest improve-
ment (table 24). Because of a lack of improvement in either
subjective or objective parameters, a decision was made to add
oral PDE-5 inhibitor therapy. At subsequent re-evaluation
6 months after this therapeutic modification, there was both a
clinical worsening (80 m reduction in 6MWD) and haemody-
namic deterioration (increased P¯pa and PVR, with associated
significant reduction in CI; table 24). In view of this objectively
defined deterioration in spite of dual oral targeted therapy,
continuous i.v. prostacyclin was added to her treatment
regimen. At the next assessment after 6 months of this three-
drug combination approach, a marked clinical and haemody-
namic improvement was observed (table 24). 3 yrs after
initiation of triple therapy the patient is alive and well.
Commentary: relevance to ESC/ERS guidelines
Regular evaluation of patients with PAH should focus on
variables with established prognostic importance, as outlined
above. Treatment decisions should be based on parameters that
reflect symptoms and exercise capacity and that are relevant in
terms of predicting outcome. Table 25 lists several parameters of
known prognostic importance that are widely used as follow-up
tools. Patients with better or worse prognosis are separated by an
intermediate group for which prognostication is more difficult.
Based on the clinical, noninvasive and invasive findings the
clinical condition of a patient can be defined as stable and
satisfactory, stable but not satisfactory, unstable and deteriorat-
ing, as follows. 1) Stable and satisfactory. Patients in this
condition should fulfil the majority of the findings listed in the
‘‘better prognosis’’ column. 2) Stable and not satisfactory. This is
a patient who, although stable, has not achieved the status that
the patient and treating physician would consider desirable.
Some of the limits described above for a stable and satisfactory
condition and included in the ‘‘better prognosis’’ column are not
fulfilled. These patients require re-evaluation and consideration
for additional or different treatment following full assessment.
3) Unstable and deteriorating. Patients in this condition fulfil the
majority of the findings listed in the ‘‘worse prognosis’’ column.
A goal-oriented treatment strategy is recommended in patients
with PAH. Treatment goals for PAH patients that may be
TABLE 26 ESC/ERS guidelines: definition of inadequate
response to pulmonary arterial hypertension
treatments
Inadequate clinical response for patients who were initially
in WHO FC II or III:
1) Resulting clinical status defined as stable and not satisfactory
2) Resulting clinical status defined as unstable and deteriorating
Inadequate clinical response for patients who were initially
in WHO FC IV:
1) No rapid improvement to WHO FC III or better
2) Resulting clinical status defined as stable and not satisfactory
WHO FC: World Health Organization functional class. Reproduced from [1] with
permission from the publisher.
TABLE 27 ESC/ERS guidelines: suggested assessments and timing for the follow-up of patients with pulmonary arterial
hypertension
At baseline
(prior to therapy)
Every 3–6 months# 3–6 months after initiation
or changes in therapy
In case of clinical worsening
Clinical assessment WHO FC/ECG X X X X
6MWT" X X X X
Cardiopulmonary exercise testing" X X X
BNP/NT-proBNP X X X X
Echocardiography X X X
RHC X+ X1 X1
WHO-FC: World Health Organization functional class; X: assessment is suggested; 6MWT: 6-min walk test; BNP: brain natriuretic peptide; NT-proBNP: N-terminal
proBNP; RHC: right heart catheterisation. #: intervals should to be adjusted to individual patients needs; ": usually one of the two exercise tests is performed; +: is
recommended (table 20); 1: should be performed (table 20). Reproduced from [1] with permission from the publisher.
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considered are those listed in the ‘‘stable and satisfactory
definition’’ and in the ‘‘better prognosis’’ column.
In the case of inadequate clinical response (table 26), sequential
combination therapy should be considered. Combination
therapy can include either an endothelin receptor agonist plus
a PDE-5 inhibitor, or a prostanoid plus an endothelin receptor
agonist, or a prostanoid plus a PDE-5 inhibitor. Appropriate
protocols for timing and dosing to limit possible side-effects of
the combination have still to be defined. In expert centres triple
combination therapy is also considered.
Balloon atrial septostomy and/or lung transplantation are
indicated for PAH with inadequate clinical response despite
optimal medical therapy or where medical treatments are
unavailable. These procedures should be performed only in
experienced centres.
Suggested follow-up strategies for patients with PAH are
reported in table 27.
CASE 11: PULMONARY VENO-OCCLUSIVE DISEASE
Case report
A previously healthy 37-yr-old female cigarette smoker (8 pack-
yrs) was referred with a 2-month history of intermittent chest
pain on a background of a 2-yr history of progressive dyspnoea.
On admission, the patient was in WHO functional class IV;
physical examination revealed a loud pulmonic component to
the second heart sound and normal pulmonary auscultation.
ECG demonstrated complete right bundle branch block. Arterial
blood gases showed severe hypoxaemia at rest (arterial oxygen
tension (Pa,O2) 5.8 kPa) while PFTs found normal values for
forced expiratory volume in 1 s, forced vital capacity and total
lung capacity, associated with a moderate impairment of DL,CO
(52%). Echocardiography estimated systolic Ppa at 72 mmHg.
RHC confirmed severe pre-capillary PH with normal left heart
filling pressures (P¯pa 68 mmHg, right atrial pressure 9 mmHg,
Ppcw 11 mmHg, CI 2.27 L?min-1?m-2 and PVR 1,010 dyn?s?cm-5).
Acute vasodilatator testing with nitric oxide showed a degree of
vasoreactivity that was insufficient to fulfil criteria for an acute
vasodilator response (decrease in P¯pa to 56 mmHg without
change in CI). 6MWD was not feasible. Ventilation/perfusion
lung scintigraphy found multiple mismatched subsegmentary
perfusion defects. HRCT showed patchy areas of centrilobular
ground-glass opacification, septal lines and mediastinal lymph
node enlargement (fig. 7). This combination of radiological
abnormalities associated with low Pa,O2 at rest and low DL,CO
was highly suggestive of a diagnosis of PVOD. Neither surgical
nor transbronchial lung biopsy, being contraindicated in
suspected PVOD, was performed. The patient was hospitalised
in the intensive care unit and treated with oxygen, diuretics and
dobutamine. Because of the poor prognosis associated with
PVOD, the risk of life-threatening pulmonary oedema with
specific PAH therapy and the requirement for inotropic support
in this case, the patient was listed for urgent double-lung
transplantation and was transplanted 1 week later. The diag-
nosis of PVODwas confirmed by pathological assessment of the
explanted lungs.
Commentary: relevance to ESC/ERS guidelines
Both PVOD and PCH are uncommon conditions, but are
increasingly recognised as causes of PAH. They have been
classified in a specific subgroup (group 19) of the clinical
classification for the pathological, clinical and therapeutic
differences with the other forms of PAH included in group 1.
The diagnosis of PVOD can be established with a high
probability by the combination of clinical suspicion, physical
examination, bronchoscopy and radiological findings. Most
patients complain of dyspnoea on exertion and fatigue, a
clinical presentation that is indistinguishable from idiopathic
PAH. Physical examination may reveal digital clubbing and bi-
basal crackles on lung auscultation, these being unusual in
other forms of PAH. Case series suggest that patients with
PVOD are more severely hypoxaemic and have a much lower
DL,CO than in other forms of PAH. HRCT scanning is the
investigation of choice. Typical findings suggestive of PVOD
are the presence of subpleural thickened septal lines, centri-
lobular ground-glass opacities and mediastinal lymphadeno-
pathy. Because PVOD may be associated with occult alveolar
haemorrhage, bronchoscopy with bronchoalveolar lavage may
be a useful tool in the diagnostic strategy. This noninvasive
approach may avoid lung biopsy in most of the cases.
58 98
FIGURE 7. High-resolution computed tomography in a pulmonary veno-occlusive disease patient showing septal lines and ground-glass opacities (a) associated with
mediastinal lymph node enlargement (arrow, b).
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Haemodynamic presentation of PVOD is similar to idiopathic
PAH. Importantly, Ppcw is almost invariably normal because
the pathological changes occur in small venulae and do not
affect the larger pulmonary veins.
There is no established medical therapy for PVOD. Most
importantly, vasodilators and especially prostanoids must be
used with great caution because of the high risk of pulmonary
oedema (table 28).
There are reports of sustained clinical improvement in
individual patients treated with these medications. Therefore,
therapy for PVOD should be undertaken only at centres with
extensive experience in the management of PH, and patients
should be fully informed about the risks.
Atrial septostomy may be considered but is usually limited by
hypoxaemia. The only curative therapy for PVOD and PCH is
lung transplantation, and similarly to idiopathic PAH there are
no reports of recurrence of disease following transplantation.
Patients with PVOD should be referred to a transplant centre
for evaluation as soon as the diagnosis is established.
CONCLUSION
We hope that these real-life cases and their accompanying
commentaries have emphasised the high clinical relevance of the
ESC and ERS guidelines, which should be largely disseminated
and implemented. On this occasion, the authors wish to thank N.
Galie`, University of Bologna, Bologna, Italy, who chaired the PH
guidelines group, and all task forcemembers, as well as members
of the guideline committees from the ESC and the ERS.
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TABLE 28 ESC/ERS guidelines: recommendations for
pulmonary veno-occlusive disease (PVOD)
Statement Class# Level"
Referral of patients with PVOD to a transplant centre
for evaluation is indicated as soon as the diagnosis
is established
I C
Patients with PVOD should be managed only in
centres with extensive experience in PAH due to
the risk of lung oedema after the initiation of
PAH-specific drug therapy
IIa C
PAH: pulmonary arterial hypertension. #: class of recommendation; ": level of
evidence. Reproduced from [1] with permission from the publisher.
REVIEW: PULMONARY HYPERTENSION GUIDELINES D. MONTANI ET AL.
290 VOLUME 18 NUMBER 114 EUROPEAN RESPIRATORY REVIEW
EUROPEAN RESPIRATORY UPDATE
Contemporary issues in pulmonary hypertension
C. Jardim, S. Hoette and R. Souza
I
n recent years, important contributions to the understand-
ing of pulmonary hypertension (PH) have been published in
core clinical journals [1]. Relevant and thought-provoking
studies evidencing the high quality of research in the PH field
have been carried out by specialists worldwide. We have
decided to focus on special issues we believe to be, on the one
hand, pertinent to the understanding of what has happened
hitherto and, on the other hand, useful to lay the new found-
ations on which future research will be based.
Amongst the articles published in the last couple of years, we
believe that the following groups of interest deserve special
attention: the summary of the fourth World Symposium
on PH; the guidelines on PH (both the American and the
European); and the studies that shed new light on the dis-
cussion of survival in PH.
FOURTH WORLD SYMPOSIUM ON PH
In June 2009, the results of the discussion of working groups on
specific issues of PH were published in 11 articles and one
editorial in the Journal of the American College of Cardiology [2–13].
The articles covered a vast array of topics on PH, from basic
research (comprising development, pathology, inflammation,
genetics, and cellular and molecular basis of PH) to clinical
issues, such as classification, diagnosis, the role of surgery and
medical treatment in pulmonary arterial hypertension (PAH).
Interestingly, there were also papers on end-points and clinical
trials, and on future perspectives for the treatment of PAH.
The article entitled ‘‘Updated clinical classification of pulmon-
ary hypertension’’ [3] aimed at grouping together different PH
manifestations with similar pathophysiological mechanisms,
clinical presentation and therapeutic options. In spite of the
maintenance of the general architecture of the classification
compared to the previous classifications (Second and Third
World Symposium on Pulmonary Hypertension in 1998
(Evian, France) and 2003 (Venice, Italy), respectively) [14],
some changes have been made to incorporate new knowledge
on the disease.
The current classification of PH comprises the following
groups, namely: 1) PAH, 19) pulmonary veno-occlusive disease
(PVOD) and/or pulmonary capillary hemangiomatosis (PCH),
2) PH owing to left heart disease, 3) PH owing to lung diseases
and/or hypoxia, 4) chronic thromboembolic hypertension, and
5) PH with unclear and/or multifactorial mechanisms [3].
Most changes were incorporated in group 1, in which we find
different subgroups. The first aspect to be highlighted is that
the term idiopathic PAH (IPAH) was maintained, once again
avoiding the use of primary and secondary PH; as stated since
the Third World Symposium in PH (Venice, 2003) [14].
PAH may occur in a familial context and in this setting up to
70% of the patients may present with bone morphogenetic
protein receptor (BMPR)-2 mutations [15, 16]. In addition, a
mutation may be found in cases with no family history of PAH
(up to 40% of such cases) [17]. Thus, it was reasonable to
replace the term ‘‘familial PAH’’ by the term ‘‘heritable PAH’’.
In this subgroup, identifiable mutations are acknowledged,
such as BMPR2 and activin receptor-like kinase-1 or endoglin.
Recently, the prognostic importance of identifying the pre-
sence of mutations has been highlighted [18, 19]. Mutation
carriers not only present the genetic anticipation phenomena,
in which symptoms start at earlier age as compared to the
parents, but are also prone to present worse clinical course or a
less favourable prognosis.
The role of drugs and toxins has been stressed and the
categorisation of risk factors and the likelihood of developing
PAH have been modified. In the previous classification, drugs
and toxins were regarded as an associated condition, i.e. just as
connective tissue disease [14]. However, recently published
data suggest that the drugs act more like a trigger not
necessarily influencing the clinical course of the disease [20].
We have also learnt that BMPR2 mutations can be found in
anorexigen-induced PH [20, 21]. Based on these data, a subtle
but significant change was made and instead of an associated
condition, the classification now states ‘‘drug and toxin-
induced PAH’’. In terms of epidemiology, this assumption
allows the inclusion of this subgroup of patients together with
patients with IPAH in clinical studies.
In the associated conditions, we have seen the incorporation of
schistosomiasis as an associated condition for the development
of PAH, and the limitation of the subgroup formerly generi-
cally called haemoglobinopathies [13] to the more specific sub-
group of chronic haemolytic anaemia.
Schistosomiasis has been studied for decades and its association
with PH has been described in the first half of the 20th Century
[22, 23]. Formerly in group 4, schistosomiasis-associated PAH
(Sch-PAH) has been reclassified into group 1. A recent study
[24] confirmed earlier studies [25], demonstrating that in
schistosomiasis most of the vascular injuries are not solely
explained by egg embolism. In addition, the occurrence of
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plexiform lesions in Sch-PAH might be indistinguishable from
those seen in IPAH. Furthermore, there is growing evidence
based on experimental models emphasising the role of
inflammatory mechanisms on the pathogenesis of Sch-PAH
[26]. Invasive haemodynamic assessment showed a PAH
prevalence of 4.6% in patients with the hepatosplenic form of
schistosomiasis. The development of PAH in this subgroup of
patients may be related to inflammation, co-existence of porto-
pulmonary hypertension and occasional increased cardiac
output to the pulmonary circulation [27]. These multiple
possible pathways may somehow explain the better clinical
course of Sch-PAH.When compared to IPAH, Sch-PAHpatients
present with a better haemodynamic profile at diagnosis and
better prognosis; nonetheless, they still have a 3-yr mortality
rate of ,15% [28]. Since schistosomiasis is a highly prevalent
disease worldwide and given the non-negligible mortality rate,
the reclassification of Sch-PAH in group 1 based on pathological
and haemodynamic studies may warrant trials with specific
treatments for this highly prevalent condition.
PAH associated with chronic haemolytic anaemias, such as
sickle-cell disease or thalassemia, remained in group 1, re-
placing the generic term haemoglobinopathies, which was
present on the previous classification. The possible mechan-
isms for the development of PH in this group include a high
cardiac output with consequential pulmonary vascular hyper-
flow and impaired nitric oxide action in the pulmonary vessels
due to chronic haemolysis. Because one or more of these
mechanisms may contribute to the elevation of pulmonary
pressure in this setting, patients may present with either
predominant pre- or post-capillary PH [29]. However, since a
significant proportion of patients with PH and haemolytic
anaemias have PAH, they were kept in group 1.
It is important to highlight that other conditions, such as
connective tissue diseases [30] or schistosomiasis [31], may
present pre- or post-capillary PH. Based on this, the classifica-
tion cannot be done solely according to the baseline disease; it
is absolutely indispensible to combine the clinical information
and the results of the invasive haemodynamic evaluation in
order to appropriately classify an individual with PH.
Finally, in group 19 we find PVOD and PCH. Although pre-
senting with different phenotypes, they have been placed
together for occasionally having similar risk factors, genetic
mutations and pathological findings, most of which they share
with IPAH. However, when it comes to response to treatment,
data is somewhat disappointing. In fact, some treatments to
IPAH may actually be deleterious for these conditions if not
used cautiously [32–35].
Group 2 comprises what is believed to be the most frequent
cause of PH. In the previous classification, left ventricular heart
disease was divided into atrial/ventricular or valvular disease
[14]. In the current classification, PH owing to left heart disease
was divided into systolic or diastolic dysfunction, maintaining
valvular disease as a separate cause. There has been an
increased interest of left ventricular dysfunction with normal
ejection fraction. Specific algorithms have been proposed to
better diagnose this clinical condition avoiding the possible
deleterious effects that inadequate treatments strategies might
cause when this condition is not recognised [4].
In group 3, a new category was added: mixed obstructive/
restrictive disease. It has been recently recognised that patients
presenting with upper lobe emphysema combined with lower
lobes interstitial infiltrate have higher incidence of PH, with
direct implication on prognosis [36, 37].
In group 4 we find chronic thromboembolic pulmonary
hypertension (CTEPH). Formerly, all causes of thromboem-
bolic disease were subclassified in proximal and distal ob-
struction [38]. Since CTEPH may be an operable form of PH
with potential cure (or significant improvement in right
ventricle function), the new classification avoids the distinction
between proximal end distal obstruction, to underline the need
of specific multidisciplinary assessment of such cases in
experienced reference centres in order to evaluate operability.
Finally, in group 5 we find PH with unclear multifactorial
mechanisms. Haematological, systemic and metabolic disor-
ders are described in this group, recognising the relationship
between these conditions and PH; however, expressing the
uncertainties about pathophysiology, treatment and outcome.
The classification working team has fortunately found an
adequate name for this set of conditions within group 5 instead
of simply calling it ‘‘PH caused by disorders directly affecting
the pulmonary vasculature’’ or ‘‘miscellaneous’’, as in pre-
vious classifications [14].
The definition of resting PH has not changed, being defined
as the presence of mean pulmonary artery pressure (P¯pa)
o25 mmHg. A resting P¯pa between 8 and 20 mmHg should be
considered normal. The authors consider that further studies are
needed to determine the natural history of individuals with a
resting P¯pa between 21 and 24 mmHg. The definition of exercise
PH is still awaiting better evidence to support it, therefore, being
excluded from the current classification [39].
A thorough search of the literature and a strict classification of
the levels of evidence of each intervention were performed to
put together an algorithm to treat patients in group 1, in each
functional class [12]. General interventions, such as anti-
coagulants, oxygen and diuretics, were incorporated into the
algorithm as expert opinion level of evidence. When it comes
to specific treatment, the following data are presented for the
same level of recommendation, in alphabetical order, not in
order of importance (all oral therapy, unless otherwise stated).
PAH class II: Level of recommendation A: ambrisentan,
bosentan, sildenafil; level of recommendation B: sitaxsentan,
tadalafil.
PAH class III: Level of recommendation A: ambrisentan,
bosentan, epoprostenol (intravenous), iloprost (inhaled), silde-
nafil; level of recommendation B: sitaxsentan, tadalafil,
treprostinil (subcutaneous); level of recommendation C:
beraprost; expert opinion B: iloprost (intravenous), treprostinil
(intravenous).
PAH class IV: Level of recommendation A: epoprostenol
(intravenous); level of recommendation B: iloprost (inhaled);
level of recommendation C: treprostinil (subcutaneous); expert
opinion B: iloprost (intravenous), treprostinil (intravenous),
initial combination therapy; expert opinion C: ambrisentan,
bosentan, sildenfil, sitaxsentan, tadalafil.
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It is also interesting to note that in the event of lack of clinical
response, a sequential combination therapy is considered with
either three classes of drugs available (phosphodiesterase-5
inhibitors, endothelin receptor antagonists and prostanoids).
This treatment approach has been reported in different settings
and with different combinations of drugs [40–42]; no specific
combination is formally recommended.
The relevance of this article is to organise the available data on
treatment in an evidence-based algorithm, considering the
incorporated practice of combination therapy, either upfront
(for the most severe cases) or add-on (in the event of lack of
clinical response).
THE EUROPEAN SOCIETY OF CARDIOLOGY/EUROPEAN
RESPIRATORY SOCIETY AND THE AMERICAN COLLEGE
OF CHEST PHYSICIANS/AMERICAN HEART
ASSOCIATION GUIDELINES
Following the publication of the summary of the Fourth World
Symposium on PH, joint guidelines from the European Society
of Cardiology/European Respiratory Society [43] for the
diagnosis and treatment of pulmonary hypertension were
published, as was the American College of Chest Physicians
(ACCP)/American Heart Association (AHA) expert consensus
on pulmonary hypertension [44]. These guidelines offered
another unique opportunity to propose useful approaches to
issues in clinical practice. Some aspects of both documents
deserve closer attention.
In the European guidelines, an interesting approach to the
likelihood of the presence of PH based on echocardiogram
findings was presented. Since echocardiogram is usually the
first assessment to detect the possibility of PH [45], it may be
reasonable to consider combined parameters to establish the
likelihood of PH. By combining the tricuspid regurgitation
velocity to other echocardiographic variables suggestive of PH
an arbitrary criteria suggest the stratification in PH unlikely,
possible and likely. The interesting aspect of this stratification
is its combination to the presence of symptoms or associated
baseline conditions in order to obtain a rational use of right
heart catheterisation or to propose the follow-up approach for
a given patient. Although arbitrary, these recommendations
are from an expert consensus and may represent innovative
ways for daily practice or at least suggest new approaches to
be addressed in future studies [46].
Conversely, the ACCP/AHA consensus suggests a practical
approach on diagnosing PH with a table of pivotal and
contingent tests. For instance, ventilation/perfusion scans are
considered to be pivotal test, whereas computed tomography
angiograms are considered to be contingent in the investiga-
tion process. By such a diagnostic approach, a more reasonable
use of the diagnostic tools is possible, based on the probability
of diagnosis, timesaving and resources.
These provocative suggestions might be considered when
adapting the diagnostic algorithms to a specific socio-geogra-
phical condition, putting together the regional characteristics
and the availability of the different diagnostic tools.
SURVIVAL
In 2009, we emphasised the role of contemporary registries in
PAH not only to better characterise the disease itself but also to
recognise that regional characteristics have to be identified in
order to appropriately extrapolate and/or adapt international
guidelines for diagnosis and treatment [1]. Interestingly, over
the past year, the survival data of some of these registries
have become available. One of the problems of dealing with
an orphan disease is its low prevalence. Consequently, an
important part of the gathered knowledge results from a small
observation series, precluding the generalisation of the find-
ings [47]. One alternative to bypass this obvious limitation is to
set up multicenter registries. However, significant caveats may
take place in such an approach and should be taken into
consideration when analysing data coming from registries
of rare diseases. Retrospective cohorts have the limitation im-
posed by missing data and reliable diagnosis, while prospec-
tive cohorts may limit the inclusion criteria too much in order
to homogenise the study population [48]. Both characteristics
may limit the extrapolation of data and should be carefully
considered. Nevertheless, three different registries had their
survival data published during the last year and from all of
them new prediction equations have emerged. This is parti-
cularly interesting since it reinforced a common feeling that the
National Institute of Health equation, published in the early
1990s [49], was no longer accurate to evaluate contemporary
data, considering the significant development in knowledge
and available therapies that has taken place in the past
decades.
THENAPPAN et al. [50] published a large monocentric registry of
PAH patients. One of the findings that was also confirmed by
the other registries is that current PAH patients present at an
older age compared to earlier studies. While in the late 1980s
the mean age at diagnosis was 37 yrs [51], in this study the
authors found a mean age of 48 yrs (patients were even older in
the other published registries). Moreover, older age at diagnosis
was independently associated with long-term survival. Of
note, the majority of patients presented in functional class III
or IV at diagnosis, although the predominant retrospective
nature of the study may have biased this finding. The authors
also described that connective tissue disease, functional ca-
pacity, right atrial pressure, cardiac index and pulmonary
vascular resistance were predictors of survival. Surprisingly,
the authors decided to build a prediction equation based not
on the prognostic variables found in their study but only on
the same hemodynamic variables used in the National Institute
of Health equation alleging their intention to make a direct
comparison to the previously described equation. The pro-
posed model was certainly a step further in the analysis of
survival data in PAH; however, by excluding significant
parameters the authors may have limited the extrapolation of
their prediction model.
In 2006, baseline data from the French National Registry on
PAH were published evidencing a PAH incidence of 2.4 cases
per 1 million adult inhabitants per year and a prevalence of
15 cases per 1 million inhabitants for PAH (5.9 cases per 1
million inhabitants for IPAH) [52]. The study included 674
cases from 17 different reference centres. By that time, the
authors had already described older age at diagnosis and a less
preserved functional class (III or IV) for the vast majority of the
patients, reinforcing the concept that even with the develop-
ment obtained in recent years the diagnosis was still late on the
disease progression.
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The 3-yr survival data for idiopathic, heritable and anorexigen-
associated PAH have been addressed in two publications this
year [12, 48]. The first study demonstrated 1-, 2- and 3-yr
survival rates of 82.9%, 67.1% and 58.2%, respectively [53].
These results, when compared to the results of the National
Institute for Health registry, suggest that survival has been
significantly but still too modestly improved, reinforcing the
concept that PAH is still a devastating clinical condition. Of
note, the authors identified three independent prognostic
factors: cardiac output and 6-min walk test (6MWT) distance
at diagnosis, and sex. Male patients notably presented with
worse prognosis compared to the predominant female sub-
group. The possible mechanisms that justify this association of
male sex and prognosis in IPAH are not clear but this now
constitutes a new issue to be addressed in future studies. Some
methodological aspects of this study deserve better attention.
The authors decided to limit their observations to a more
homogeneous population; for this, not only did they limit
the population to patients with idiopathic, heritable and
anorexigen-induced PAH but also decided to consider only
the data obtained at diagnosis, in an attempt to deal with a
more robust data set. Another important aspect was the
distinction between newly diagnosed patients (incident) and
prevalent patients (diagnosed before study enrolment). It is
well known that the inclusion of prevalent cases in observa-
tional studies may impose a significant bias if the mortality
rate is not constant during time, which is the case for PAH.
By distinguishing both populations, the authors tried to mini-
mise this bias. However, the arbitrary cut-off for combining the
prevalent and incident groups in order to perform the survival
analysis (the authors joined prevalent patients diagnosed,3 yrs
of study enrolment and performed a left truncation analysis) still
imposed a bias to the analysis. It is important to notice that no
specific treatment algorithm, besides the international guidelines
available at the time [54], was imposed; thus the study tried to
reflect ‘‘real life’’ in PAH management.
In another study, the authors analysed the significant dif-
ference on survival between incident and prevalent cases [55].
In addition, the trend in survival was associated with the time
from diagnosis in the prevalent population; the shorter the
time from diagnosis the more the prevalent subgroup resem-
bled the incident group, with worse prognosis. This study also
reinforced the concept that different diagnoses within group 1
have different survival rates. We also have to consider that
there are different survival rates in different groups of PAH,
e.g. a worse prognosis in connective tissue disease-PAH and a
better prognosis in HIV-PAH, congenital heart disease-PAH
and Sch-PAH [56–58].
Moreover, a new prognostic equation for idiopathic, heritable
and anorexigen-induced PAH was proposed based on the
three prognostic markers found on the multivariate analysis
(sex, 6MWT and cardiac output), thus incorporating markers
other than the common haemodynamic ones, possibly increas-
ing the representativeness of the equation. This assumption,
however, has to be properly validated in a different population
prior to being accepted.
Another important registry whose data have been published
this year is the REVEAL registry (Registry to Evaluate Early
and Long-Term PAH Disease Management). The registry
comprises the efforts of 54 different centres in the USA and
has been evaluated in three articles addressing different
characteristics of this comprehensive study on PAH [59–61].
The first article described the baseline demographic character-
istics of the 2,967 patients included in the registry [59]. This
study confirmed the shift toward older age at diagnosis in
PAH. 46% of included patients presented with IPAH; con-
sidering patients with associated causes for PAH, connective
tissue disease associated-PAH accounted for almost half of the
cases. It is interesting to note the low prevalence of HIV
associated-PAH in the REVEAL study (,2.2%) as compared to
the prevalence found in the French Registry (6.2%). How much
of this can be attributed to lower awareness about the as-
sociation in the US as compared to France where a quite recent
multicenter prevalence study was performed [62] is still a
matter of debate.
An interesting comparison between the REVEAL registry and
other historic or non-US contemporary registries recently
became available, reported by FROST et al. [61]. In this study
the authors selected the subgroups within the REVEAL
registry that could be directly compared to other studies. In
addition, different aspects of the registry not previously
addressed were analysed. One peculiar aspect is the behaviour
of the female/male ratio increasing with survival post-
diagnosis. One might link this finding to a worse prognosis
for the male sex found in the French Registry [53], strengthen-
ing the need to address the role of sex in PAH survival in a
specific study with an appropriate design.
The incidence for idiopathic and familial PAH found in the
registry was 1.1 cases per million while the prevalence of PAH
was 12.4 cases per million which is comparable to the
previously described rates [52] providing consistent data for
contemporary use.
Finally, a third study analysing survival of PAH patients
included in the REVEAL registry has been published [60]. The
authors decided not to limit their study population, including
all forms of PAH now within group 1 of the classification and
available at the time of the study initiation [14]. By doing so,
the authors tried to make the analyses reproducible in all
subgroups; as if a proposition of this approach is of indubitable
value, it may impose limitations to the analysis itself. Another
methodological issue that has to be accounted for is the fact that
the data used in the analyses was collected within a certain
period of time and not necessarily at the diagnosis. In addition,
prevalent and incident cases were considered together which
could have resulted in somehow optimistic survival rates. The
authors, however, carefully included time from diagnosis in the
analysis in order to categorise the patients; nevertheless, no
statistical significance was found regarding this dichotomisa-
tion of the study population. Of note is the fact that the
comparison was made between patients diagnosed within
90 days prior to study enrolment and patients diagnosed
.90 days before enrolment, a rather small time-frame to
properly distinguish the two study populations if the results
of the prevalent population from the French study is considered
[55]. This is particularly important since the vast majority of the
REVEAL population comprises prevalent patients.
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This large cohort allowed the identification of multiple prog-
nostic factors, such as the origin of PAH (different diagnoses
within group 1), age, functional class, 6MWT distance, cardiac
function, B-type natriuretic peptide, echocardiographic finding
of pericardial effusion and diffusing capacity of the lung for
carbon monoxide. Based on these variables, the authors were
able not only to develop a prognostic equation but to create a
‘‘stratification of risk’’ considering 1-yr survival. This stratifica-
tion confirmed a concept suggested in 2006 in an article by
MCLAUGHLIN and MCGOON [63] in which the authors described
several conditions that could be reflecting a higher risk of death.
The REVEAL study allowed the proper validation of the
concept and also identified the group of variables that should
be considered in this matter.
Taken together, these registries brought important information
to the field by identifying subgroups with worse prognosis that
should be better addressed in terms of treatment strategies.
There are certainly numerous possibilities to explore in the
future, such as upfront combination therapy and earlier
indication for epoprostenol. These studies provided us with
goals to be reached in order to possible interfere in the
prognosis of PAH patients.
In summary, the last couple of years have been quite prolific in
terms of baseline concepts that will allow the delineation of
better studies in the near future. Besides the development of
new therapies, the advances to be reached will depend on
strong foundations regarding concepts and understanding of
the natural course of the disease; doubtlessly these recent
studies represent a significant step forward in this sense.
STATEMENT OF INTEREST
None declared.
REFERENCES
1 Souza R, Jardim C. Trends in pulmonary arterial hypertension. Eur
Respir Rev 2009; 18: 7–12.
2 Humbert M, McLaughlin VV. The 4th World Symposium on
Pulmonary Hypertension. Introduction. J Am Coll Cardiol 2009; 54:
Suppl. 1, S1–S2.
3 Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical
classification of pulmonary hypertension. J Am Coll Cardiol 2009;
54: Suppl. 1, S43–S54.
4 Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assess-
ment, and treatment of non-pulmonary arterial hypertension
pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1,
S85–S96.
5 Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth
factors, and pulmonary vascular remodeling. J Am Coll Cardiol
2009; 54: Suppl. 1, S10–S19.
6 Machado RD, Eickelberg O, Elliott CG, et al. Genetics and
genomics of pulmonary arterial hypertension. J Am Coll Cardiol
2009; 54: Suppl. 1, S32–S42.
7 Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical
modalities of treatment in pulmonary hypertension. J Am Coll
Cardiol 2009; 54: Suppl. 1, S67–S77.
8 McLaughlin VV, Badesch DB, Delcroix M, et al. End points and
clinical trial design in pulmonary arterial hypertension. J Am Coll
Cardiol 2009; 54: Suppl. 1, S97–S107.
9 Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular
basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;
54: Suppl. 1, S20–S31.
10 Ghofrani HA, Barst RJ, Benza RL, et al. Future perspectives for the
treatment of pulmonary arterial hypertension. J Am Coll Cardiol
2009; 54: Suppl. 1, S108–S117.
11 Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and
assessment of pulmonary arterial hypertension. J Am Coll Cardiol
2009; 54: Suppl. 1, S55–S66.
12 Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based
treatment algorithm in pulmonary arterial hypertension. J Am Coll
Cardiol 2009; 54: Suppl. 1, S78–S84.
13 Tuder RM, Abman SH, Braun T, et al. Development and pathology
of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1,
S3–S9.
14 Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of
pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12,
5S–12S.
15 Cogan JD, Pauciulo MW, Batchman AP, et al. High frequency of
BMPR2 exonic deletions/duplications in familial pulmonary
arterial hypertension. Am J Respir Crit Care Med 2006; 174: 590–598.
16 Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene
rearrangements account for a significant proportion of mutations
in familial and idiopathic pulmonary arterial hypertension. Hum
Mutat 2006; 27: 212–213.
17 Machado RD, Aldred MA, James V, et al. Mutations of the TGF-
beta type II receptor BMPR2 in pulmonary arterial hypertension.
Hum Mutat 2006; 27: 121–132.
18 Girerd B, Montani D, Coulet F, et al. Clinical outcomes of
pulmonary arterial hypertension in patients carrying an
ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010; 181:
851–861.
19 Sztrymf B, Coulet F, Girerd B, et al. Clinical outcomes of
pulmonary arterial hypertension in carriers of BMPR2 mutation.
Am J Respir Crit Care Med 2008; 177: 1377–1383.
20 Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial
hypertension associated with fenfluramine exposure: report of
109 cases. Eur Respir J 2008; 31: 343–348.
21 Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline
mutations in pulmonary hypertension associated with fenflur-
amine derivatives. Eur Respir J 2002; 20: 518–523.
22 Shaw AP, Ghareeb A. The pathogenesis of pulmonary schistoso-
miasis in Egypt with special reference to Ayerza’s disease. J Pathol
Bacteriol 1938; 46: 401–424.
23 Souza R, Fernandes CJ, Jardim CV. Other causes of PAH
(schistosomiasis, porto-pulmonary hypertension and hemolysis-
associated pulmonary hypertension). Semin Respir Crit Care Med
2009; 30: 448–457.
24 Pozzan J, Souza R, Jardim C. Histopathological features of
pulmonary vascular disease in chronic Schistosomia mansoni
infection are not different from those in idiopathic pulmonary
hypertension. Presented at the American Thoracic Society Annual
Congress, Toronto, Canada; 2008: A443.
25 Chaves E. The pathology of the arterial pulmonary vasculature in
manson’s schistosomiasis. Dis Chest 1966; 50: 72–77.
26 Graham BB, Mentink-Kane MM, El-Haddad H, et al.
Schistosomiasis-induced experimental pulmonary hypertension:
role of interleukin-13 signaling. Am J Pathol 2010; 177: 1549–1561.
27 Hovnanian A, Hoette S, Fernandes CJ, et al. Schistosomiasis
associated pulmonary hypertension. Int J Clin Pract Suppl 2010;
165: 25–28.
28 dos Santos Fernandes CJ, Jardim CV, Hovnanian A, et al. Survival
in schistosomiasis-associated pulmonary arterial hypertension.
J Am Coll Cardiol 2010; 56: 715–720.
29 Anthi A, Machado RF, Jison ML, et al. Hemodynamic and
functional assessment of patients with sickle cell disease and
pulmonary hypertension. Am J Respir Crit Care Med 2007; 175:
1272–1279.
30 de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac
abnormalities by Doppler echocardiography in a large nationwide
UPDATE ON PH C. JARDIM ET AL.
270 VOLUME 19 NUMBER 118 EUROPEAN RESPIRATORY REVIEW
multicentric cohort of patients with systemic sclerosis. Ann Rheum
Dis 2008; 67: 31–36.
31 Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations
of hepatosplenic schistosomiasis. Circulation 2009; 119: 1518–1523.
32 Montani D, Jais X, Price LC, et al. Cautious epoprostenol therapy is
a safe bridge to lung transplantation in pulmonary veno-occlusive
disease. Eur Respir J 2009; 34: 1348–1356.
33 Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-
occlusive disease. Eur Respir J 2009; 33: 189–200.
34 Montani D, Jais X, Dorfmuller P, et al. Goal-oriented therapy in
pulmonary veno-occlusive disease: a word of caution. Eur Respir J
2009; 34: 1204–1206.
35 Palazzini M, Manes A. Pulmonary veno-occlusive disease mis-
diagnosed as idiopathic pulmonary arterial hypertension. Eur
Respir Rev 2009; 18: 177–180.
36 Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in
patients with combined pulmonary fibrosis and emphysema
syndrome. Eur Respir J 2010; 35: 105–111.
37 Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis
and emphysema: a distinct underrecognised entity. Eur Respir J
2005; 26: 586–593.
38 Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic
pulmonary hypertension. Eur Respir J 2004; 23: 637–648.
39 Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure
during rest and exercise in healthy subjects: a systematic review.
Eur Respir J 2009; 34: 888–894.
40 Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan
with epoprostenol in pulmonary arterial hypertension:
BREATHE-2. Eur Respir J 2004; 24: 353–359.
41 Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented
treatment and combination therapy for pulmonary arterial
hypertension. Eur Respir J 2005; 26: 858–863.
42 Galie N, Negro L, Simonneau G. The use of combination therapy
in pulmonary arterial hypertension: new developments. Eur Respir
Rev 2009; 18: 148–153.
43 Galie N, Hoeper MM, Humbert M, et al. Guidelines for the
diagnosis and treatment of pulmonary hypertension. Eur Respir J
2009; 34: 1219–1263.
44 McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009
expert consensus document on pulmonary hypertension a report of
the American College of Cardiology Foundation Task Force on
Expert Consensus Documents and the American Heart Association
developed in collaboration with the American College of Chest
Physicians; American Thoracic Society, Inc.; and the Pulmonary
Hypertension Association. J Am Coll Cardiol 2009; 53: 1573–1619.
45 Vachie´ry J-L, Coghlan G. Screening for pulmonary arterial
hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162–169.
46 Montani D, O’Callaghan DS, Jaı¨s X, et al. Implementing the ESC/
ERS pulmonary hypertension guidelines: real-life cases from a
national referral centre. Eur Respir Rev 2009; 18: 272–290.
47 McLaughlin VV, Suissa S. Prognosis of pulmonary arterial
hypertension: the power of clinical registries of rare diseases.
Circulation 2010; 122: 106–108.
48 Provencher S, Souza R. Predicting survival in pulmonary arterial
hypertension: time to move forward. Eur Respir J 2010; 35: 958–959.
49 D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with
primary pulmonary hypertension. Results from a national
prospective registry. Ann Intern Med 1991; 115: 343–349.
50 Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial
hypertension: a reappraisal of the NIH risk stratification equation.
Eur Respir J 2010; 35: 1079–1087.
51 Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary
hypertension. A national prospective study. Ann Intern Med
1987; 107: 216–223.
52 Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial
hypertension in France: results from a national registry. Am J
Respir Crit Care Med 2006; 173: 1023–1030.
53 Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with
idiopathic, familial, and anorexigen-associated pulmonary arterial
hypertension in the modern management era. Circulation 2010;
122: 156–163.
54 Galie N, Seeger W, Naeije R, et al. Comparative analysis of clinical
trials and evidence-based treatment algorithm in pulmonary
arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 81S–88S.
55 Humbert M, Sitbon O, Yaici A, et al. Survival in incident and
prevalent cohorts of patients with pulmonary arterial hyperten-
sion. Eur Respir J 2010; 36: 549–555.
56 Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan
in patients with HIV-associated pulmonary arterial hypertension.
Eur Respir J 2009; 33: 92–98.
57 Kawut SM, Taichman DB, Archer-Chicko CL, et al.Hemodynamics
and survival in patients with pulmonary arterial hypertension
related to systemic sclerosis. Chest 2003; 123: 344–350.
58 Beghetti M, Tissot C. Pulmonary arterial hypertension in
congenital heart diseases. Semin Respir Crit Care Med 2009; 30:
421–428.
59 Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial
hypertension: baseline characteristics from the REVEAL Registry.
Chest 2010; 137: 376–387.
60 Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting
survival in pulmonary arterial hypertension: insights from the
Registry to Evaluate Early and Long-Term Pulmonary Arterial
Hypertension Disease Management (REVEAL). Circulation 2010;
122: 164–172.
61 Frost AE, Badesch DB, Barst RJ, et al. The Changing Picture of
Pulmonary Arterial Hypertension (PAH) Patients in the United
States: How the REVEAL Registry Differs From Historic and Non-
US Contemporary Registries. Chest 2010 [Epub ahead of print DOI:
10.1378/chest.10-0075].
62 Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of
HIV-related pulmonary arterial hypertension in the current
antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177:
108–113.
63 McLaughlin VV, McGoon MD. Pulmonary arterial hypertension.
Circulation 2006; 114: 1417–1431.
C. JARDIM ET AL. UPDATE ON PH
EUROPEAN RESPIRATORY REVIEW VOLUME 19 NUMBER 118 271
J Bras Pneumol. 2011;37(3):389-403
catheterization of the right ventricle (RV) and 
pulmonary arteries, thereby revolutionizing 
knowledge in the area of cardiopulmonary 
medicine. Access to hemodynamic pressure and 
flow measurements, as well as to blood gas 
measurements, provided a unique opportunity 
for advances in the assessment of pulmonary 
circulation, which became recognized as an 
exclusively arterial system, characterized by 
high compliance and low resistance, capable of 
accommodating large blood volumes and high 
blood flows at low pressures.(3)
Invasive hemodynamic assessment has 
become a valuable imaging tool, because it has 
Introduction
The physiology of the pulmonary circulation 
has only recently come to be understood. 
That is because the techniques available at the 
beginning of the 20th century did not allow direct 
assessment of the pulmonary vasculature. Until 
the late 1930s, there were no methods capable 
of providing information about cardiopulmonary 
interaction or the ventilation/perfusion ratio. 
The milestone breakthrough came in 1940, 
when the integration of the physiological 
studies by Cournard et al.(1) and Forssmann’s 
self-experimentation in 1929,(2) which consisted 
of radiographic documentation of the presence 
of a catheter in his own heart, culminated in 
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Abstract
Knowledge of the structure and function of pulmonary circulation has evolved considerably in the last few 
decades. The use of non-invasive imaging techniques to assess the anatomy and function of the pulmonary vessels 
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resonance imaging (MRI) techniques have been 
found to play an important role in the dynamic, 
real-time assessment of the microcirculation. 
The innovative technique known as electrical 
impedance tomography (EIT) is a promising tool.
This article reviews the characteristics, 
limitations, and roles of the various imaging 
technologies currently available for the 
assessment of the pulmonary circulation, as well 
as for the diagnosis and management of PH and 
pulmonary thromboembolism (PTE).
Chest X-ray
Chest X-ray should be among the initial tests 
in the assessment of PH because it is readily 
available, is inexpensive, and facilitates the 
diagnosis.
Chest X-ray changes are seen in more than 
85% of patients with a confirmed diagnosis of 
PH.(4) The major changes found include increased 
pulmonary artery diameter at the hilar level, in 
78% of cases (Figure 1); peripheral tapering of 
vessels, in 62%; and hyperlucent lung periphery, 
in 9% (Figure 2). The pulmonary artery diameter 
at the hilar level can be determined by measuring 
the interlobar artery diameter. The maximum 
transverse diameter of the right interlobar artery, 
as measured from its lateral aspect to the air 
column of the intermediate bronchus, is 16 
mm in men and 15 mm in women.(5) Because 
of the difficulty in assessing the left pulmonary 
artery by posteroanterior chest X-ray, the vessel 
should be assessed by lateral X-ray, beginning 
at the circular transparency created by the left 
upper lobe bronchus (which is visualized as 
being telescoped) and extending to the posterior 
margin of the vessel saddling the bronchus 
(Figure 1). The maximum limit of normality 
is 18 mm. A hilar-thoracic index (sum of the 
diameters of the pulmonary hila divided by that 
of the chest) above 38% is classically described, 
being present in approximately 75% of patients 
with PH (Figure 1).(6) Vascular calcification, 
usually located in the pulmonary artery trunk 
(PAT) or in its hilar branches, is rarely detected. 
This change is most commonly associated with 
congenital heart diseases and chronic central 
embolism.
Chest X-ray can facilitate the differential 
diagnosis with pulmonary parenchymal disease, 
heart failure, COPD, and kyphoscoliosis, as 
well as raising the suspicion of pulmonary 
clarified not only the physiological aspect of the 
pulmonary circulation but also the anatomical 
distribution of the pulmonary vessels and 
features of the right heart.
After the anatomical and functional status of 
the pulmonary circulation had been addressed, 
right heart catheterization came to be widely 
used for the assessment of the pulmonary 
vasculature, especially in the presence of disease, 
such as pulmonary hypertension (PH). However, 
despite being considered the gold standard, 
the method has major limitations by current 
standards, because it is invasive in nature, costly, 
and involves the use of radiation. However, the 
push to develop noninvasive techniques for 
monitoring pulmonary circulation was soon to 
begin.
Great efforts have been made to identify 
noninvasive imaging methods that reflect 
the anatomical and functional status of the 
pulmonary circulation in an accurate and 
reproducible way. However, noninvasive 
assessment of the pulmonary circulation is quite 
difficult. First, because no method has sufficient 
sensitivity to assess the most important aspect of 
the pulmonary circulation and the seat of most 
diseases: the microcirculation. Second, because 
much of the information about the pulmonary 
vasculature is indirect. When diseased, the 
small blood vessels lose the mutual exclusivity 
between high compliance and low resistance.
(3) The loss of elasticity and increased vascular 
impedance directly affect the RV. Therefore, 
imaging of the RV might indirectly characterize 
the status of the pulmonary circulation. However, 
it is also difficult to study the RV, because of 
its anatomical position in relation to the left 
ventricle (LV), its complex crescent-shaped 
geometry, and its thin walls. All of this makes 
the assessment of systolic function, as well as 
the assessment of myocardial volumes and mass, 
a challenge for noninvasive imaging methods. 
The available methods employ different imaging 
technologies to generate information about 
pulmonary circulation. Chest X-ray is the 
simplest example. Despite its limitations, chest 
X-ray can reveal abnormalities that are not 
identified clinically. Echocardiography and CT of 
the pulmonary arteries (CT angiography), both of 
which are well-known and widely used, provide 
valuable information about the right heart and 
pulmonary arteries. Novel CT and magnetic 
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Although the presence of PH can be 
suggested by conventional X-ray, the specificity 
of this method and its degree of accuracy in 
estimating the severity of PH are controversial.(7) 
Several factors, such as the size of the patient, 
the distance between the X-ray tube and the 
film, and the distance between the pulmonary 
artery and the film, affect the interlobar artery 
measurements. Many of the parameters used 
are subjective, and the measurements correlate 
poorly with the degree of PH.(7) Nevertheless, 
routine chest X-ray plays a central role in the 
initial investigation of dyspnea, as well as in the 
initial evaluation of patients with suspected PH.
Echocardiography
Transthoracic Doppler echocardiography 
is the most sensitive noninvasive method for 
estimating pulmonary artery pressure (PAP) 
when there is suspicion of PH.(8)
However, RV ejection fraction and volumes 
cannot be calculated with the use of the 
mathematical equations usually employed to 
study the LV. Therefore, several echocardiographic 
parameters have been developed to assess 
RV function and the hemodynamics of the 
pulmonary artery. The most widely used of 
those methods is based on the identification of 
thromboembolic disease when there are findings 
of oligemia, multiple areas of consolidation 
suggestive of pulmonary infarction, or 
asymmetry among the major pulmonary arteries 
(Figure 2).(7)
Figure 1 - Posteroanterior chest X-ray (in a) and lateral chest X-ray (in b) of a 28-year-old female patient 
with idiopathic pulmonary arterial hypertension. Note the dilated pulmonary artery trunk (1), the hilar-thoracic 
index (2) + (3) > 38% (4), and the left pulmonary artery > 18 mm (5) in profile.
Figure 2 - Anteroposterior chest X-ray of a 
41-year-old female patient. Note the following: 
subsegmental wedge-shaped opacity in the right 
upper lobe (1), suggestive of pulmonary infarction; 
prominence of the 2nd arch (2), suggestive of 
pulmonary hypertension; left lung oligemia (3); and 
nodular opacities with ill-defined borders (4). The 
patient had metastatic choriocarcinoma with tumor 
embolism.
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PH.(10) In the presence of low regurgitant flow, 
the estimation of RVSP becomes less sensitive, 
because of the low signal intensity, which might 
lead to the underestimation of pressure values. 
However, the presence of extremely severe 
TR might also lead to the underestimation of 
pressure measurements, because equalizes 
the RA and RV pressures, resulting in a weak 
Doppler signal. Conversely, the method might 
also overestimate RVSP values.
Another way to estimate PASP by 
echocardiography is by calculating the inferior 
vena cava compressibility index, as described 
by Pepi et al.(11) The authors found a strong 
correlation between RA pressure and the 
aforementioned index. With the use of a more 
reliable RA measurement, the percentage error 
in estimating PASP by the Bernoulli equation 
tricuspid regurgitation (TR). Measurement of TR 
provides an estimate of the pressure gradient 
in the right heart. The first studies involving 
continuous wave Doppler echocardiography 
were published in the mid-1980s.(9,10) The 
technique consists of measuring peak velocity of 
tricuspid regurgitation (VTR), which provides an 
estimate of the regurgitant flow from the RV 
to the right atrium (RA), as shown in Figure 3. 
With the use of the simplified Bernoulli equation 
(∆P = 4 × VTR2), it is possible to convert the flow 
measurement into an estimate of pressure. By 
adding this pressure gradient and an estimate of 
RA pressure, we obtain RV peak systolic pressure 
(RVSP), an approximation of the pulmonary 
artery systolic pressure (PASP), provided that 
there is no obstruction of the RV outflow 
tract. An RVSP > 35-40 mmHg is suggestive of 
Figure 3 - Echocardiography images. Note the intensity of the continuous wave Doppler signal of the tricuspid 
regurgitant jet during ventricular systole (in a) and the dilated right heart (in b). Note the pressure overload 
in the right ventricle (RV), leading to paradoxical interventricular (IV) septal motion to the left, and the 
reduction in the size of the left ventricle (LV) during diastole (in c). During ventricular systole, the IV septum 
remains flattened (in d). Imaging provided by Dr. Fabio Lario, attending physician in the Department of 
Echocardiography of the Heart Institute of the University of São Paulo School of Medicine Hospital das Clínicas.
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A less pronounced or absent A-wave on the 
PAP curve, probably attributable to increased 
PADP, is highly suggestive of PH. However, 
in patients with RV dysfunction, a normal 
A-wave does not rule out PH. Measurement the 
acceleration time of the pulmonary artery flow 
also has good accuracy in detecting increased 
PAP, representing an estimate of the mean 
pulmonary artery pressure (mPAP).(17) In addition, 
the finding of an increased RV systolic time 
interval is a highly specific echocardiographic 
sign of PH, albeit one with low sensitivity.
(16) Other echocardiographic signs, such as 
right heart enlargement, pericardial effusion, 
RV dysfunction, paradoxical interventricular 
septal motion, and reduced LV filling volumes, 
also corroborate the presence of PH (Figure 
3).(18) Provided that their limitations are taken 
into account and that they are evaluated and 
interpreted in the light of the clinical context, all 
these parameters can be useful in the diagnosis 
and follow-up of patients with PH.
Variations in PASP values can depending 
on the conditions and the characteristics of the 
population evaluated (age, level of exercise, level 
of fitness, and stress level). It has been reported 
that RVSP values are above 40 mmHg in 6% 
of subjects over 50 years of age and in 5% of 
those with a body mass index of 30 kg/m2.(18) 
Therefore, slightly increased values should be 
interpreted with caution.
In the context of acute PTE, echocardiography 
is highly valuable. Despite having no diagnostic 
power, except in cases of saddle PTE that 
can be visualized by Doppler, the method can 
predict mortality from thromboembolic events 
and possibly assist in the decision-making 
process regarding treatment. By providing 
morphological and functional information 
about the RV, echocardiography directly 
assesses the magnitude of the effect that 
pulmonary circulation obstruction has on the 
RV. Analyzing a cohort of a large population-
based study,(19) one group of authors(20) observed 
that the finding of RV dysfunction on baseline 
echocardiography has a high positive predictive 
value for lower 30-day survival. The risk of 
death, reported in that study, was nearly twice 
as high in the patients with such dysfunction. In 
one systematic review,(21) the combined results 
of five studies evaluating the prognostic role of 
RV dysfunction as assessed by echocardiography 
decreases, thus increasing the accuracy of the 
method.
In the 1990s, in order to improve the accuracy 
of the echo signal, the addition of intravenous 
contrast material to continuous wave Doppler 
echocardiography provided the opportunity to 
improve the sensitivity of the method. Materials 
such as 5% glucose microbubbles, sonicated 
human albumin, and indocyanine green increase 
echo intensity without affecting VTR. One group 
of authors(12) observed that, in a small patient 
sample (comprising 39 patients, most of whom 
had left heart disease), the estimation of PASP 
with the use of contrast resulted lower than the 
estimation of PASP with the use of right heart 
catheterization, the standard error for the latter 
being ± 5 mmHg in 51% of the patients and ± 
10 mmHg in 82%.
At the beginning of the 21st century, 
two other indexes gained popularity in the 
echocardiographic evaluation of patients with 
PH. In a population of 26 patients with PH 
(known as primary PH at the time), Tei et al.
(13) described an index of combined systolic and 
diastolic function, known as the Tei index, which 
is obtained by dividing the sum of systolic and 
diastolic isovolumetric intervals by the ejection 
time. The Tei index was found to be a good 
predictor of survival in this population. Described 
in 1984 for the LV, the tricuspid annular plane 
systolic excursion (TAPSE) index reflects the 
longitudinal tricuspid annular motion during 
ventricular systole and correlates strongly with 
RV ejection fraction. Because TAPSE is a direct 
method that does not depend on ventricular 
geometry, it is quite reproducible and easy to 
obtain. In 2006, one group of authors(14) showed 
that a TAPSE index < 1.8 cm is indicative of 
more advanced RV dysfunction and correlates 
with a lower 19-month survival rate, especially 
in patients with pulmonary arterial hypertension 
(PAH).
Other echocardiographic parameters can also 
be used in the evaluation of PH. Measurement 
of TR at the opening of the pulmonary valve is 
used for estimating pulmonary artery diastolic 
pressure (PADP).(15) It is also possible to estimate 
pulmonary vascular resistance, which correlates 
with invasive hemodynamic measurement.(16) 
Atrial contraction and the subsequent increase 
in intracavitary pressure result in the formation 
of a characteristic wave, known as the A-wave. 
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hemangiomatosis, fibrosing mediastinitis, 
pulmonary vasculitis, and pulmonary artery 
sarcoma.
The most recent PH guidelines(26) recommend 
scintigraphy as the diagnostic method of choice 
for ruling out chronic PTE. In a patient with 
PH, a negative or low-probability scan virtually 
excludes chronic PTE, whereas a high-probability 
scan has a specificity of 96% for the diagnosis 
of chronic PTE in the presence of one or more 
segmental perfusion defects (Figure 4).(26)
CT
Obtaining images with the CT technique 
essentially consists of rotating a system 
comprising an X-ray tube and detectors around 
the body, and this introduces an innovation 
compared with routine X-ray: cross-sectional 
visualization of the various anatomical structures 
without overlap. However, because it is a system 
with weighty components, image acquisition 
speed has always been a major limitation of the 
method, presenting a particular hindrance in the 
assessment of the thoracic structures, which are 
constantly in motion.
The development of MDCT scanners, 
also known as multislice CT scanners, has 
revolutionized the history of CT, overcoming the 
temporal limitations of image acquisition. When 
compared with the conventional technology, 
MDCT allows a larger volume of tissues or 
structures to be represented in thinner slices 
(0.60-1.25 mm vs. 2-5 mm) at shorter intervals 
(2-8 s vs. 18-30 s), improving spatial resolution 
and reducing the occurrence of motion artifacts, 
all of this in a single breath hold.
In the assessment of the pulmonary 
circulation, the combination of the MDCT 
technology and automated injection of 
intravenous contrast material allows anatomical 
distinction of vascular structures and high-
quality pulmonary vessel opacification. In 
addition, the nearly isotropic characteristic of 
voxels substantially improves image reformatting, 
optimizing multiplanar image acquisition.
In PH, CT angiography has diagnostic 
importance and is of great value in the 
etiological investigation.(27) The method allows 
the imaging assessment of the RV, PAT, and 
peripheral pulmonary circulation.
In CT angiography, the RV can be visualized 
with high spatial resolution. Interventricular 
revealed that the relative risk of death in patients 
with such dysfunction was 2.5 (95% CI: 1.2-5.5). 
This finding is of great importance because it 
identifies a subgroup of patients who are at high 
risk for complications and who, at admission, are 
stable from a hemodynamic standpoint.
In summary, echocardiography is widely 
available, inexpensive, and quite safe. Despite 
its limitations, echocardiography represents an 
important diagnostic and monitoring tool in 
PH and in PTE when used in combination with 
other markers.
Ventilation/perfusion scintigraphy
The major role of ventilation/perfusion 
scintigraphy in patients with PH is to distinguish 
chronic thromboembolic PH from other causes 
of PH.
The role of scintigraphy in the assessment of 
patients with PH, as well as in the assessment 
of patients with acute pulmonary embolism,(22) 
is well-established. A study conducted in 
1994 involved 75 patients with documented 
causes of PH.(23) Of the 25 patients with 
chronic thromboembolic PH, 24 (96%) had 
high-probability scans and 1 (4%) had an 
intermediate-probability scan. Conversely, of 
the 35 patients with primary PH, 33 (94%) 
had low-probability scans, 1 (3%) had an 
intermediate-probability scan, and 1 (3%) had 
a high-probability scan. Of the 15 patients with 
non-thromboembolic secondary PH, the result 
was less accurate: 10 (67%) had low-probability 
scans, 3 (20%) had intermediate-probability 
scans, and 2 (13%) had high-probability scans. 
In view of the poorer yield in this third group of 
patients, the great importance of scintigraphy, in 
the context of PH, lies in the fact that it can rule 
out thromboembolic disease: a low-probability 
scan definitely excludes this disease. Another 
study showed that, in comparison with 
multidetector CT (MDCT), scintigraphy has 
far greater sensitivity for detecting chronic 
pulmonary embolism (96% vs. 51%).(24)
The typical pattern of scintigraphy findings 
in primary PH is that of poor perfusion (mottled 
pattern) in the periphery of the lung.(25) There 
is some correlation between the degree of 
perfusion heterogeneity in primary PH and 
patient prognosis.(25) Occasionally, multiple, small 
perfusion defects can be found in pulmonary 
veno-occlusive disease, pulmonary capillary 
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in more than three lung lobes, was found to have 
a specificity of 100%.(31) Very similar findings 
were observed in a retrospective study of PH in 
patients with parenchymal lung disease.(31)
In the assessment of peripheral pulmonary 
circulation, CT angiography can uniformly 
access vessels of up to 2-3 mm with nearly 
constant opacification, high resolution, and 
no image overlap. This characteristic greatly 
contributes to the anatomical assessment of 
the pulmonary circulation. However, when 
it comes to visualization and quantification 
of the pulmonary microcirculatory flow, the 
method once again has functional limitations. 
The limited microcirculatory blood flow during 
vasoconstriction and vascular remodeling, 
characteristic of PH, can be visualized on 
HRCT scans (parenchymal window) as a mosaic 
perfusion pattern, which is present in patients 
with PH of various causes (Figure 5).(32) In some 
cases, there are also areas of increased lung 
parenchymal attenuation that are attributable 
to microcirculatory flow redistribution when 
the number and diameter of the vessels are 
increased in these regions. Both phenomena, 
mosaic perfusion and flow redistribution, are 
findings that are particularly more prevalent in 
septal dilatation, hypertrophy, flattening, and 
bowing are findings that strongly correlate with 
the presence of PH (Figure 5). Traditionally, 
however, the tomographic image of the RV is only 
static, causing a major limitation in its functional 
assessment. The use of electrocardiographic 
gating, that is, coupling of image acquisition 
with cardiac electrical phenomena, provides a 
partial solution to this limitation, allowing image 
reconstruction in any phase of the cardiac cycle 
as well as access to measurements of ventricular 
function and volumes.(28)
When technically well performed, CT 
angiography provides anatomically precise 
images of the PAT and allows its morphological 
assessment. Measurement of the PAT, with the 
use of axial slices, is performed at its bifurcation 
orthogonally to its longest axis and laterally to 
the ascending aorta. In a study of 32 cases of 
PH,(29) the 28.6 mm PAT diameter was strongly 
associated with the presence of PH as determined 
by invasive hemodynamic assessment. In a small 
population of 5 cases of HIV-related PH,(30) a 
PAT diameter > 29 mm showed a sensitivity and 
specificity, for the diagnosis of PH, of 87% and 
89%, respectively; this aspect, combined with 
the presence of an artery-to-bronchus ratio > 1 
Figure 4 - Ventilation/perfusion lung scintigraphy images of a 59-year-old male patient undergoing etiological 
investigation of pulmonary hypertension and with normal findings on CT angiography of the pulmonary 
arteries. Right posterior oblique images: ventilation (in a) and perfusion (in b). Note the normal distribution of 
ventilation and the multiple, bilateral segmental perfusion defects, predominantly in the right lung. The patient 
was diagnosed with distal, chronic pulmonary thromboembolism.
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scanners created another danger: the possibility 
of an excessive number of false-positive results. 
However, that possibility was ruled out in a 
recent study.(38)
Because CT angiography analyzes the RV with 
high image resolution, it can serve as a marker 
of risk in patients with acute PTE, who have 
traditionally been stratified by echocardiography 
findings.(39) It is well established that the 
finding of RV dysfunction by echocardiography 
identifies a subgroup of patients at high risk 
for complications, worse prognosis, and higher 
mortality. A multiplanar reconstruction of a four-
chamber view of the heart(40) or an axial view 
of the ventricles(41) allows the calculation of a 
simple ratio—RV diastolic diameter ÷ LV diastolic 
diameter = the RV/LV ratio. An RV/LV ratio > 
0.90 correlates strongly with RV dysfunction as 
determined by echocardiography,(42) as well as 
showing potential cost-effectiveness and being a 
potential prognostic marker for CT angiography. 
In a recent systematic review,(21) the analysis of 
the combined results of two studies evaluating 
the prognostic role of RV dysfunction as assessed 
by tomography revealed that the relative risk of 
this dysfunction for predicting death was 2.3 
(95% CI: 0.90-5.98). In cases of distal chronic 
PTE, however, CT angiography has limitations, 
and ventilation/perfusion scintigraphy has 
become the test of choice.(43)
MRI
The MRI technique holds great prospects for 
the assessment of the pulmonary circulation. 
chronic PTE. Dual-source CT, a new imaging 
technique in which images are obtained with 
two X-ray tubes, each with a different voltage, 
can access regional lung perfusion with greater 
accuracy, providing functional information.(33) 
This technology makes it possible to perform a 
CT angiography study and a perfusion study in 
a single test.
Having been widely studied, CT angiography 
has gained significant ground in the evaluation 
of acute PTE, becoming as accurate as pulmonary 
angiography but without its invasive nature. 
Some authors consider CT angiography to be 
the diagnostic imaging method of choice in the 
assessment of acute PTE.(34-36) This is explained 
by the various advantages of CT angiography: 
its high resolution allows the visualization 
of arteries and filling defects up to the distal 
portion of the pulmonary vasculature, reaching 
subsegmental vessels of 2-3 mm (Figure 6); 
it has excellent interobserver agreement, far 
superior to that of scintigraphy; its sensitivity 
is so high that a negative test result allows 
the safe discontinuation of anticoagulation 
therapy.(37) One must be alert, however, to the 
dangers inherent in the method. Technical 
or pathophysiological factors might lead to 
the interpretation of pseudo-filling defects, 
providing false-positive results. The possibility 
of motion artifacts in patients with tachypnea 
should be taken into consideration, as should 
the time interval between contrast injection and 
image acquisition, as well as the occurrence of 
hypoxic pulmonary vasoconstriction in poorly 
aerated regions. The advent of 64-channel 
Figure 5 - CT angiography image (in a) and HRCT image (in b) of a male patient with thrombotic pulmonary 
hypertension. In a, note the increased pulmonary artery trunk and the increased bronchial artery diameter 
(arrow). In b, note the mosaic perfusion pattern.
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resulting in high spatial resolution during 
periods of apnea lasting less than 30 s.
Chief among the useful functions of 
pulmonary MRA is its great importance in 
detecting acute or chronic pulmonary embolism. 
In this context, a study published in 2002(47) 
evaluated 141 patients with suspected PTE and 
with abnormal perfusion scintigraphy findings. 
The sensitivity of MRA for segmental and central 
embolism (84% and 100%, respectively) was 
found to be comparable to that of pulmonary 
arteriography. However, for subsegmental 
embolism, the sensitivity of MRA was low (40%). 
Other studies(48,49) have confirmed these findings, 
and MRA plays a very interesting role in patients 
with suspected PTE who have contraindications 
to the use of iodinated contrast material or 
who want to avoid ionizing radiation. Another 
promising use of MRA is in the noninvasive 
evaluation of patients with PAH. One group of 
authors(50) investigated the use of MRI in the 
evaluation of responders to vasodilator testing 
with inhaled NO. When analyzing the mean 
pulmonary artery distensibility, those authors 
found a sensitivity of 100% in the identification 
of responders, with a specificity of 56% when 
compared with hemodynamic evaluation with a 
pulmonary artery catheter.
The functional assessment of microcirculation 
is also possible with the use of MRI. One group 
of authors(51) compared perfusion changes 
detected on MRI with those detected on 
The method comprises excellent characteristics, 
such as low operator dependence, high accuracy, 
and good reproducibility.(44)
The MRI technique can be used for 
the assessment of the lung parenchyma 
and pulmonary circulation, as well as for 
the dynamic analysis of the heart. In the 
assessment of the lung parenchyma, MRI faces 
some challenges: low proton density of the 
lung parenchyma, resulting in a low signal/
noise ratio; signal loss during physiological 
motion of the intrathoracic organs; and the 
combination of air and soft tissues, which 
increases its susceptibility to artifacts. Despite 
these problems, some adjustments in the form 
of image acquisition make MRI an interesting 
tool in the assessment of the lung parenchyma. 
Some authors have suggested that, for specific 
applications, MRI findings are equivalent to 
CT findings, although MRI should not yet be 
used for the aforementioned purpose in routine 
clinical practice.(45) There is as yet no systematic 
evaluation of MRI as a means of assessing the 
lung parenchyma of patients with PH.
Since 1993, when the technique known as 
enhanced three-dimensional magnetic resonance 
arteriography (MRA) was published,(46) there have 
been many advances in the assessment of the 
intrathoracic vessels. This technique consists of 
the injection of paramagnetic contrast material 
and ultra-fast T1-weighted image acquisition, 
a b
Figure 6 - CT angiography images of patients with chronic thromboembolism (in a) and acute thromboembolism 
(in b). In a, note the increased pulmonary artery trunk and the eccentric thrombus in the right pulmonary 
artery. In b, the arrow indicates a central filling defect in a subsegmental arterial branch.
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image acquisition, which provides data 
for the determination of cardiac output, 
the evaluation of valvular regurgitation, 
the assessment of diastolic ventricular 
filling, and the quantification of cardiac 
shunts. Cardiac MRI has advantages 
over thermodilution in the acquisition of 
cardiac output measurements because 
it is noninvasive, it is less dependent on 
changes from one cardiac cycle to another, 
and it is not as strongly affected by TR.(56)
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assessment of myocardial contrast after 
gadolinium infusion can directly show 
nonviable areas of the myocardium. One 
group of authors(57) described a pattern 
of myocardial contrast enhancement 
in patients with PH. Delayed contrast 
enhancement was present within the 
RV insertion points and interventricular 
septum of 23 of the 25 patients studied. The 
extent of delayed contrast enhancement 
correlated with worse RV function.
In addition, the method shows potential 
for the molecular assessment of the pulmonary 
circulation and the heart. It is possible, for 
instance, to evaluate and quantify areas of 
apoptosis and the degree of apoptosis in vivo.(58)
In Brazil, MRI is quite costly and is not widely 
available. Although preliminary in nature, the 
findings related to the use of MRI as a diagnostic 
and prognostic tool in the assessment of PH 
seem promising.
EIT
The concept of electrical impedance can be 
defined in various ways: the relationship between 
the voltage gradient generated in an electrical 
circuit and the resulting electrical current; the 
combination of resistance and reactance; and 
the total opposition that a circuit offers to 
the flow of alternating current at a particular 
frequency. Essentially, higher resistance (or lower 
conductance) in a circuit, structure, or tissue 
translates to higher electrical impedance values.
A system developed in the 1980s in the 
United Kingdom makes it possible to measure 
the impedance of a structure or tissue by placing 
pairs of electrodes in rows on its surface. Sending 
electrical currents of low amperage and low 
frequency through these electrodes generates 
a voltage gradient, which, in turn, results in 
pulmonary perfusion scintigraphy in patients 
with pulmonary embolism, pneumonia, and 
COPD. The tests were evaluated by two observers, 
and there was moderate concordance (kappa 
coefficient range: 0.52-0.57) between the two 
techniques.
The most common use of MRI in PH remains 
the assessment of the RV. This technique 
allows the acquisition of high-resolution 
dynamic images of myocardial contraction and 
does not depend on anatomical conditions 
(pulmonary emphysema, obesity, etc.) as does 
echocardiography.
In patients with PH, cardiac MRI is especially 
important for the assessment of the following 
parameters (Figure 7):
v9HQWULFXODU PRUSKRORJ\&7 LPDJHV WKDW
make it possible to determine the size 
and volume of the heart chambers, as 
well as wall thickness, and muscle mass. 
End-diastolic RV volume is significantly 
increased in PH. One group of authors(52) 
studied the role of cardiac MRI in the 
prognostic evaluation of patients with PH 
and observed that patients with increased 
diastolic RV volume and reduced systolic 
RV volume or reduced diastolic LV volume 
have a worse prognosis at 12-month 
follow-up. The study suggests that MIR 
can also be used as a tool for monitoring 
and evaluating treatment response.(52) In 
addition, MRI can analyze RV mass, which, 
during increased afterload, is significantly 
increased. Evidence suggests that RV mass 
index correlates well with mPAP.(53)
v9HQWULFXODUIXQFWLRQG\QDPLFLPDJHVWKDW
reproduce the entire cardiac cycle can be 
obtained with electrocardiographic gating 
and have high accuracy and reproducibility 
in the analysis of ventricular function.(54) 
Another interesting tool is the evaluation 
of diastolic RV dysfunction and the 
behavior of the RV following treatment. 
v,QWHUYHQWULFXODU VHSWDO FRQILJXUDWLRQ
distortions in the normal morphology 
of the interventricular septum can be 
observed in patients with PH. These 
quantifiable changes correlate with mPAP 
and prognosis.(55)
v)ORZ DQDO\VLVYROXPHWULF IORZ
measurements can be obtained with the 
use of contrast material and sequential 
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two materials with opposite resistances, share 
the same compartment and vary their volumes 
rhythmically during the cardiorespiratory cycle. 
The periodic change in intrathoracic blood 
volume during cardiac work and the distension 
of pulmonary microcirculation resulting from 
the blood flow through the pulmonary vessels 
are associated with the cyclic change in the 
electrical properties of the lung parenchyma 
over time. The increased blood volume in the 
lung parenchyma results in a 1% decrease in 
lung electrical impedance (blood being five time 
less resistant than is air).
an electron flow that can be estimated or 
measured. A mathematical algorithm for image 
reconstruction can transform the measured value 
of electrical impedance into pixels, the basic unit 
of the composition of an image. With the cross-
sectional distribution of the electrodes in rows, 
it is possible to obtain a cross-sectional image of 
the distribution of electrical impedance within 
the geometric plane defined by the electrodes. 
This system is known as EIT.
The biological properties of the chest 
provide a valuable opportunity for assessment 
with the use of EIT, because air and blood, 
Figure 7 - Magnetic resonance images of a 35-year-old male patient with idiopathic pulmonary arterial 
hypertension. In a and b, note the dilated right ventricle (RV), interventricular septal flattening; and increased 
RV mass. Axial images acquired at end-diastole (in c) and at end-systole (in d). Note the following: the diameter 
of the pulmonary artery trunk (PAT) is greater than that of the aorta (Ao); the PAT diameter during diastole 
differs from its diameter during systole, allowing the estimation of the PAT pulsatility index; and contrast 
enhancement of the PAT is greater during ventricular systole.
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resistance, regardless of the increase in systolic 
volume. In another study,(60) the differences in 
the impedance of the pulmonary circulation 
were analyzed in 21 patients with idiopathic 
PAH (IPAH) and 30 healthy subjects. The authors 
observed a reduction in impedance change in 
the IPAH group, which provides support for the 
use of EIT in the assessment of the pulmonary 
circulation and of PH.
In Brazil, a 32-electrode EIT scanner is being 
developed for the assessment of lung perfusion. 
In the context of IPAH, the images obtained with 
this new scanner (Figure 8) are encouraging, 
demonstrating not only a reduction in electrical 
impedance, as in the two aforementioned 
studies, but also a change in the impedance 
wave morphology, which might correlate with 
the pulse wave of the pulmonary circulation.
References
1. Cournard A, Riley RL, Breed ES et al. Measurement 
of cardiac output in man using the technique of 
catheterization of right auricle or ventricle. J Clin Invest. 
1945; 24 (1): 106-16.
2. Steckelberg JM, Vliestra RE, Ludwig J, Mann RJ. Werner 
Forssmann (1904--1979) and his unusual success story. 
Mayo Clin Proc. 1979; 54 (11): 746-8.
3. Souza R. Assessment of compliance in pulmonary 
arterial hypertension. Eur Heart J. 2008; 29: 1603-4.
4. Paciocco G, et al. Pulmonary hypertension. Chest. 1998; 
114 (4S): 375S-6S.
5. Lupi HE, et al. Indications and radiological measurements 
in the evaluation of pulmonary artery hypertension. 
Arch Inst Cardiol Mex. 1975; 45: 34-42.
Regional changes in blood flow can be 
visualized by EIT in two ways. The first, which 
is based on the indicator dilution technique, 
involves the use of an electrically conducting 
fluid as contrast material, similarly to CT and 
MRI studies. The second approach analyzes the 
changes in the lung parenchyma impedance 
resulting from the change in systolic volume 
during the cardiac cycle, cycle by cycle. Coupling 
of image acquisition with the R-wave on 
electrocardiogram (the ECG-gated technique) 
filters ventilation-related fluctuations, obtaining 
only those that are due to circulation. The 
resulting image is likely to reflect pulmonary 
circulation pulsatility or distensibility.
An excellent model of disease in the 
pulmonary microcirculation is PAH, in which 
vascular remodeling directly affects the 
distensibility properties of microcirculation. 
When vascular compliance is reduced, with 
consequent accommodation of lower volumes, 
the electrical impedance change in PH is likely 
to be decreased as well. In one study,(59) EIT 
was used in patients with PH for determining 
vascular response to vasodilator testing with 
epoprostenol during invasive hemodynamic 
assessment. Of the 8 patients evaluated, 7 did 
not meet the vasodilator response criteria, EIT 
showing no impedance change in those 7. In 
the lone responder, the increase in impedance 
change was found to correlate strongly with 
decreases in mPAP and pulmonary vascular 
Figure 8 - Electrical impedance tomography images obtained at the level of the 4th intercostal space. In a, 
normal findings in a 27-year-old female patient. In b, abnormal findings in a 31-year-old female patient with a 
20-year history of idiopathic pulmonary arterial hypertension. Note the difference in the range of the electrical 
impedance signal (intensity and extent) in areas 1 and 2, probably associated with normal vascular compliance 
(in a) and reduced vascular compliance (in b).
a b
1
12 2
The role of imaging techniques in the assessment of pulmonary circulation
J Bras Pneumol. 2011;37(3):389-403
401
(PIOPED). The PIOPED Investigators. JAMA. 1990; 
263(20): 2753-9.
23. Worsley DF, Palevsky HI, Alavi A. Ventilation-Perfusion 
Lung Scanning in the Evaluation of Pulmonary 
Hypertension. J Nucl Med. 1994; 35(5): 793-6.
24. Tunariu N et al.  Ventilation-Perfusion Scintigraphy Is 
More Sensitive than Multidetector CTPA in Detecting 
Chronic Thromboembolic Pulmonary Disease as a 
Treatable Cause of Pulmonary Hypertension. J Nucl 
Med. 2007; 48(5): 680-4.
25. Fukuchi K, et al. Quantitative Analysis of Lung Perfusion 
in Patients with Primary Pulmonary Hypertension. J 
Nucl Med. 2002; 43(6): 757-61.
26. Hoeper MM, Barberà JA, Channick RN. Diagnosis, 
assessment, an treatment of non-pulmonary arterial 
hypertension pulmonary hypertension. J Am Coll 
Cardiol. 2009; 54: S85-96.
27. Ley S, Kreitner K-F, Fink C, et al. Assessment of 
pulmonary hypertension by CT and MR imaging. Eur 
Radiol. 2004; 14: 359-68.
28. McLure LER, Peacock AJ. Imaging of the heart in 
pulmonary hypertension. Int J Clin Pract. 2007; 65: 
15S-26S.
29. Kuriyama K, Gamsu G, Stern RG, et al. CT-determined 
pulmonary artery diameters in predicting pulmonary 
hypertension. Invest Radiol. 1984; 19: 16-22.
30. Bugnone AN, Viamonte M Jr, Garcia H. Imaging findings 
in human immunodeficiency virus-related pulmonary 
hypertension: report of five cases and review of the 
literature. Radiology. 2002; 223: 820-827.
31. Tan RT, Kuzo R, Goodman LR, et al. Utility of CT scan 
evaluation for predicting pulmonary hypertension in 
patients with parenchymal lung disease. Chest. 1998; 
113: 1250-6.
32. Sheerick AD, Swensen SJ, Hartman TE. Mosaic pattern 
of lung attenuation on CT scans: frequency among 
patients with pulmonary artery hypertension of different 
causes. ARJ. 1997; 169: 79-82.
33. Thieme SF, Becker CR, Hacker M, Nikolaou K, Reiser MF, 
Johnson TR. Dual energy CT for the assessment of lung 
perfusion--correlation to scintigraphy. Eur J Radiol. 
2008; 68(3): 369-74. 
34. Remy-Jardin M, Ghaye B, Remy J. Spiral computed 
tomography angiography of pulmonary embolism. Eur 
Resp Mon. 2003; 27: 124-43.
35. Ferreti GR, Bosson JL, Buffaz PD, et al. Acute 
pulmonary embolism: role of helical CT in 164 patients 
with intermediate probability in ventilation-perfusion 
scintigraphy and normal results at duplex US of the legs. 
Radiology. 1997; 205: 453-8.
36. Mayo JR, Remy-Jardin M, Muller NL, et al. Pulmonary 
embolism: prospective comparison of spiral CT and 
ventilation-perfusion scintigraphy. Radiology. 1997; 
205: 447-52.
37. Goodman LR, Lipchick RJ, Kuzo RS, et al. Subsequent 
pulmonary embolism: risk after a negative helical CT 
pulmonary angiogram – prospective comparison with 
scintigraphy. Radiology. 2000; 215: 535-42. 
38. Sohnsa C, Amarteifioa E, Sossallab S, Heuserc M, 
Obenauera S. 64-Multidetector-row spiral CT in 
pulmonary embolism with emphasis on incidental 
findings. Clinical Imaging. 2008; 32: 335-41. 
39. Quiroz R, Kucher N, Schoepf UJ, et al. Right ventricular 
enlargement on chest computed tomography: prognostic 
6. Lupi E, et al. A radiologic index of pulmonary arterial 
hypertension. Chest. 1975; 68 (1): 28-31.
7. Terence KT, John RM. Diagnosis of pulmonary arterial 
hypertension. Clin Chest Med. 2007; 28 (1): 59-73.
8. Celermajer DS, Marwick T. Echocardiographic and 
right heart catheterization techniques in patients with 
pulmonary arterial hypertension. Int J Cardiol. 2008; 
125: 294–303.
9. Berger M, Haimowitz A, Van Tosh A et al. Quantitative 
assessment of pulmonary hypertension in patients with 
tricuspid regurgitation using continuous wave Doppler 
ultrasound. J Am Coll Cardiol. 1985; 6: 359.
10. Kitabatake, Inoue M, Asao M, et al. Noninvasive 
evaluation of pulmonary hypertension by a pulsed 
Doppler technique. Circulation. 1983; 68: 302-9
11. Pepi M, Tamborini G, Sganzerla P. The noninvasive 
estimation of right atrial pressure improves the 
Doppler evaluation of the pulmonary systolic pressure. 
Cardiologia. 1991; 36: 117-22.
12. Tokushima T, Utsunomiya T, Yoshida K et al. Estimation 
of the systolic pulmonary arterial pressure using 
contrast-enhanced continuous-wave Doppler in 
patients with trivial tricuspid regurgitation. Jpn Heart 
J. 1999; 40: 311-20.
13. Tei C, Dujardin KS, Hodge DO, et al. Doppler 
Echocardiographic index for assessment of global right 
ventricular function. J Am Soc Echocardiogr. 1996; 9: 
838-47.
14. Forfia Pr, Fisher MR,  Mathai FC, et al. Tricuspid 
annular displacement predicts survival in pulmonary 
hypertension. Am J Respir Crit Care Med. 2006; 174: 
1034-41.
15. Lanzarini L, Fontana A, Lucca E, et al. Noninvasive 
estimation of both systolic and diastolic pulmonary 
artery pressure from Doppler analysis of tricuspid 
regurgitant velocity spectrum in patients with chronic 
heart failure. Am Heart J. 2002; 144: 1087-94.
16. Selimovic N, Rundqvist B, Bergh C-H, et al. Assessment 
of pulmonary vascular resistance by Doppler 
echocardiography in patients with pulmonary arterial 
hypertension. J Heart Lung Transplant. 2007; 26: 
927-34.
17. Bossone E, Duong-Wagner TH, Paciocco G, et al. 
Echocardiographic features of  primary pulmonary 
hypertension. J Am Soc Echocardiogr. 1999; 12: 655-62.
18. McQuillan BM, Picard MH, Leavitt M, Weyman AE. 
Clinical correlates and reference intervals for pulmonary 
artery systolic pressure among echocardiographically 
normal subjects. Circulation. 2001; 104: 2797-802.
19. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary 
embolism: clinical outcomes in the International 
Cooperative Pulmonary Embolism Registry (ICOPER). 
Lancet. 1999; 353: 1386-9.
20. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic 
Role of Echocardiography Among Patients With Acute 
Pulmonary Embolism and a Systolic Arterial Pressure 
of 90 mm Hg or Higher. Arch Intern Med. 2005; 165: 
1777-81.
21. Sanchez O, Trinquart L, Colombet I, et al. Prognostic 
value of right ventricular dysfunction in patients with 
haemodynamically stable pulmonary embolism: a 
systematic review. Eur Heart J. 2008; 29: 1569-77.
22. Value of the ventilation/perfusion scan in acute 
pulmonary embolism. Results of the prospective 
investigation of pulmonary embolism diagnosis 
402 Hovnanian A, Menezes E, Hoette S, Jardim C, Jasinowodolinski D, Souza R
J Bras Pneumol. 2011;37(3):389-403
to Administration of Iodinated Contrast Material. Am J 
Roentgenol. 2007; 188: 1246-54.
50. Jardim C, et al. Pulmonary artery distensibility in 
pulmonary arterial hypertension: an MRI pilot study. Eur 
Respir J. 2007; 29: 476-81.
51. Amundsen T, et al. Perfusion abnormalities in 
pulmonary embolism studied with perfusion MRI and 
ventilation-perfusion scintigraphy: An intra-modality 
and inter-modality agreement study. J Magn Reson 
Imaging. 2002 15: 386-94.
52. van Wolferen SA, et al. Prognostic value of right 
ventricular mass, volume, and function in idiopathic 
pulmonary arterial hypertension. Eur Heart J. 2007; 28: 
1250-7. 
53. Saba TS, et al. Ventricular mass index using magnetic 
resonance imaging accurately estimates pulmonary 
artery pressure. Eur Respir J. 2002; 20: 1519-24.
54. Hoeper MM, et al. Evaluation of Right Ventricular 
Performance With a Right Ventricular Ejection Fraction 
Thermodilution Catheter and MRI in Patients With 
Pulmonary Hypertension. Chest. 2001; 120: 502-7.
55. Roeleveld RJ, et al. Interventricular Septal Configuration 
at MR Imaging and Pulmonary Arterial Pressure in 
Pulmonary Hypertension. Radiology. 2005; 234: 710-7.
56. Mousseaux E, et al. Pulmonary Arterial Resistance: 
Noninvasive Measurement with Indexes of Pulmonary 
Flow Estimated at Velocity-encoded MR Imaging-
Preliminary Experience. Radiology. 1999; 212: 896-902.
57. Blyth KG, et al. Contrast enhanced-cardiovascular 
magnetic resonance imaging in patients with pulmonary 
hypertension. Eur Heart J. 2005 26: 1993-9.
58. Sosnovik DE, et al. Magnetic resonance imaging of 
cardiomyocyte apoptosis with a novel magneto-optical 
nanoparticle. Magn Reson Med. 2005; 54: 18-24.
59. Smit HJ, Vonk Noordegraaf A, Marcus JT, et al. 
Determinants of pulmonary perfusion measured by 
electrical impedance tomography. Eur J Appl Physiol. 
2004; 92: 45-9.
60. Smit HJ, Vonk Noordegraaf A, Boonstra A, Vries PM, 
Postmus PE. Assessment of the pulmonary volume pulse 
in idiopathic pulmonary arterial hypertension by means 
of electrical impedance tomography. Respiration. 2006, 
73: 597-602.
role in acute pulmonary embolism. Circulation. 2004; 
109: 2401-4.
40. Kamel EM, Schmidt S, Doenz F, et al. Computed 
Tomographic Angiography in Acute Pulmonary 
Embolism: Do We Need Multiplanar Reconstructions to 
Evaluate the Right Ventricular Dysfunction? J Comput 
Assist Tomogr. 2008; 32: 438-43.
41. Schoepf UJ, Kucher N, Kipfmueller F, et al. Right 
ventricular enlargement on chest computed tomography: 
a predictor of early death in acute pulmonary embolism. 
Circulation. 2004; 110: 3276-8. 
42. van der Meer RW, Pattynama PM, van Strijen 
MJ, et al. Right ventricular dysfunction and pulmonary 
obstruction index at helical CT: prediction of clinical 
outcome during 3-month follow-up in patients with 
acute pulmonary embolism. Radiology. 2005; 235: 
798-803.
43. Dias BA, Jardim C, Hovnanian A, Fernandes CJ, Souza 
R. Chronic Thromboembolic Pulmonary Hypertension: 
Diagnostic Limitations. J Bras Pneumol. 2008; 34 (7): 
532-6.
44. Ley S, et al. Assessment of pulmonary hypertension by 
CT and MR imaging. Eur Radiol. 2004; 14: 357-8.
45. Biederer J, et al. Lung Morphology: Fast MR Imaging 
Assessment with a Volumetric Interpolated Breath-Hold 
Technique: Initial Experience with Patients. Radiology. 
2003; 226: 242-9.
46. Prince MR, et al. Dynamic gadolinium-enhanced three-
dimensional abdominal MR arteriography. J Magn 
Reson Imaging. 1993; 3: 877-81.
47. Oudkerk M, et al. Comparison of contrast-enhanced 
magnetic resonance angiography and conventional 
pulmonary angiography for the diagnosis of pulmonary 
embolism: a prospective study. Lancet. 2002; 359: 
1643-7.
48. Meaney JFM, et al. Diagnosis of Pulmonary Embolism 
with Magnetic Resonance Angiography. N Engl J Med. 
1997. 336: 1422-7.
49. Ersoy H, et al. Time-Resolved MR Angiography: A 
Primary Screening Examination of Patients with 
Suspected Pulmonary Embolism and Contraindications 
The role of imaging techniques in the assessment of pulmonary circulation
J Bras Pneumol. 2011;37(3):389-403
403
About the authors
André Hovnanian
Physician. Pulmonary Hypertension Group, Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine Hospital das 
Clínicas – São Paulo, Brazil.
Eduardo Menezes
Physician. Pulmonary Hypertension Group, Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine Hospital das 
Clínicas – São Paulo, Brazil.
Susana Hoette
Physician. Pulmonary Hypertension Group, Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine Hospital das 
Clínicas – São Paulo, Brazil.
Carlos Jardim
Attending Physician. Pulmonary Hypertension Group, Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da 
Faculdade de Medicina da Universidade de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine 
Hospital das Clínicas – São Paulo, Brazil.
Dany Jasinowodolinski
Physician. Pulmonary Hypertension Group, Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine Hospital das 
Clínicas – São Paulo, Brazil.
Rogério Souza
Tenured Professor. Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da Universidade 
de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine Hospital das Clínicas – São Paulo, Brazil.
